Orphan Drug Designations and Approvals List as of 06-01-2016
Governs July 1, 2016 - September 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester	n/a	10/12/2011	Treatment of Fragile X syndrome	Novartis Pharmaceuticals Corp.
2	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate	n/a	6/5/2013	Treatment of pancreatic cancer	EMD Serono
3	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate	n/a	3/9/2012	Treatment of soft tissue sarcoma	Threshold Pharmaceuticals, Inc.
4	(1OR)-7-amino-12-fluoro-2,10,16-trimethyl-15 oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile	n/a	6/23/2015	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer	Pfizer, Inc.
5	(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-	n/a	2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Pfizer, Inc.
6	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	1/29/2004	Treatment of T-cell non-Hodgkin's lymphoma	Mundipharma Research Limited
7	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/13/2004	Treatment of acute lymphoblastic leukemia	Mundipharma Research Limited

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
8	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/10/2004	Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia	Mundipharma Research Ltd.
9	(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride	n/a	9/15/2010	Treatment of infantile spasms.	Catalyst Pharmaceuticals, Inc.
10	(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1"S)-7,9-acrolein acetal-11(15-1)-abeotaxane	n/a	6/23/2014	Treatment of progressive supranuclear palsy	Cortice Biosciences, Inc.
11	(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride	n/a	5/18/2016	Treatment of Rett Syndrome.	Anavex Life Sciences Corporation
12	(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione)	n/a	10/14/2015	Treatment of systemic sclerosis.	Genkyotex Innovation SAS

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
13	(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-l-yl) nona-2,4,6,8-tetraen-l-yl acetate	n/a	12/2/2010	Treatment of retinitis pigmentosa	QLT Inc.
14	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)	n/a	12/2/2010	Treatment of Leber congential amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	QLT, Inc.
15	(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid	n/a	10/31/2012	Treatment of primary biliary cirrhosis	Albireo AB
16	(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid	n/a	10/31/2012	Treatment of progressive familial intrahepatic cholestatis	Albireo AB

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
17	(2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide	Fk778	1/10/2005	Prevention of acute rejection following kidney, heart, and liver transplantation	Fujisawa Healthcare, Inc.
18	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of pancreatic cancer	NATCO Pharma Limited
19	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of chronic myelogenous leukemia.	NATCO Pharma Limited
20	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019	n/a	3/18/2011	Treatment of Glioma	NATCO Pharma Limited
21	(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne	n/a	4/30/2014	Treatment of multiple myeloma	VivoLux AB
22	(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	n/a	12/9/2015	Treatment of Fragile X Syndrome.	Centre National de la Recherche Scientifique (CNRS)
23	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate	n/a	9/11/2014	Treatment of Gaucher disease	Genzyme

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
24	(3S)-1-azabicylo[2.2.2]oct-3yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate	n/a	8/26/2014	Treatment of Fabry's disease	Genzyme Corporation
25	(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine	n/a	7/5/2007	Treatment of tuberculosis	Global Alliance for TB Drug Development
26	(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid	n/a	8/19/2003	Treatment of patients undergoing solid organ transplantation.	Pfizer Global Research and Development
27	(3S)-3-[({1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl}amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt	n/a	4/25/2016	For mobilization of hematopoietic stem cells	Aviara Pharmaceuticals, Inc/

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
28	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary sclerosing cholangitis	Shire Human Genetic Therapies, Inc.
29	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary biliary cirrhosis	Shire Human Genetic Therapies, Inc.
30	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of alagille syndrome	Shire Human Genetic Therapies, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
31	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Shire Human Genetic Therapies, Inc.
32	(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride	n/a	7/24/2013	Treatment of trigeminal neuralgia	Convergence Pharmaceuticals Ltd.
33	(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxyamide	n/a	4/14/2016	Treatment of ovarian cancer	DebioPharm International SA
34	(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/2011	Treatment of soft tissue sarcoma	CytRx Corporation
35	(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)	n/a	2/21/2014	Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics	DARA BioSciences, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
36	(6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid	n/a	10/13/2015	Treatment of cystic fibrosis.	Corbus Pharmaceuticals, Inc.
37	(6aR, 10aR)-3-(1â¿¿,1â¿¿-dimethylheptyl)-Î¿8-tetrahydro-cannabinol-9-carboxylic acid	n/a	6/10/2015	Treatment of systemic sclerosis	Corbus Pharmaceuticals, Inc.
38	(6R,S)5,10-methylene-tetrahydrofolic acid	Cofactor	8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Adventrx Pharmaceuticals, Inc.
39	(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid	n/a	12/8/2004	Prevention of post-operative complications of aortic anuerysm surgical repair	Inotek Pharmaceuticals Corporation
40	(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)	n/a	4/21/2016	Treatment of Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients	Neem Biotech Ltd.
41	(monomethoxypolyethylene glycol) recombinant adenosine deaminase	n/a	3/19/2015	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency	Sigma-Tau Pharmaceuticals, Inc.
42	(N-[2,6-bis(1-methylethyl)-pheyl-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	3/9/2012	Treatment of adrenocortical carcinoma	Atterocor, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
43	(R)-1-(2,2-difluorobenzo [d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide	n/a	4/24/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
44	(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/2011	Treatment of idiopathic pulmonary fibrosis	Bristol-Myers Squibb Company
45	(R)-1-[1-(4-Acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea	n/a	5/12/2016	Treatment of gastric neuroendocrine tumors (gastric NETs).	Trio Medicines Ltd.
46	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole	n/a	7/12/2007	Treatment of pulmonary tuberculosis.	Otsuka Pharmaceutical Company, Ltd

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
47	(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride	n/a	12/19/2007	Treatment of small cell lung cancer.	AbbVie, Inc
48	(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride	n/a	11/19/2015	Treatment of cholangiocarcinoma.	ArQule, Inc.
49	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc.
50	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	n/a	7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc.
51	(RS)-baclofen, naltrexone and D-sorbitol	n/a	3/17/2014	Treatment of Charcot-Marie-Tooth disease type 1A	Pharnext SAS
52	(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine	n/a	11/5/2014	Treatment of acute myeloid leukemia	BerGenBio AS

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
53	(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2",4",5",7"-tetranitro-9"-fluorenylideneaminooxy)propionyl]- 1H-pyrano[3',4',6',7',] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride	Lipotecan	10/6/2010	Treatment of hepatocellular carcinoma	TLC Biopharmaceuticals, Inc.
54	(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile	n/a	1/26/2015	Treatment of pemphigus vulgaris	Almirall S.A.
55	(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium	n/a	11/17/2014	Treatment of pulmonary arterial hypertension	Pulmokine, Inc.
56	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/2013	Treatment of follicular lymphoma	Infinity Pharmaceuticals, Inc.
57	(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid	n/a	2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Ferrokin BioSciences, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
58	(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	BioMed Valley Discoveries, Inc.
59	(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide	n/a	10/22/2015	Treatment of Waldenstrom macroglobulinemia.	Acerta Pharma BV
60	(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazine-1-yl)-N-(pyridine-2-yl)-benzamide	n/a	9/21/2015	Treatment of mantle cell lymphoma.	Acerta Pharma BV
61	(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride	n/a	11/17/2014	Treatment of inherited mitochondrial respiratory chain diseases	Khondrion BV
62	(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	n/a	4/29/2015	Treatment of Hodgkin lymphoma	Incyte Corporation
63	(S)-8-{2-Amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester	n/a	10/6/2015	Treatment of pulmonary arterial hypertension (PAH).	KAROS Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
64	(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	n/a	8/31/2015	Treatment of soft tissue sarcoma.	Loxo Oncology, Inc.
65	(S)-perillyl alcohol temozolomide	n/a	11/12/2014	Treatment of glioma	NeOnc Technologies, Inc.
66	(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)	n/a	3/28/2006	Treatment of acute sensorineural hearing loss	Auris Medical, Inc.
67	(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of diffuse large B-cell lymphoma	Karyopharm Therapeutics, Inc.
68	1 8-(p[131I]-iodophenyl)octadecyl phosphocholine	n/a	12/3/2014	Treatment of multiple myeloma	Cellectar Biosciences, Inc.
69	1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	n/a	11/19/2012	Treatment of erythromelalgia	Teva Pharmaceuticals
70	1,2:5,6-Dianhdrogalactitol, NSC-132313	n/a	1/31/2012	Treatment of malignant gliomas	DelMar Pharmaceuticals, Inc.
71	1,2:5,6-dianhydrogalactitol	n/a	3/10/2016	Treatment of medulloblastoma.	DelMar Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
72	1,2:5,6-dianhydrogalactitol	n/a	4/19/2016	Treatment of ovarian cancer.	DelMar Pharmaceuticals, Inc. (Clinical Operations)
73	1,5-(Butylimino)-1,5 dideoxy,D-glucitol	n/a	5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences
74	1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one	n/a	4/6/2016	Treatment of frontotemporal dementia.	Anavex Life Sciences Corp.
75	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of myelodysplastic syndrome	Cyclacel Limited
76	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of acute myelogenous leukemia	Cyclacel Limited
77	1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol; 1H-1-(3-[18F]fluoro-2-hydroxypropyl0-2-nitroimidazole (18F-Misonidazole)	n/a	4/6/2016	Diagnostic for management of glioma.	Advanced Imaging Projects, LLC
78	1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole	n/a	1/6/2016	As a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma.	Advanced Imaging Projects, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
79	1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-l-yl)-1,3-thiazol-2-yl]carbamoyl}- 2-pyridyl) piperidine-4-caboxylic acid Monomaleate	n/a	9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Eisai, Inc.
80	1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide	n/a	7/8/2015	Treatment of multiple myeloma	Cleave Biosciences, Inc.
81	1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid	n/a	3/31/2015	Treatment of systemic sclerosis	Inventiva Pharma
82	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/2009	Treatment of acute myeloid leukemia	Astex Therapeutics Ltd
83	1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene	n/a	1/9/2012	Treatment of poliovirus infection.	ViroDefense, Inc.
84	10 synthetic peptides targeting 5 tumor asociated antigens	n/a	1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Orphan Synergy Europe Pharma (OSE Pharma)
85	111Indium pentetreotide	Somatother	6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
86	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/2011	Treatment of pancreatic cancer	Oncos Therapeutics
87	131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I	n/a	3/28/2016	Treatment of Acute Myeloid Leukemia (AML)	Actinium Pharmaceuticals, Inc.
88	17 amino acid peptide	n/a	1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung tranplantation	Apeptico Forschung und Entwicklung GmbH
89	17-a-hydroxyprogesterone caporate (oral formulation)	n/a	6/1/2015	Prevention of preterm birth in women with a singleton pregnancy	Lipocine, Inc.
90	17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/2004	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
91	177-LU-DOTA-GlyGlyNle-CycMSHhex	n/a	4/16/2015	Treatment of Stage IIB through IV malignant melanoma	SolaranRx, Inc.
92	177Lu-tetraxetan-tetulomab	Betalutin	5/14/2014	Treatment of Follicular Lymphoma	Nordic Nanovector AS
93	18-(p-[124I]-iodophenyl)octadecyl phosphocholine	n/a	4/30/2014	Diagnostic for the management of glioma	Cellectar Biosciences, Inc.
94	18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane	n/a	1/26/2015	Diagnostic to be used in the management of multiple system atrophy (MSA)	Advanced Imaging Projects, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
95	1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]	n/a	2/17/2016	Treatment of spinal and bulbar muscular atrophy	Allianz Pharmascience Ltd.
96	2 dimethylbutyrate	n/a	6/18/2008	Treatment of beta thalassemia	HemaQuest Pharmaceuticals, Inc.
97	2'-deoxycytidine	n/a	9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D.
98	2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide	n/a	5/10/2016	Treatment of acromegaly	Antisense Therapeutics Limited
99	2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/2012	Treatment of amyotrophic lateral sclerosis	LifeSplice Pharma LLC
100	2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)	n/a	3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Millennium Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
101	2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-	n/a	1/15/2015	Treatment of congenital adrenal hyperplasia (CAH)	Neurocrine Biosciences, Inc.
102	2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate	n/a	9/10/2015	Treatment of Charcot-Marie Tooth disease.	InFlectis BioScience
103	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione	n/a	9/21/2010	Treatment of idiopathic pulmonary fibrosis.	GenKyoTex S.A.
104	2-(2-phenylvinyl)-4-[-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/2010	Treatment of acute myeloid leukemia.	EntreMed, Inc.
105	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	7/1/2014	Treatment of hepatocellular carcinoma	CASI Pharmaceuticals, Inc.
106	2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/2008	Treatment of multiple myeloma.	EntreMed, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
107	2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt	n/a	3/18/2009	Treatment of ovarian carcinoma	EntreMed, Inc.
108	2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-l-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl) piperidin-4-yl)azetidin-3-yl)acetonitrile adipate	n/a	1/26/2015	Treatment of pancreatic cancer	Incyte Corporation
109	2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate	Atiprimod	12/2/2003	Treatment of mulitple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc.
110	2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate	Atiprimod	9/18/2006	Treatment of carcinoid tumors	Callisto Pharmaceuticals, Inc.
111	2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline	n/a	6/1/2015	Treatment of acute myeloid leukemia	Aptose Biosciences, Inc.
112	2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide	n/a	5/13/2015	Treatment of cystic fibrosis	Flatley Discovery Lab
113	2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	n/a	8/15/2003	Treatment of cystic fibrosis	Inologic, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
114	2-0-desulfated heparin	Aeropin	9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
115	2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3-propanediol hydrochloride	n/a	10/6/2015	Prevention of graft versus host disease.	Novartis Pharmaceuticals Corporation
116	2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride	n/a	5/18/2016	Treatment of spinocerebellar ataxia.	Biohaven Pharmaceuticals, Inc.
117	2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Can-Fite BioPharma Ltd.
118	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Sarmustine	11/15/2001	Treatment for malignant glioma	Pangene Corporation
119	2-chloroethyl-3-sarcosinamide-1-nitrosourea	n/a	8/3/2001	Treatment for malignant gliomas	Lawrence Panasci, MD
120	2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate	n/a	9/18/2015	Treatment of Ebola virus disease	Gilead Sciences, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
121	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde	n/a	12/29/2015	Treatment of sickle cell disease (SCD).	Global Blood Therapeutics, Inc.
122	2-hydroxypropyl-B-cyclodextrin	Kleptose	2/18/2013	Treatment of Niemann Pick disease, type C.	Vtesse, Inc.
123	2-iminobiotin	n/a	2/24/2009	Treatment of perinatal asphyxia.	Neurophyxia B.V.
124	2-methoxyestradiol	Pulmolar	4/11/2005	Treatment of pulmonary arterial hypertension	PR Pharmaceuticals, Inc.
125	2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate	n/a	4/9/2015	Treatment of anal cancer	Eli Lilly and Company
126	2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole	Prevonco (Tm)	8/27/2008	Treatment of hepatocellular carcinoma.	BioQuant, Inc.
127	2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acet amide	n/a	9/29/2015	Treatment of nuclear protein in testis (NUT) midline carcinoma.	Tensha Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
128	2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate	n/a	7/16/2014	Treatment of acute myeloid leukemia	OncoEthix SA
129	2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide	n/a	12/18/2007	Treatment of malignant melanoma stages IIb through IV.	AbbVie, Inc.
130	2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid	n/a	6/2/2014	Treatment of Huntington's disease.	Pfizer Inc.
131	2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/2013	Treatment of patients with systemic sclerosis	Sanofi U. S., Inc.
132	2-[4-[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	4/15/2015	Treatment of patients with Frederickson Type I or V hyperlipoproteinemia	CymaBay Therapeutics, Inc.
133	2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	3/18/2015	Treatment of homozygous familial hypercholesterolemia (HoFH)	CymaBay Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
134	2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate	n/a	1/19/2010	Treatment of acute myeloid leukemia	AstraZeneca Pharmaceuticals LP
135	2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid	n/a	6/23/2015	Treatment of malignant melanoma stages IIB to IV.	Rgenix, Inc.
136	2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid	n/a	6/16/2015	Treatment of glioblastoma multiforme.	Rgenix, Inc.
137	2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid	n/a	6/16/2015	Treatment of ovarian cancer.	Rgenix, Inc.
138	2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid	n/a	8/28/2014	Treatment of pulmonary arterial hypertension	Arena Pharmaceuticals, Inc.
139	20-mer complementary to Akt mRNA	n/a	12/10/2004	Treatment of stomach cancer	Rexahn Corporation
140	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of ovarian cancer	Rexahn Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
141	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of glioblastoma	Rexahn Corporation
142	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of pancreatic cancer	Rexahn Corporation
143	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of renal cell carcinoma	Rexahn Corporation
144	225Ac-lintuzumab	n/a	11/25/2014	Treatment of acute myelogenous leukemia	Actinium Pharmaceuticals, Inc.
145	24,25 dihydroxycholecalciferol	n/a	2/27/1987	Treatment of uremic osteodystrophy.	Lemmon Company
146	2S,4R ketoconazole	n/a	3/9/2012	Treatment of endogenous Cushing's syndrome	Cortendo AB (HQ address)
147	3,4 diaminopyridine and choline bitartrate	n/a	4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	MS Therapeutics Limited
148	3,4-diaminopyridine	n/a	12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company
149	3,5,3'-triiodothyroacetate	n/a	9/20/2000	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D.
150	3,5-diiodothyropropionic acid	n/a	5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Zarion Pharmaceuticals P/L

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
151	3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	9/11/1998	Treatment of Kaposi's sarcoma.	Sugen, Inc.
152	3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	3/23/2000	Treatment of von Hippel-Lindau disease.	Sugen, Inc.
153	3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)	n/a	7/14/2015	Treatment of fibrodysplasia ossificans progressiva.	La Jolla Pharmaceutical Company, Inc.
154	3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)	n/a	7/14/2015	Treatment of fibrodysplasia ossificans progressiva.	La Jolla Pharmaceutical Company, Inc.
155	3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione	n/a	3/29/2016	Treatment of glioblastoma	Actuate Therapeutics
156	3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	n/a	3/2/2010	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
157	3-bromopyruvate	n/a	4/29/2014	Treatment of pancreatic cancer	PreScience Labs, LLC
158	3-bromopyruvate	n/a	3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
159	3-chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone	n/a	10/25/2013	Treatment of Rett syndrome	Neurolixis, Inc.
160	3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride	n/a	7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Seaside Therapeutics
161	3-pentylbenzenacetic acid sodium salt	n/a	2/11/2015	Treatment of idiopathic pulmonary fibrosis.	ProMetic Life Sciences, Inc.
162	3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid	n/a	12/23/2014	Prevention of acute attacks of angioedema in individuals with hereditary angioedema	BioCryst Pharmaceuticals, Inc.
163	3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate	n/a	11/9/2015	Treatment of Proteus Syndrome.	ArQule, Inc.
164	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of follicular lymphoma	Kiadis Pharma Canada, Inc.
165	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of diffuse large B-cell lymphoma	Kiadis Pharma Canada, Inc.
166	4,5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
167	4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Provectus Pharmaceuticals, Inc.
168	4-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl)	n/a	10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Dynogen Pharmaceuticals, Inc.
169	4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/2005	Treatment of Huntington's disease.	Teva Branded Pharmaceutical Products R&D
170	4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid	n/a	3/24/2015	Prevention of scarring post ab externo glaucoma surgery	Clanotech AB
171	4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	AbbVie
172	4-(6-(4-(piperazin-1-yl)phenyl_pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride	n/a	4/15/2013	Treatment of fibrodysplasia ossificans progressiva	La Jolla Pharmaceutical Company, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
173	4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one	n/a	5/4/2015	Treatment of congenital long QT syndrome	Gilead Sciences, Inc.
174	4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one	n/a	9/23/2014	Treatment of pancreatic cancer.	Rexahn Pharmaceuticals, Inc.
175	4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone	n/a	8/22/2007	Treatment of hepatocellular carcinoma.	Ligand Pharmaceuticals, Inc.
176	4-Aminopyridine	n/a	12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Acorda Therapeutics, Inc.
177	4-aminosalicylic acid	Pamisyl (P-D), Rezipas (Squibb)	12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D.
178	4-aminosalicylic acid	Paser Granules	4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Jacobus Pharmaceutical Co., Inc.
179	4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/2006	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev,

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
180	4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl	n/a	9/29/2015	Treatment of cerebral cavernous malformation.	REcursion Pharmaceuticals, LLC
181	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/2010	Treatment of pancreatic cancer.	Apogee Biotechnology Corporation
182	4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide	n/a	2/8/2016	Treatment of retinitis pigmentosa	Shire HGT, Inc.
183	4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate	n/a	11/18/2015	Treatment of patients with Duchenne Muscular Dystrophy.	ARMGO Pharma, Inc.
184	4-[131I]iodo-L-phenylalanine	n/a	1/4/2011	Treatment of glioma.	Therapeia GmbH & Co KG
185	4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide	n/a	7/30/2008	Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.	SuperGen, Inc.
186	4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol	n/a	10/4/2011	Treatment of chronic myeloid leukemia	Piramal Enterprises Limited

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
187	4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxyl]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt	n/a	9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Deciphera Pharmaceuticals, LLC
188	4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol	n/a	9/23/2011	Treatment of idiopathic pulmonary fibrosis	Celgene Corporation
189	4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid	n/a	5/19/2014	Treatment of Acute Myeloid Leukemia	Roche Genentech
190	40K PEGylated recombinant factor IX	n/a	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease)	Novo Nordisk, Inc.
191	5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+	n/a	3/31/2015	Treatment of diffuse large B-cell lymphoma.	Idera Pharmaceuticals, Inc.
192	5'-GCCATGGTTTTTTCTCAGG-3'	n/a	10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Sarepta Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
193	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/2007	Treatment of osteosarcoma (bone cancer)	Dr. Reddy's Laboratories, Inc.
194	5,5',5"-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	n/a	8/20/2003	Treatment of pancreatic cancer	Now Pharm AG
195	5,6-dihydro-5-azacytidine	n/a	5/11/1992	Treatment of malignant mesothelioma.	ILEX Oncology, Inc.
196	5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride	n/a	9/4/2014	Treatment of Huntington's disease	Prana Biotechnology Limited
197	5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one	n/a	6/18/2007	Prevention of acute radiation syndrome	Humanetics Corporation
198	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	n/a	4/18/2011	Treatment of progressive supranuclear palsy.	Mithridion, Inc.
199	5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide	n/a	1/15/2015	Treatment pulmonary arterial hypertension	Gilead Sciences, Inc.
200	5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole	n/a	11/22/2011	Treatment of Duchenne Muscular Dystrophy	Summit Corporation plc

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
201	5-aminolevulinic acid	Gliolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO garde III and IV)	NX Development Corporation
202	5-aza-2'-deoxycytidine	n/a	8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.
203	5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/2006	Treatment of sickle cell disease	Baxalta US, Inc.
204	5-imino-13-deoxydoxorubicin HCl	n/a	12/31/2015	Treatment of soft tissue sarcoma	Gem Pharmaceuticals, LLC
205	5-iodo-2-pytimidinone-2'-deoxyribose	n/a	5/26/2006	Treatment of malginant glioma	Hana Biosciences, Inc.
206	5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol	Resveratrol	3/13/2008	Treatment of MELAS syndrome	Sirtris Pharmaceuticals, Inc.
207	5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine	n/a	8/25/2009	Treatment of spinal muscular atrophy	Pfizer Incorporated
208	GAATATTAACAIACTGACAAGTC-n/a		10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Sarepta Therapeutics, Inc.
209	6,8-bis-benzylsulfanyl-octanoic acid	n/a	8/22/2011	Treatment of acute myeloid leukemia.	Cornerstone Pharmaceuticals, Inc.
210	6,8-bis-benzylsulfanyl-octanoic acid	n/a	2/6/2006	Treatment of pancreatic cancer	Cornerstone Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
211	6,8-bis-benzylsulfanyl-octanoic acid	n/a	9/26/2013	Treatment of myelodysplastic syndrome	Cornerstone Pharmaceuticals, Inc.
212	6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one	n/a	9/4/2014	Treatment of sickle cell disease	Pfizer, Inc.
213	6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate	n/a	4/14/2014	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
214	6-alpha-ethylchenodeoxycholic acid	n/a	4/9/2008	Treatment of primary sclerosing cholangitis	Intercept Pharmaceuticals, Inc.
215	6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamide	n/a	10/15/2013	Treatment of stage IIb-IV melanoma	Millennium Pharmaceuticals, Inc.
216	6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one	n/a	6/18/2015	Treatment of Netherton syndrome	Sixera Pharma AB
217	6-mercaptopurine oral liquid	n/a	12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Orbona Pharma Ltd
218	6-methoxy-3-(3',4',5'-trimethoxybenzoyl) indole	n/a	5/11/2016	Treatment of cholangiocarcinoma	SynCore Biotechnology Co. Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
219	6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine	n/a	6/12/2014	Treatment of multiple myeloma	DARA BioSciences, Inc.
220	6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide	n/a	2/11/2016	Treatment of glioblastoma multiforme (GBM).	Upsher-Smith Laboratories, Inc.
221	6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dione	n/a	4/27/2016	Treatment of symptomatic obstructive hypertrophic cardiomyopathy	MyoKardia, Inc.
222	68G-OPS202, small somatostatin analog labeled with 68Gallium	n/a	9/24/2014	Management of gastroenteropancreatic neuroendocrine tumors.	OctreoPharm Sciences GmbH
223	7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/2011	Treatment of gliomas.	Intsel Chimos SA
224	7-ethyl-10-hydroxycamptothecin (EHC)	n/a	4/13/2016	Treatment of small cell lung cancer.	Nippon Kayaku Co., Ltd.
225	8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one	n/a	1/21/2015	Treatment of glioblastoma multiforme	Diffusion Pharmaceuticals, Inc.
226	8-methoxsalen	Uvadex	6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
227	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride	n/a	9/3/2009	Treatment of ovarian cancer.	Merck Sharp & Dohme Corp.
228	9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester	n/a	5/23/2016	Treatment of Friedreich's Ataxia	Retroitope, Inc.
229	9-nitro-20-(S)-camptothecin	Camvirex	5/15/2001	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc.
230	9-nitro-20-(S)-camptothecin	n/a	9/16/1996	Treatment of pancreatic cancer.	SuperGen, Inc.
231	90Y-DOTA-tyr3-Octreotide	n/a	1/20/2016	Treatment of neuroendocrine tumors	M. Sue O'Dorisio, MD, PhD
232	90Y-hPAMA4	Pan-Cide	1/29/2004	Treatment of pancreatic cancer	Immunomedics, Inc.
233	a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy	n/a	4/29/2014	Treatment of Stage II to IV invasive cervical carcinoma	Advaxis, Inc.
234	A-dmDT390-bisFv(UCHT1)	Resimmune	10/9/2014	Treatment of cutaneous T-cell lymphoma	Angimmune, LLC
235	a-Galactosidase A	Plant-Produced Human A-Glactosidase A	1/21/2003	Treatment of Fabry's disease	iBio, Inc.
236	A10 & AS2-1 Antineoplaston	n/a	9/3/2004	Treatment for patients with brain stem glioma	Burzynski Research Institute, Inc.
237	aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1	n/a	9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Sparks Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
238	AAV-G6Pase vector	n/a	3/11/2013	Treatment of glycogen storage disease type Ia	GlyGenix Therapeutics, Inc.
239	abatacept	Orencia	5/30/2013	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Orban Biotech LLC
240	ABCA4 DNA nanoparticles	n/a	10/28/2015	Treatment of Stargardt Macular Degeneration	Copernicus Therapeutics, Inc.
241	abeotaxane inhibitor of microtubules	n/a	10/7/2011	Treatment of gliomas	Cortice Biosciences
242	abeotaxane inhibitor of microtubules	n/a	4/18/2011	Treatment of pediatric neuroblastoma.	Cortice Biosciences
243	Abetimus	n/a	7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.
244	Ac-Ile-Cys-Val-Trp(1-Me)-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys-Thr-AEEA-Lys-PEG 40KDa-Lys-AEEA-Thr-Cys-Arg-His-ALa-Gly-Trp-Asp-Gln-(1-Me)Trp-Val-Cys-Ile-Ac	n/a	4/20/2014	Treatment of paroxysmal nocturnal hemoglobinuria	Apellis Pharmaceuticals, Inc.
245	acadesine	n/a	5/4/2011	Treatment of multiple myeloma	Advancell-Advanced In Vitro Cell Technologies S.A.
246	acadesine	n/a	3/3/2011	Treatment of chronic lymphocytic leukemia	Avanced In Vitro Cell Technologies, S.L.
247	acamprosate	n/a	3/25/2013	Treatment of fragile X syndrome	Confluence Pharmaceuticals, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
248	acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylmaide disulfide	n/a	11/24/2015	Treatment of acute myeloid leukemia.	Genus Oncology, LLC
249	acetyl-l-carnitine	n/a	7/24/2012	Treatment of Fragile X syndrome	Sigma-Tau Pharmaceuticals, Inc.
250	acetyl-l-carnitine (ALC)	n/a	3/18/2011	Treatment of Rett syndrome	Sigma-Tau Pharmaceuticals, Inc.
251	Acetylcysteine	Mucomyst/Mucomyst 10 Iv	8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company
252	acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals, Inc.
253	acetylcysteine effervescent tablets for oral solution	n/a	2/24/2015	Preventing hepatic injury from acetaminophin overdose	Arbor Pharmaceuticals, Inc.
254	ActRIIB-IgG1)	n/a	8/16/2010	Treatment of Duchenne muscular dystrophy	Acceleron Pharma, Inc.
255	acyclovir	n/a	5/3/2016	Treatment of herpetic keratitis.	Cumulus Pharmaceuticals LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
256	acyclovir	n/a	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	Fera Pharmaceuticals
257	Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus	n/a	3/17/2014	Treatment of ovarian cancer	Oncos Therapeutics
258	adalimumab	Humira	5/13/2015	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	AbbVie, Inc.
259	adalimumab	n/a	7/10/2014	Treatment of Behcet's disease	Mucora
260	adalimumab	Humira	10/19/2006	Treatment of pediatric Crohn's disease.	AbbVie, Inc.
261	adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie Inc.
262	adalimumab	Humira	5/13/2014	Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis	AbbVie, Inc.
263	adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	AbbVie, Inc.
264	aden-associated virus vector serotype 9 expressing human a-L-iduronidase	n/a	9/29/2015	Treatment of mucopolysaccharidosis Type I (MSP I).	REGENXBIO, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
265	adeno associated viral vector containing human ARSB gene	n/a	3/17/2011	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Fondazione Telethon
266	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Lysogene
267	adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	n/a	3/14/2014	Treatment of hemophilia B	Baxter Healthcare Corporation
268	Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/2007	Treatment of lipoprotein lipase deficiency	uniQure B.V.
269	adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	n/a	11/18/2015	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	LYSOGENE
270	adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA	n/a	3/16/2016	Treatment of CLN2 disease (neuronal ceroid lipofuscinosis (NCL)) caused by TPP1 deficiency.	Spark Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
271	adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX	n/a	9/21/2015	Treatment of hemophilia B.	Spark Therapeutics, Inc.
272	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/2012	treatment of retinitis pigmentosa	Genable Technologies Limited
273	adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/2010	Treatment of Duchenne muscular dystrophy.	uniQure B.V.
274	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc.
275	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc.
276	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Gen Sight Biologics

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
277	Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/2007	Treatment of Pompe disease	Audentes Therapeutics, Inc.
278	adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/2007	Treatment of X-linked juvenile retinoschisis (XLRS).	Applied Genetic Technologies Corporation
279	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/2012	Treatment of homozygous familial hypercholesterolemia	ReGenX Biosciences LLC
280	adeno-associated viral vector expressing the human vascular endothelial growth factor gene	n/a	12/31/2015	Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated	Integene International Holding, LLC
281	adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene	n/a	11/5/2014	Treatment of choroideremia	NightstaRx Ltd.
282	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Laboratorios del Dr. Esteve, S.A.
283	adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene	Calmarythm	10/2/2014	Treatment of catecholaminergic polymorphic ventricular tachycardia	Audentes Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
284	adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene	n/a	3/18/2015	Treatment of Retinitis Pigmentosa due to autosomal recessive RPE65 gene mutations	Spark Therapeutics, Inc.
285	adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene	n/a	9/30/2014	Treatment of spinal muscular atrophy	AveXis, Inc.
286	adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene	n/a	7/16/2015	Treatment of mucopolysaccharidosis type II (Hunter syndrome).	Laboratorios del Dr. Esteve, S.A.
287	Adeno-associated virus serotype rh10 vector encoding the human factor IX gene	n/a	8/25/2015	Treatment of hemophilia B.	Dimension Therapeutics
288	adeno-associated virus transgene of follistatin	n/a	11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Milo Biotechnology
289	adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS)	n/a	11/16/2015	Treatment of X-linked retinoschisis	Paul A. Sievig, MD, PhD, National Eye Institute, NIH
290	adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII	n/a	2/29/2016	Treatment of Hemophilia A.	BioMarin Pharmaceutical, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
291	adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Laboratorios del Dr. Esteve, S.A.
292	Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter	n/a	9/4/2014	For the treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)	Columbia University Medical Center
293	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/2011	Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)	Eli Lilly and Company
294	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/2005	Treatment of malignant brain tumors	Advantagene, Inc.
295	adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	n/a	6/8/2015	Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)	PNP Therapeutics, Inc.
296	Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex	n/a	7/23/2015	Treatment of malignant glioma.	Ziopharm Oncology, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
297	adenovirus associated viral vector serotype 5 containing the human RPE65 gene	n/a	3/10/2016	Treatment of Leber congenital amaurosis	MeiraGTx Limited
298	adenovirus associated viral vector serotype 8 containing the human CNGB3 gene	n/a	3/10/2016	Treatment of achromatopsia due to mutations in the CNGB3 gene.	MeiraGTx Limited
299	adenovirus containing a human FAS-c gene	n/a	4/2/2012	Treatment of malignant glioma	Vascular Biogenics Ltd
300	adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma	n/a	10/1/2014	Treatment of glioma	DNAtrix, Inc.
301	Adenovirus encoding the recombinant CD40 ligand	n/a	4/19/2016	Treatment of stage IIb through IV melanoma.	Memgen LLC
302	Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)	n/a	9/4/2014	Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)	Etubics Corporation
303	adenovirus vaccine encoding reduced expression in immortalized cell protein	n/a	7/14/2015	Treatment of mesothelioma	MTG Biotherapeutics
304	Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadfviii	12/15/1999	Treatment of hemophilia A.	GenStar Therapeutics Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
305	adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/2012	Treatment of MPS-1, including Hurler syndrome	Athersys, Inc.
306	adult hemogenic endothelial cells	n/a	5/27/2015	Treatment of aplastic anemia	HemoGenyx LLC
307	ADXS11-001	n/a	8/12/2013	Treatment of HPV-positive associated anal cancer	Advaxis, Inc.
308	aerosolized beractant	n/a	3/11/2013	Treatment of respiratory distress syndrome	Beena G. Sood, MD, MS
309	AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/2010	Treatment of ovarian cancer	Aeterna Zentaris
310	afamelanotide	n/a	7/17/2008	Treatment of erythropoietic porphyrias	Clinuvel Inc.
311	afamelanotide	n/a	5/14/2014	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Clinuvel, Inc.
312	afamelanotide	n/a	2/4/2016	Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease)	Clinuvel Inc.
313	afamelanotide	n/a	12/11/2009	Treatment of solar urticaria	Clinuvel, Inc.
314	afatinib	Gilotrif(R)	6/4/2014	Treatment of malignant brain and central nervous system tumors	Boehringer Ingelheim Pharmaceuticals, Inc.
315	afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Boehringer Ingelheim Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
316	afatinib	Gilotrif(R)	8/3/2015	Treatment of non-small cell lung cancer with squamous histology.	Boehringer Ingelheim Pharmaceuticals, Inc.
317	Albendazole	Albenza	1/18/1996	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	Amedra Pharmaceuticals LLC
318	Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Amedra Pharmaceuticals LLC
319	Albuterol	n/a	3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc.
320	Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Chiron Corporation
321	Aldesleukin	Proleukin	3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Prometheus Laboratories, Inc.
322	Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Chiron Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
323	Aldesleukin	Proleukin	11/24/1998	For the treatment non-Hodgkin's lymphoma.	Prometheus Laboratories, Inc.
324	aldoxorubicin	n/a	9/24/2014	Treatment of ovarian cancer	CytRx Corporation
325	aldoxorubicin	n/a	9/24/2014	Treatment of small cell lung cancer	CytRx Corporation
326	aldoxorubicin	n/a	9/24/2014	Treatment of glioblastoma multiforme	CytRx Corporation
327	alectinib	Alecensa	1/27/2015	Treatment of ALK-positive non-small cell lung cancer	Genentech, Inc.
328	alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Genzyme Corporation
329	Alendronate disodium	Fosamax	2/13/2001	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D.
330	Alfentanil	n/a	7/8/2005	Management of postherpetic neuralgia	Cinergen, LLC
331	Alfentanil	n/a	8/9/2005	Treatment of painful HIV-associated neuropathy	Cinergen, LLC
332	alfimeprase	n/a	9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Niche Therapeutics, LLC
333	algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/2010	Treatment of pancreatic cancer.	NewLink Genetics Corporation
334	Alglucerase injection	Ceredase	7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation
335	Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
336	alicaforsen	n/a	6/24/2008	Treatment of pouchitis.	Atlantic Healthcare Limited
337	alisertib	n/a	7/12/2013	Treatment of small cell lung cancer	Millennium Pharmaceuticals, Inc.
338	Alitretinoin	Panretin	4/10/1992	Treatment of acute promyelocytic leukemia	Ligand Pharmaceuticals, Inc.
339	Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Eisai, Inc
340	all-cis-docosa-4,7,10,13,16,19-hexaenoic acid	Retriacyl	5/21/2014	Treatment of retinitis pigmentosa	Natac Pharma, S.L.
341	allantoin	Alwextin	11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Scioderm, Inc.
342	allogeneic cardiosphere-derived cells	n/a	4/21/2015	Treatment of Duchenne Muscular Dystrophy	Capricor, Inc.
343	allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)	n/a	12/2/2010	Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neuropenia, thrombocytopenia, lymphopenia, and anemia).	Fate Therapeutics, Inc.
344	allogeneic Epstein-Barr virus cytotoxic T lymphocytes	n/a	2/4/2016	Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders.	ATARA Biotherapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
345	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Pluristem Therapeutics, Inc.
346	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/2013	Treatment of Aplastic Anemia	Pluristem Therapeutics, Inc.
347	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	12/29/2015	For the treatment of severe preeclampsia	Pluristem Therapeutics, Inc
348	allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells	n/a	4/20/2016	Treatment of acute myeloid leukemia	IPD-Therapeutics BV
349	allogeneic hematopoietic stem cell	Atir	2/2/2010	Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.
350	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end satge renal disease receiving hemodialysis or preparing for hemodialysis	Shire
351	Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Motorgraft (Tm)	1/17/2014	Treatment of Amyotrophic Lateral Sclerosis	California Stem Cell Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
352	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/1997	Treatment of pancreatic cancer	Applied Immunotherapeutics, LLC
353	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/2004	Treatment of retinitis pigmentosa	Neurotech USA, Inc.
354	Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro	n/a	1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	MolMed S.p.A.
355	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Neurotech USA, Inc.
356	allopregnanolone	n/a	7/12/2013	Treatment of Neimann-Pick disease, type C	La Jolla Pharmaceutical Company, Inc.
357	allopregnanolone	n/a	4/20/2014	Treatment of status epilepticus	Sage Therapeutics

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
358	Allopurinol sodium	Aloprim For Injection	10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc
359	allosteric activator of the red blood cell-specific form of pyruvate kinase	n/a	3/24/2015	Treatment of pyruvate kinase deficiency	Agios Pharmaceuticals, Inc.
360	alpha melanotropin	n/a	9/2/2010	Treatment of chronic beryllium disease	mondoBIOTECH Laboratories AG
361	alpha-1 proteinase inhibitor (human)	Glassia	10/23/2014	Treatment of graft versus host disease	Kamada Ltd.
362	alpha-1 proteinase inhibitor (human)	Glassia	7/28/2011	Treatment of patients with recent onset (	Kamada, Ltd.
363	Alpha-galactosidase A	Cc-Galactosidase	6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	David Calhoun, Ph.D.
364	Alpha-galactosidase A	Replagal	6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Shire Human Genetic Therapies, Inc.
365	Alpha-galactosidase A	Fabrase	7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J. M.D.
366	Alpha-melanocyte stimulating hormone	n/a	8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
367	Alpha-tocopherol quinone	n/a	3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Penwest Pharmaceuticals Company
368	alpha-tocotrienol quinone	n/a	10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases.	Edison pharmaceuticals, Inc.
369	alpha1 proteinase inhibitor (human)	n/a	1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Grifols Therapeutics, Inc.
370	Alpha1-antitrypsin(human)	n/a	4/3/2008	Treatment of bronchiectasis	Kamada Ltd.
371	alpha1-proteinase inhibitor (human)	n/a	4/6/2012	Treatment of cystic fibrosis	Grifols Therapeutics, Inc.
372	alpha1-proteinase inhibitor (human)	Prolastin(R)-C	3/3/2015	Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.	Grifols Therapeutics, Inc.
373	Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation
374	alpha1-proteinase inhibitor (human)	n/a	2/20/2009	Treatment of cystic fibrosis	CSL Behring LLC
375	Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/2004	Inhalation therapy for the treatment of congential deficiency of alpha1-proteinase inhibitor.	Kamada Ltd.
376	Alpha1-Proteinase Inhibitor (Human)	Arc-Api	9/1/2004	Treatment of cystic fibrosis	Kamada Ltd.
377	alteplase	Activase	1/27/2003	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Daniel F. Hanley, MD

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
378	altiratinib	n/a	8/19/2014	Treatment of glioblastoma multiforme.	Deciphera Pharmaceuticals, LLC
379	Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.
380	Alvocidib	n/a	4/13/2007	Teatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Tolero Pharmaceuticals, Inc.
381	alvocidib	n/a	4/21/2014	Treatment of acute myeloid leukemia	Tolero Pharmaceuticals, Inc.
382	ALX-0081 nanobody, directed towards the human A1 domain of von Willebrand factor	n/a	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Ablynx NV
383	Amantadine HCl	n/a	7/20/2015	Treatment of levodopa-induced dyskinesia	Osmotica Pharmaceutical Corporation
384	Amantadine hydrochloride	Nurelin	4/9/2015	Treatment of levodopa-induced dyskinesia	Adamas Pharmaceuticals, Inc.
385	amatuximab	n/a	9/28/2012	Treatment of mesothelioma	Morphotek, Inc.
386	ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Gilead Colorado
387	ambroxol	n/a	6/29/2011	Treatment of Gaucher disease	Belrose Pharma, Inc.
388	amifampridine phosphate	n/a	3/3/2015	Treatment of congenital myasthenic syndromes	Catalyst Pharmaceuticals

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
389	amifampridine phosphate	n/a	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Catalyst Pharmaceuticals, Inc.
390	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Clinigen Group plc
391	Amifostine	Ethyol	10/4/1999	Treatment of myelodysplastic syndromes.	Clinigen Group plc
392	Amifostine	Ethyol	11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Clinigen Group plc
393	Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc.
394	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Clinigen Group plc
395	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc.
396	amikacin sulfate	n/a	1/5/2015	Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	PlumeStars s.r.l.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
397	Aminocaproic acid	Caprogel	1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School
398	aminolevulinic acid hydrochloride	Levulan	3/20/2007	Treatment of esophageal dysplasia	DUSA Pharmaceuticals, Inc.
399	Aminosalicylic acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Jacobus Pharmaceutical Company
400	Aminosidine	Gabbromicina	11/15/1993	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D.
401	Aminosidine	Gabbromicina	5/14/1993	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D.
402	Aminosidine	Paromomycin	9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D.
403	aminosidine	Paromomycin	3/29/2005	Treatment of visceral leishmaniasis	The Institute for One World Health
404	Amiodarone	Amio-Aqueous	8/17/1993	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc.
405	Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories
406	amitriptyline and ketamine	Amiket(Tm)	1/19/2010	Treatment of postherpetic neuralgia	Immune Pharmaceuicals, Inc.
407	ammonium tetrathiomolybdate	n/a	5/5/2008	Treatment of idiopathic pulmonary fibrosis	Pipex Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
408	Ammonium tetrathiomolybdate	Coprexa	1/31/1994	Treatment of Wilson's disease.	Pipex Pharmaceuticals, Inc.
409	amphotericin B	n/a	9/15/2010	Treatment of visceral leishmaniasis.	iCo Therapeutics Inc.
410	Amphotericin B inhalation powder	n/a	12/15/2005	Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies	Novartis Pharmaceuticals Corporation
411	Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Liposome Company, Inc.
412	Amyl nitrite, sodium nitrite, sodium thiosulfate	Cyanide Antidote Kit	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
413	amylopectin	n/a	3/24/2015	Treatment of glycogen storage disease types Ia and Ib	Michael K. Davis, MD, MBA
414	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/2011	Treatment of hemophilia B	uniQure, B.V.
415	ANA-conjugated dactunomycin nanoemulsion	n/a	7/7/2015	Treatment of Ewing sarcoma	NanoSmart Pharmaceuticals, Inc.
416	Anagrelide	Agrylin	7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
417	Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp.
418	Anagrelide	Agrylin	6/11/1985	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp.
419	anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Swedish Orphan Biovitrum AB (publ)
420	Ananain, comosain	Vianain	1/21/1992	For the enzymatic debridement of severe burns.	Genzyme Corporation
421	Anatibant	n/a	4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Xytis, Inc.
422	Ancrod	Viprinex	10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
423	andexanet alfa	n/a	2/23/2015	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	Portola Pharmaceuticals
424	anfibatide	n/a	3/10/2016	Treatment of thrombotic thrombocytopenic purpura.	Lee's Pharmaceutical (Hong Kong) Limited
425	Angiotensin (1-7)	n/a	11/26/2013	Treatment of limb-girdle muscular dystrophy	US Biotest, Inc.
426	Angiotensin (1-7)	n/a	2/8/2016	Treatment of LAMA2-related muscular dystrophy	Tarix Orphan, LLC
427	angiotensin (1-7)	n/a	8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	US Biotest, Inc.
428	angiotensin (1-7)[A(1-7)]	n/a	7/25/2013	Treatment of Duchenne muscular dystrophy	US Biotest, Inc.
429	angiotensin 1-7	n/a	1/29/2010	Treatment of sarcoma.	W. Jeffrey Petty, MD

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
430	Angiotensin 1-7	Marstem	8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation
431	Angiotensin 1-7	n/a	2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals
432	angiotensin 1-7	n/a	6/17/2010	To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and aneima)in hematopoietic stem cell transplants.	US Biotest, Inc.
433	Angiotensin-(1-7)	n/a	9/13/2011	Treatment of pulmonary arterial hypertension.	US Biotest, Inc.
434	anisina	n/a	7/14/2015	Treatment of neuroblastoma.	Novogen Ltd
435	anlotinib hydrochloride	n/a	12/31/2015	Treatment of ovarian cancer	Advenchen Laboratories, LLC
436	antagonist of the complement 5a receptor	n/a	11/17/2014	Treatment of atypical hemolytic uremic syndrome	ChemoCentryx, Inc.
437	antagonist of the complement 5a receptor	n/a	6/2/2014	Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome.	ChemoCentryx, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
438	antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9	n/a	12/23/2014	Treatment of Waldenstrom's macroglobulinemia	Idera Pharmaceuticals, Inc.
439	anthrax immune globulin (human)	n/a	7/29/2008	Treatment of inhalational anthrax	Cangene Corp. - Emergent Biosolutions
440	Anthrax Vaccine Adsorbed	Biothrax	4/11/2014	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Emergent BioDefense Operations Lansing LLC
441	anti human Nogo-A human monoclonal antibody	n/a	10/20/2008	Treatment of acute spinal cord injury	Novartis Pharmaceuticals Corporation
442	anti-Beta1 integrin monoclonal antibody	n/a	1/13/2015	Treatment of ovarian cancer	OncoSynergy, Inc.
443	Anti-Beta1 integrin monoclonal antibody	n/a	8/7/2014	Treatment of glioblastoma	OncoSynergy, Inc.
444	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/2013	Treatment of graft versus host disease	Xenikos BV
445	anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/2008	Treatment of Hodgkin lymphoma	Xencor, Inc.
446	Anti-eTau Humanized IgG4 Monoclonal Antibody	n/a	5/13/2015	Treatment of Progressive Supranuclear Palsy	Britol-Myers Squibb Company
447	anti-HER2 bispecific antibody	n/a	5/18/2016	Treatment of ovarian cancer	Zymeworks, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
448	anti-inhibitor coagulant complex	Feiba	4/12/2013	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Baxalta US, Inc.
449	anti-interferon-gamma Fab from goats	n/a	11/18/2003	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, Inc.
450	anti-Lewis Y humanized monoclonal antibody	n/a	3/9/2012	Treament of ovarian cancer	Recepta Biopharma S.A.
451	anti-sense oligonucleotide consisting of 2Ã¿Æ¿Ã¿â¿¿Ã¿â¿¿Ã¿Â¢Ã¿Æ¿Ã¿Â¢Ã¿Â¢Ã¢â¿¿Â¬Ã¿Â¡Ã¿â¿¿Ã¿Â¬Ã¿Æ¿Ã¿Â¢Ã¿Â¢Ã¢â¿¿Â¬Ã¿Â¾Ã¿â¿¿Ã¿Â¢0-Me RNA with a phosphorothioate backbone	n/a	9/23/2013	Treatment of cystic fibrosis	ProQR Therapeutics III B.V.
452	Anti-T cell receptor murine monoclonal antibody	n/a	4/3/2009	Prophylaxis of acute rejection of solid organ transplantation	Tolera Therapeutics, Inc.
453	anti-T-lymphocyte immune globulin, rabbit	Atg-Fresenius(R)	3/26/2010	Prevention of graft versus host disease (GVHD)	Neovii Biotech NA, Inc.
454	anti-T-lymphocyte immune globulin, rabbit	n/a	9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Neovii Biotech NA, Inc.
455	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	1/12/2011	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Tolera Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
456	anti-TCR murine monoclonal antibody (MAb, type IgM)	n/a	6/7/2010	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	Tolera Therapeutics, Inc.
457	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/2005	Treatment of primary malignant brain tumors	Bradmer Pharmaceuticals, Inc.
458	anti-thymocyte globulin [rabbit]	Thymoglobulin	5/25/2010	Prophylaxis of acute organ rejection in patients receiving renal transplants	Genzyme Corporation
459	Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/1993	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research
460	anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)	n/a	11/17/2014	Treatment of pediatric ulcerative colitis (0 through 16 years of age)	Avaxia Biologics, Incorporated
461	antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/2002	Treatment of renal cell carcinoma	AEterna Zentaris, Inc.
462	antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E	n/a	7/21/2014	Treatment of gastric cancer	Millennium Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
463	Antiepilepsirine	n/a	3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital
464	Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Grifols Biologicals Inc.
465	Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation
466	Antihemophilic factor (recombinant)	Refacto, Xyntha	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Wyeth Pharmaceuticals, Inc.
467	antihemophilic factor (recombinant), Fc fusion protein	Eloctate	11/23/2010	Treatment of hemophilia A	Biogen Idec Inc.
468	antihemophilic factor (recombinant), porcine sequence	Obizur	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Baxalta US, Inc.
469	Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	CSL Behring

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
470	antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/2012	Treatment of mesothelioma	Bayer HealthCare Pharmaceuticals, Inc.
471	antineoplaston A10, antineoplaston AS2-1	n/a	11/21/2008	Treatment of gliomas	Burzynski Research Institute, Inc.
472	antinuclear antibody conjugated liposomal doxorubicin	n/a	2/3/2015	Treatment of Ewing's sarcoma.	NanoSmart Pharmaceuticals, Inc.
473	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/2005	Treatment of acute myeloid leukemia	Lorus Therapeutics, Inc.
474	antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc
475	antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA	n/a	5/25/2016	Treatment of Leber's congenital amaurosis.	ProQR Therapeutics IV B.V.
476	Antisense oligonucleotide directed against connexin43	Nexagon	4/27/2009	Treatment of persistent corneal epithelial defects	CoDa Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
477	antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	n/a	7/24/2012	Treatment of familial amyloid polyneuropathy	Isis Pharmaceuticals, Inc.
478	Antisense oligonucleotide targeted to the huntingtin protein	n/a	12/29/2015	Treatment of Huntington's disease	Isis Pharmaceuticals, Inc.
479	Antithrombin III (human)	Thrombate Iii	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation
480	Antithrombin III (human)	Atnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB
481	Antithrombin III human	Antithrombin Iii Human	1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross
482	Antivenin crotaline (pit-viper) equine immune F(ab)2)	Anavip	1/29/2004	Treatment of envenomation by Crotaline snakes	Rare Disease Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
483	Antivenin, crotalidae polyvalent immune Fab (ovine)	Crofab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc.
484	Antivenom (crotalidae) purified (avian)	n/a	2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc.
485	antroquinonol	Hocena(R)	4/30/2015	Treatment of acute myeloid leukemia	Golden Biotechnology Corporation
486	antroquinonol	n/a	7/23/2015	Treatment of hepatocellular carcinoma	Golden Biotechnology Corporation
487	antroquinonol	n/a	1/21/2015	Treatment of pancreatic cancer	Golden Biotechnology Corp.
488	aphidicolin	n/a	4/20/2016	Treatment of Ebola virus infection	Biospherics.net LLC
489	apolipoprotein E mimetic peptide	n/a	12/3/2012	Treatment of homozygous familial hypercholesterolemia	LipimetiX Development, LLC
490	Apomorphine	n/a	7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc.
491	Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	US WorldMeds, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
492	Apomorphine hydrochloride	n/a	5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	NeuroHealing Pharmaceuticals, Inc.
493	apremilast	n/a	1/17/2013	Treatment of Behcet's disease	Celgene Corporation
494	Aprotinin	Trasylol	11/17/1993	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	Bayer Corporation
495	AQ-13 (4-aminoquinoline analog)	n/a	9/12/2008	Treatment of malaria	Immtech Pharmaceuticals, Inc.
496	Arenegyr	n/a	8/22/2008	Treatment of malignant pleural mesothelioma	MolMed S.p.A.
497	Arginine butyrate	n/a	4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
498	arimoclomol	n/a	3/29/2005	Treatment of amyotrophic lateral sclerosis	CytRx Corporation
499	arimoclomol citrate	n/a	1/13/2015	Treatment of Neimann-Pick disease, type C	Orphazyme ApS
500	aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Otsuka Pharmaceutical Development
501	arsenic	Trisenox	11/2/2001	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Teva Branded Pharmaceutical Products R&D, Inc.
502	Arsenic trioxide	Trisenox	3/4/2005	Treatment of malignant glioma	Teva Branded Pharmaceutical Products R&D, Inc.
503	Arsenic trioxide	Trisenox	5/13/2003	Treatment of chronic lymphocytic leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
504	arsenic trioxide	Trisenox	6/13/2003	Treatment of liver cancer	Teva Branded Pharmaceutical Products R&D, Inc.
505	Arsenic trioxide	Trisenox	4/28/2000	Treatment of multiple myeloma.	TEVA Branded Pharmaceutical Products R & D, Inc.
506	arsenic trioxide	Trisenox	7/17/2000	Treatment of myelodysplastic syndrome.	Teva Branded Pharmaceutical Products R&D, Inc.
507	arsenic trioxide	Trisenox	10/18/2001	Treatment of chronic myeloid leukemia	Teva Branded Pharmaceutical Products R*D, Inc.
508	Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Cephalon

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
509	arsenic trioxide capsule (oral)	n/a	11/2/2015	Treatment of acute promyelocytic leukemia.	Orsenix Holdings BV
510	artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Novartis Pharmaceuticals
511	Artesunate	n/a	3/28/2006	Immediate treatment of malaria	US Army Medical Materiel Development Activity
512	Artesunate	n/a	7/19/1999	Treatment of malaria.	World Health Organization
513	arylsulfatase A (rhASA)	n/a	2/27/2008	Treatment of metachromatic leukodystrophy	Shire Human Genetic Therapies, Inc.
514	Ascorbic acid	Ascor L 500	8/31/2007	Treatment of scurvy	McGuff Pharmaceuticals Inc.
515	ascorbic acid	n/a	5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Murigenetics SAS
516	Asfotase alfa	Strensiq	9/12/2008	Treatment of hypophosphatasia	Alexion Pharmaceuticals, Inc.
517	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	GlaxoSmithKline Biologicals, S.A.
518	ataluren	n/a	9/1/2015	Treatment of aniridia	PTC Therapeutics, Inc.
519	ataluren	Translarna	12/10/2014	Treatment of mucopolysaccharidosis type I	PTC Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
520	ataluren	n/a	3/10/2008	Treatment of spinal muscular atrophy	PTC Therapeutics, Inc.
521	ataluren	n/a	9/1/2004	For use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene	PTC Therapeutics, Inc.
522	ataluren	n/a	1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene	PTC Therapeutics, Inc.
523	Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc.
524	Atovaquone	Mepron	8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development
525	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/2007	Treatment of primary central nervous system malignancies	TVAX Biomedical, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
526	auranofin	Ridaura	4/30/2010	Treatment of amebiasis	Ctr for Discovery & Innovation in Parasitic Diseas
527	autologous adipose derived mesenchymal stromal cells	n/a	10/22/2014	Treatment of amyotrophic lateral sclerosis	Mayo Clinic
528	autologous adipose tissue derived mesenchymal stem cells	n/a	5/4/2016	Treatment of Buerger's disease (thromboangiitis obliterans).	Biostar Stem Cell Research Institute
529	autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA	n/a	10/21/2014	Treatment of adenosine deaminase deficient severe combined immunodeficiency	Donald B. Kohn, MD - Professor, UC-UCLA
530	Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)	n/a	11/13/2014	Treatment of acute lymphoblastic leukemia (ALL)	Juno Therapeutics, Inc.
531	autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)	n/a	1/15/2015	Treatment of severe combined immune deficiency-X1	Boston Children's Hospital

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
532	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/2010	Treatment of Wiskott Aldrich syndrome	GlaxoSmithKline Intellectual Property Development
533	autologous CD34+ hematopoietic stem cells tranduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/2012	Treatment of andrenoleukodystrophy	bluebird bio, Inc.
534	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	2/26/2014	For the treatment of Sickle Cell Disease	bluebird bio Inc.
535	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/2013	Treatment of B-thalassemia major and intermedia	bluebird bio, Inc.
536	autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor	n/a	4/27/2016	Treatment of diffuse large B-cell lymphoma	Juno Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
537	autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	11/6/2014	Treatment of acute lymphoblastic leukemia (inclusive of B-cell acute lymphoblastic leukemia)	Juno Therapeutics, Inc.
538	Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against the NY-ESO-1 protein	n/a	3/28/2016	Treatment of soft tissue sarcoma.	Adaptimmune, LLC
539	autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/2013	Prevention of graft rejection following solid organ transplantation	iREG Medical AB
540	Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/2007	Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy	Cellular Bioengineering, Inc.
541	autologous dendritic cells pulsed with allogeneic tumor cell lysate	n/a	5/6/2014	Treatment of malignant mesothelioma	Amphera BV
542	Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	Dcvax-Brain	11/29/2002	Treatment of primary brain malignant cancer	Northwest Biotherapeutics, Inc.
543	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1-glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/2010	Treatment of ovarian cancer.	Prima Biomed Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
544	Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc.
545	Autologous Engineered Skin Substitute	Permaderm	6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Amarantus BioScience Holdings, Inc.
546	autologous Epstein-Barr virus specific T-cells	n/a	3/9/2015	Treatment of Epstein-Barr virus positive non-Hodgkin lymphomas.	Cell Medica, Inc.
547	autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2Ã¢â¿¬â¿¢-deoxycytidine	Alecsat	9/13/2013	Treatment of glioblastoma multiforme	CytoVac A/S
548	autologous ex vivo expanded polyclonal CD4+CD25+CD1271o/-FOXP3+ Regulatory T cells	n/a	5/10/2016	Treatment of type 1 diabetes mellitus with residual beta cell function	Caladrius Biosciences
549	autologous genetically modified human dermal fibroblasts	n/a	6/10/2014	Treatment of dystrophic epidermolysis bullosa.	Fibrocell Technologies, Inc.
550	Autologous incubated macrophage	n/a	9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Proneuron Biotechnologies, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
551	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Theralux Photodynamic Therapy	4/3/2008	Treatment of chronic graft versus host disease	Kiadis Pharma Canada, Inc.
552	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Biovest International, Inc.
553	autologous neo-uninary conduit	n/a	6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Tengion, Inc.
554	Autologous olfactory neural progenitors	Rhinocytes	2/1/2008	Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C	RhinoCyte, Inc.
555	autologous olfactory neural progenitors	Rhinocytes	12/31/2008	Treatment of amyotrophic lateral sclerosis	RhinoCyte, Inc.
556	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	TissueTech, Inc.
557	autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	Kite Pharma, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
558	autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	3/14/2014	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
559	Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	1/31/2014	For the treatment of Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals Corporation
560	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/28/2016	Treatment of mantle cell lymphoma.	Kite Pharma, Inc.
561	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/25/2016	Treatment of follicular lymphoma.	Kite Pharma, Inc.
562	Autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/2016	Treatment of acute lymphoblastic leukemia. (ALL).	Kite Pharma, Inc.
563	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/2016	Treatment of chronic lymphocytic leukemia.	Kite Pharma, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
564	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/2016	Treatment of primary mediastinal B-cell lymphoma.	Kite Pharma, Inc.
565	autologous T-lymphocytes transduced with anti-BCMA02 CAR lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the human B cell maturation antigen	n/a	5/11/2016	Treatment of multiple myeloma	bluebird bio, Inc.
566	autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line	n/a	5/6/2015	Treatment of glioblastoma	Sebastiano Gattoni-Celli, MD
567	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/2002	Treatment of renal cell carcinoma	Agenus, Inc.
568	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/2002	Treatment of metastatic melanoma	Agenus, Inc.
569	autologous umbilical cord blood	n/a	7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Duke University
570	autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Glaxo Group Limited

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
571	Autolymphocyte therapy	n/a	7/12/1994	Treatment of renal cell carcinoma.	Cytogen Corporation
572	avicin d	n/a	3/24/2015	Treatment of multiple myeloma	Avicin Therapeutics Ltd.
573	aviptadil	n/a	2/22/2005	Treatment of pulmonary arterial hypertension	Mondobiotech Laboratories AG
574	Azacitidine	Vidaza	6/18/2008	Treatment of acute myeloid leukemia	Celgene Corporation
575	azacitidine	Vidaza	12/3/2001	Treatament of myelodysplastic syndromes	Celgene Corporation
576	Azathioprine	Imuran	9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc.
577	aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Gilead Sciences (formerly Corus Pharma)
578	Azurin-p28	n/a	12/2/2015	Treatment of glioma.	CDG Therapeutics, Inc.
579	Bacillus Calmette-Guerin vaccine	n/a	8/9/2006	Treatment of stage IIb through IV metastatic melanoma	OncoVac Corporation
580	Bacillus subtilis oxalate decarboxylase	n/a	2/29/2016	Treatment of pediatric hyperoxaluria	Allena Pharmaceuticals
581	Bacitracin	Altracin	3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
582	Baclofen	Lioresal Intrathecal	9/26/1994	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc.
583	baclofen	Lioresal Intrathecal	11/10/1987	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc.
584	baclofen	n/a	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Metacel Pharmaceuticals, LLC
585	baclofen	Gablofen	10/28/2015	Treatment of complex regional pain syndrome.	Mallinckrodt, Inc.
586	baclofen	n/a	12/2/2003	Treatment of dystonia	Medtronic Neurological
587	bacterium Bacteroides thetaiotaomicron	n/a	9/26/2013	Treatment of active Crohn's disease in the pediatric population	4D Pharma Research Ltd
588	Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Salix Pharmaceuticals, Inc.
589	Bardoxolone	n/a	8/6/2008	Treatment of pancreatic cancer	Reata Pharmaceuticals, Inc.
590	bardoxolone	n/a	3/30/2015	Treatment of pulmonary arterial hypertension	Reata Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
591	Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation
592	basimglurant	n/a	3/9/2012	Treatment of Fragile X Syndrome	Hoffmann-La Roche, Inc.
593	beclomethasone	n/a	3/4/2009	Treatment of pediatriac patients with ulcerative colitis	Aptalis Pharma US, Inc.
594	beclomethasone 17,21-dipropionate	n/a	11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Soligenix, Inc
595	beclomethasone 17,21-dipropionate	Orbec(R)	7/24/2009	Treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation	Soligenix, Inc.
596	beclomethasone 17,21-dipropionate	Bec	8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Soligenix, Inc.
597	beclomethasone 17,21-diproprionate	n/a	12/18/2007	Treatment of pediatric patients with Crohn disease.	Soligenix, Inc.
598	Beclomethasone dipropionate	n/a	3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Soligenix, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
599	bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol	Sirturo	1/10/2005	Treatment of active tuberculosis	Janssen Research & Development, LLC
600	belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Bristol-Myers Squibb Company
601	Belinostat	Beleodaq	9/3/2009	Treatment of peripheral T-cell lymphoma (PTCL).	Spectrum Pharmaceuticals, Inc.
602	beloranib	n/a	1/15/2013	Treatment of Prader-Willi syndrome	Zafgen, Inc.
603	bendamustine for 50 ml admixture	Bendeka	7/2/2014	Treatment of chronic lymphocytic leukemia	Eagle Pharmaceuticals, INc.
604	bendamustine for 50ml admixture	Bendeka	7/2/2014	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Eagle Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
605	bendamustine hydrochloride	Treanda	11/26/2013	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Cephalon, Inc.
606	Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Cephalon, Inc.
607	bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/2013	Treatment of chronic lymphocytic leukemia	Supratek Pharma, Inc.
608	Bendamustine oral doseage formulation	n/a	11/5/2015	Treatment of chronic lymphocytic leukemia	Exinda Theapeutics LLC
609	benznidazole	n/a	4/14/2014	Treatment of Chagas disease	Chemo Research, S.L.
610	benzoate	Naben	7/6/2012	Treatment of pediatric schizophrenia	SyneuRx International (Taiwan) Corp.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
611	Benzoate and phenylacetate	Ucephan	1/21/1986	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	ImmunexImmunex
612	benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp.
613	Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide	Total Block Vl Spf 75	8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd.
614	Benzydamine hydrochloride	Tantum	5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc.
615	Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid	Pre-Pen/Mdm	9/28/1987	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	AllerQuest LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
616	Beractant	Survanta Intratracheal Suspension	12/20/1993	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories
617	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome	Ross Laboratories
618	Beraprost	n/a	4/29/1999	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	LungRx, Inc.
619	beraprost sodium 314d	n/a	12/22/2011	Treatment of pulmonary arterial hypertension	Lung Rx, Inc.
620	Beta alethine	Betathine	3/24/1997	Treatment of metastatic melanoma.	Dovetail Technologies, Inc.
621	Beta alethine	Betathine	3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.
622	Betahistine dihydrochloride	n/a	11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Floyd R. Sallee, M.D., Ph.D.
623	Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Jazz Pharmaceuticals
624	betamethasone	n/a	10/7/2015	Treatment of Ataxia Telangiectasia.	Grace Therapeutics, LLC
625	Betulinic acid	n/a	8/9/2007	Topical treatment of metastatic melanoma	Advanced Life Sciences, Inc. (ALS)

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
626	bevacizumab	Avastin	10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Genentech, Inc.
627	bevacizumab	Avastin	11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Genentech, Inc.
628	bevacizumab	n/a	10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Terence M. Davidson, MD
629	bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Genentech, Inc.
630	bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma	Genentech, Inc.
631	bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Genentech, Inc.
632	bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Genentech, Inc.
633	bevacizumab	Avastin	10/20/2004	Treatment of pancreatic cancer	Genentech, Inc.
634	bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Genentech, Inc.
635	bevacizumab	n/a	3/10/2016	Treatment of Coat's disease	MicroSert, Ltd.
636	bevacizumab	Avastin	1/27/2016	Treatment of mesothelioma	Genentech, Inc.
637	Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Eisai, Inc.
638	bezafibrate	Bezalip	7/24/2013	For therapeutic treatment of Barth syndrome	Barth Sydrome Foundation, Inc.
639	BF2.649 (Pitolisant)	n/a	5/17/2010	Treatment of narcolepsy	Bioprojet Pharma
640	bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine	Fang	10/22/2014	Treatment of Ewing's sarcoma	Gradalis, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
641	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	4/18/2011	Treatment of ovarian cancer	Gradalis, Inc.
642	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	2/17/2012	Treatment of stage IIB to IV melanoma	Gradalis, Inc.
643	bifidobacterium infantis 35624	n/a	3/24/2008	Treatment of pediatric ulcerative colitis	Alimentary Health Limited
644	bifidobacterium longum infantis 35624	n/a	1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health Limited
645	Bindarit	n/a	2/3/1998	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc.
646	binimetinib	n/a	7/31/2014	Treatment of ovarian cancer	Array Biopharma, Inc.
647	binimetinib	n/a	11/19/2013	Treatment Stage IIB-IV melanoma.	Array BioPharma, Inc.
648	Bio-engineered oral mucosal tissue	n/a	4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	TissueTech, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
649	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc.
650	biocarbonate infusate	Normocarb Hf	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Dialysis Solutions, Inc.
651	Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/2000	Treatment of sickle cell disease.	ICAgen Inc.
652	bisantrene HCl	n/a	2/14/2014	Treatment of acute myeloid leukemia	Update Pharma, Inc.
653	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Merrimack Pharmaceuticals, inc.
654	bispecific antibody (monoclonmal antibody)	n/a	8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Merrimack Pharmaceuticals, Inc.
655	bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Sanofi-Aventis US, Inc.
656	bivalent anti-human myostatin adnectin-IgG1	n/a	2/10/2015	Treatment of duchenne muscular dystrophy	Bristol-Myers Squibb Co.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
657	bivalirudin	Angiomax	11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	The Medicines Company
658	Bleomycin	Blenoxane	2/9/1999	Treatment of pancreatic cancer.	Genetronics, Inc.
659	Bleomycin	n/a	12/20/2010	Treatment of pancreatic cancer.	CIRJ Company Ltd.
660	Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute
661	blinatumomab	n/a	2/6/2006	Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement	Amgen, Inc.
662	blinatumomab	n/a	5/16/2008	Treatment for hairy cell leukemia.	Amgen, Inc.
663	Blinatumomab	n/a	5/16/2008	Treatment of chronic lymphocytic leukemia	Amgen, Inc.
664	blinatumomab	n/a	5/16/2008	Treatment of acute lymphocytic leukemia	Amgen, Inc.
665	blinatumomab	n/a	5/16/2008	Treatment of prolymphocytic leukemia	Amgen, Inc.
666	Bone marrow-derived mononuclear cells	n/a	5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	t2cure GmbH
667	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
668	bortezomib	Velcade	5/30/2012	Treatment of mantle cell lymphoma.	Millennium Pharmaceuticals, Inc.
669	bortezomib	Velcade	2/3/2015	Treatment of acute lymphoblastic leukemia	Millennium Pharmaceuticals, Inc.
670	bortezomib	Velcade	1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.
671	Bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd.
672	bosutinib	Bosulf	2/24/2009	Treatment of chronic myelogenous leukemia	Wyeth Pharmaceuticals, Inc.
673	Botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc.
674	Botulinum toxin type A	Dysport	8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Biopharm Limited
675	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
676	Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited
677	Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Allergan, Inc.
678	Botulinum toxin type A	Dysport	3/23/1989	Treatment of essential blepharospasm.	Porton International, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
679	Botulinum toxin type A	n/a	9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc.
680	Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Soltice Neurosciences, LLC
681	Botulinum toxin type F	n/a	10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited
682	botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)	n/a	6/29/2011	Treatment of botulism.	Cangene Corporation
683	Botulism immune globulin	Babybig	1/31/1989	Treatment of infant botulism.	California Department of Health Services
684	Bovine colostrum	n/a	11/19/1990	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM
685	Bovine immunoglobulin concentrate, Cryptosporidium parvum	Sporidin-G	3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc.
686	bovine lactoferrin	n/a	2/19/2015	Prevention of late-onset sepsis in very low birth weight infants	Metrodora Therapeutics, LLC
687	bovine lactoferrin	n/a	2/23/2015	Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams)	Metrodora Therapeutics, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
688	Bovine whey protein concentrate	Immuno-C	9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc.
689	Branched chain amino acids	n/a	12/23/1988	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center
690	brentuximab vedotin	Adcetris	10/23/2008	Treatment of anaplastic large cell lymphoma	Seattle Genetics, Inc.
691	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.
692	brentuximab vedotin	Adcetris	9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	Seattle Genetics, Inc.
693	brentuximab vedotin	n/a	5/23/2016	Treatment of adult T-cell leukemia/lymphoma	Seattle Genetics, Inc.
694	brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Seattle Genetics, Inc.
695	brentuximab vedotin	Adcetris(R)	1/31/2014	Treatment of patients with diffuse large B-cell lymphoma.	Seattle Genetics, Inc.
696	brentuximab vedotin	Adcetris	4/15/2013	Treatment of patients with peripheral T-cell lymphoma, not otherwise specified	Seattle Genetics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
697	brigatinib	n/a	4/28/2016	Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).	ARIAD Pharmaceuticals, Inc.
698	brilliant blue G	Brilliant Peel	12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Fluron GmbH - Subsidiary of Geuder AG
699	Brilliant Blue G	Dorc Ilm-Blue	7/31/2012	To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders	Dutch Opthalmic Research Center
700	Brimonidine	Alphagan	2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc.
701	Brivaracetam	n/a	10/5/2005	Treatment of symtomatic myoclonus	UCB Pharma, Inc.
702	Broxuridine	Broxine/Neomark	9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc.
703	Bruton's Tyrosine Kinase (Btk) Inhibitor	n/a	5/13/2015	Treatment of chronic lymphocytic leukemia (CLL).	Acerta Pharma BV
704	bryostatin 1	n/a	3/31/2015	Treatment of Fragile X Syndrome.	Neurotrope BioScience, Inc.
705	bryostatin-1	n/a	12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
706	Bucillamine	n/a	10/22/2015	Treatment of cystinuria	Revive Therapeutics, Ltd.
707	budesonide	n/a	12/20/2006	Treatment of patients with eosinophilic esophagitis	Shire ViroPharma Incorporated
708	budesonide	Nefecon	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Pharmalink AB
709	budesonide	Uceris	5/6/2013	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Santarus, Inc.
710	Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma	Lukare Medical, LLC
711	Buffered Ursodeoxycholic Acid	Ursocarb	9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Digestive Care, Inc.
712	bupivacaine	Transdur	6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	Impax Laboratories, Inc.
713	bupivacaine hydrochloride	n/a	5/31/2016	treatment of pain associated with postherpetic neuralgia.	Grace Therapeutics, LLC
714	Buprenorphine hydrochloride	Subutex	6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
715	buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Reckitt Benckiser Pharmaceuticals, Inc.
716	busulfan	Partaject	11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc.
717	Busulfan	Spartaject	7/7/1997	Treatment of primary brain malignancies.	SuperGen, Inc.
718	Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Otsuka Pharmaceutical Company
719	Busulfan	Spartaject	4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc.
720	Buthionine sulfoxamine	n/a	10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
721	Buthionine sulfoxamine	n/a	10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	USC-CHLA Institute for Pediatric Clinical Research
722	butylidenephthalide	n/a	8/5/2015	Treatment of Malignant Glioma	Everfront Biotech, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
723	Butyrylcholinesterase	n/a	3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc.
724	Butyrylcholinesterase	n/a	9/30/1992	Treatment of post-surgical apnea.	Shire Laboratories Inc.
725	C1 esterase inhibitor (human)	Cinryze(R)	7/16/2004	Treatment of angioedema	Shire
726	C1 esterase inhibitor (human)	n/a	8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation
727	C1-esterase inhibitor (recombinant)	Ruconest	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Santarus, Inc.
728	C1-esterase-inhibitor, human, pasteurized	Berinert	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	CSL Behring LLC
729	C20-D3-retinyl acetate	n/a	9/16/2010	Treatment of Stargardt's disease	Alkeus pharmaceuticals, Inc.
730	C21H27O10P	Minnelide	3/30/2015	Treatment of gastric cancer.	Minneamrita Therapeutics, LLC
731	C24H28N8O7S2	n/a	4/2/2015	Treatment of diffuse large B-cell lymphoma (DLBCL).	Curis, Inc.
732	C66H100N6O27	n/a	3/11/2013	Treatment of of hepatocellular carcinoma	GenSpera, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
733	cabozantinib	Cometriq	11/29/2010	Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.	Exelixis, Inc.
734	Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	O.P.R. Development, L.P.
735	caffeine and sodium benzoate	n/a	8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Luitpold Pharmaceuticals, Inc.
736	Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation
737	Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Fresenius Medical Care North America
738	Calcium acetate	n/a	6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company
739	calcium benzoate and risperidone	n/a	12/20/2010	Treatment of pediatric patients with schizophrenia	University of California, Los Angeles
740	Calcium carbonate	R & D Calcium Carbonate/600	6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc.
741	Calcium gluconate	Calgonate	11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
742	Calcium gluconate gel	H-F Gel	5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calgonate Corporation
743	Calcium gluconate gel 2.5%	n/a	9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc.
744	calfactant	Infasurf	9/5/2000	Treatment of acute respiratory distress syndrome (ARDS)	ONY, Inc.
745	calfactant	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc.
746	camostat	n/a	5/18/2011	Treatment of chronic pancreatitis	NIXS Corporation
747	canakinumab	Ilaris	12/5/2013	Treatment of familial mediterranean fever	Novartis Pharmaceuticals Corporation
748	canakinumab	Ilaris	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Novartis Pharmaceuticals Corporation
749	canakinumab	Ilaris	12/5/2013	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Novartis Pharmaceuticals Corporation
750	canakinumab	n/a	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Novartis Pharmaceuticals Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
751	canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Novartis Pharmaceuticals Corporation
752	cannabidiol	n/a	8/20/2014	Treatment of glioblastoma multiforme	Insys Therapeutics, Inc.
753	cannabidiol	n/a	4/19/2016	Treatment of tuberous sclerosis complex.	GW Pharma Ltd.
754	cannabidiol	n/a	2/23/2016	Treatment of Fragile X syndrome	Zynerba Pharmaceuticals, Inc.
755	cannabidiol	n/a	6/23/2014	Treatment of Lennox-Gastaut syndrome	Insys Therapeutics, Inc.
756	cannabidiol	n/a	7/23/2015	Treatment of infantile spasms	Insys Therapeutics, Inc.
757	cannabidiol	n/a	11/17/2014	Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)	Insys Therapeutics, Inc.
758	cannabidiol	n/a	7/1/2014	Treatment of Dravet syndrome	Insys Therapeutics, Inc.
759	cannabidiol	n/a	9/24/2014	Treatment of glioma	Insys Therapeutics, Inc.
760	cannabidiol	n/a	7/14/2015	Prevention of Graft versus Host Disease (GVHD).	Talent biotechs Ltd.
761	cannabidiol	n/a	4/22/2015	Treatment of neonatal hypoxic ischemic encephalopathy	GW Pharma Ltd.
762	cannabidiol	n/a	11/14/2013	Treatment of Dravet syndrome.	GW Pharma Ltd.
763	cannabidiol;	n/a	2/27/2014	Treatment of Lennox-Gastaut syndrome	GW Pharma Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
764	cantharidin	n/a	7/24/2012	Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa	Orenova Group, LLC
765	cantrixil	n/a	4/20/2015	Treatment of ovarian cancer	CanTx, Inc.
766	caprine hyperimmune serum against HIV lysate	n/a	10/28/2009	Treatment of amyotrophic lateral sclerosis	Daval International Limited
767	caprine hyperimmune serum against HIV lysate	n/a	2/14/2014	Treatment of systemic sclerosis	Daval International Limited
768	Capsaicin	n/a	9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Centrexion Corporation
769	capsaicin	Qutenza	5/2/2003	Treatment of painful HIV-associated neuropathy	Acorda Therapeutics, Inc.
770	capsaicin	n/a	10/23/2002	Treatment of erythromelalgia	Acorda Therapeutics, Inc.
771	Capsaicin	n/a	8/3/2005	Treatment of postherpetic neuralgia.	TheraQuest Biosciences, LLC
772	capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Acorda Therapeutics, Inc.
773	carbenoxolone	n/a	7/2/2014	Treatment of Huntington's Disease	Oxalys Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
774	carbetocin	n/a	4/11/2014	Treatment of Prader Willi syndrome	Ferring Pharmaceuticals, Inc.
775	carbon dioxide	n/a	12/17/2015	Treatment of trigeminal neuralgia	Capnia, Inc.
776	carbon monoxide	n/a	9/28/2012	Treatment of sickle cell disease	Hillhurst Biopharmaceuticals, Inc.
777	carboxy pyrrolidine hexanoyl pyrrolidine carboxylate	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline
778	cardiotrophin-1	n/a	10/16/2014	Prevention of ischemia-reperfusion injury in kidney transplant recipients	Digna Biotech, S.L.
779	cardiotrophin-1	n/a	6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Digna Biotech, S.L.
780	cardiotrophin-1	n/a	9/13/2011	Treatment of acute liver failure	Digna Biotech S.L.
781	carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
782	carglumic acid	Carbaglu	6/17/2014	Treatment of organic acidemias	Orphan Europe SARL
783	carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe SARL
784	carisbamate	n/a	3/16/2012	Management of patients with infantile spasms	SK Life Science, Inc.
785	carlumab	n/a	10/24/2006	Treatment of pancreatic cancer	Centocor, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
786	Carmustine	n/a	7/3/2000	Treatment of intracranial malignancies.	Direct Therapeutics, Inc.
787	Cascara sagrada fluid extract	n/a	3/21/1989	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation
788	CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid	n/a	2/18/2016	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	Bellicum Pharmaceuticals, Inc.
789	catumaxomab	n/a	7/1/2009	Treatment of gastric cancer	Neoviibiotech North America, Inc.
790	Catumaxomab	Removab	6/9/2006	Treatment of ovarian cancer	Neoviibiotech North America, Inc.
791	CD40/CD80/CD86 modified autologous dendritic cell therapy	n/a	12/20/2013	Treatment Type 1 diabetes mellitus patients with residual beta cell function	DiaVacs, Inc.
792	cediranib	n/a	12/13/2010	Treatment of glioblastoma	National Institutes of Health
793	Ceftriaxone sodium	Rocephin	3/28/2006	Treatment of amyotrophic lateral sclerosis	Mass General Hospital
794	celiprolol	n/a	1/5/2015	Treatment of Ehlers-Danlos syndrome	Acer Therapeutics, Inc.
795	cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/2013	Prevention of graft versus host disease	Enlivex Therapeutics Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
796	Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated
797	cenersen	Aezea	2/27/2008	Treatment of chronic lymphocytic leukemia	Eleos, Inc.
798	cenersen	Aezea	6/18/2008	Treatment of stage IIB through IV melanoma	Eleos, Inc.
799	cenersen	n/a	5/8/2006	Treatment of acute myeloid leukemia	Eleos, Inc.
800	Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Rare Disease Therapeutics, Inc.
801	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Genzyme Corporation
802	cerebrolysin	n/a	4/5/2016	Treatment of frontotemporal dementia, including all subvariants	EVER Neuro Pharma GmbH
803	ceritinib	Zykadia	9/27/2013	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Novartis Pharmaceuticals Corp.
804	cethromycin	n/a	2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Advanced LIfe Sciences, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
805	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Advanced Life Sciences, Inc.
806	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Advanced Life Sciences, Inc.
807	cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	ImClone Systems Incorporated
808	Chelating agent delivering Holmium-166	n/a	2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation
809	chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/1990	Treatment of ovarian cancer.	Cytogen Corporation
810	Chenodeoxycholic acid	Chenofalk	1/29/2004	Treatment of cerebrotendinous xanthomatosis	Dr. Falk Pharma GmbH
811	chenodeoxycholic acid	n/a	2/12/2007	Treatment of cerebrotendinous xanthomatosis	Baxalta US, Inc.
812	chenodiol	Chenix	9/21/1984	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age	Solvay
813	chenodiol	Chenadal	3/22/2010	Treatment of cerebrotendinous xanthomatosis	Retrophin, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
814	chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2	n/a	11/25/2014	Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)	BioMarin Pharmaceutical, Inc.
815	Chimeric monoclonal antibodies, c-alphaStx2	n/a	10/4/2005	For treatment of shiga-toxin producing bacterial infection	Thallion Pharmaceuticals, Inc.
816	chimeric monoclonal antibody against Claudin 6	n/a	3/18/2013	Treatment of ovarian cancer	Ganymed Pharmaceuticals AG
817	chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/2013	Treatment of pancreatic cancer	Ganymed Pharmaceuticals AG
818	chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/2012	Treatment of gastric cancer	GANYMED Pharmaceuticals AG
819	Chimeric monoclonal antibody to mesothelin	n/a	10/31/2006	Treatment of pancreatic cancer	Morphotek, Inc.
820	Chimeric, humanized monoclonal antibody to staphylococcus	n/a	8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc.
821	Chlorhexidine gluconate mouthrinse	Peridex	8/18/1986	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company
822	chlorobutanol/propylene glycol/hydrochloric acid	Patul-End	2/18/1997	Treatment of patulous eustachian tube	Ear Foundation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
823	chloropyramine	n/a	10/22/2010	Treatment of pancreatic cancer	CurFAKtor Pharmaceuticals, LLC
824	chloroquine	n/a	5/20/2015	Treatment of glioblastoma multiforme.	DualTpharma B.,V.
825	chlorotoxin	n/a	12/2/2008	Treatment of stage IIb, IIc, III & IV melanoma	Morphotek, Inc.
826	Chlorotoxin	n/a	12/18/2007	Treatment of malignant glioma	Morphotek, Inc.
827	chlorotoxin conjugated to indocyanine green dye	n/a	6/23/2015	Diagnostic for the management of malignant brain tumors	Blaze Bioscience, Inc.
828	cholest-4-en-3-one, oxime	n/a	2/17/2009	Treatment of spinal muscular atrophy.	Genentech, Inc.
829	cholic acid	Cholbam	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Retrophin, Inc.
830	Choline chloride	Intrachol	2/10/1994	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	QOL Therapeutics EU Ltd
831	Choline chloride	Intrachol	7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	QOL Therapeutics EU Ltd
832	choline tetrathiomolybdate	n/a	8/25/2011	Treatment of Wilson's disease.	Wilson Therapeutics AB
833	Chondrocyte-alginate gel suspension	n/a	12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
834	chromium picolinate and chromium histidinate	n/a	12/22/2014	Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age)	JDS Therapeutics, LLC
835	Ciliary neurotrophic factor	n/a	1/30/1992	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc
836	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.
837	cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc.
838	Cintredekin Besudotox	n/a	4/30/2010	Treatment of idiopathic pulmonary fibrosis	Insys Therapeutics, Inc.
839	ciprofloxacin	n/a	6/1/2011	The management of bronchiectasis	Aradigm Corporation
840	ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Bayer HealthCare Pharmaceuticals, Inc.
841	ciprofloxacin dry powder inhaler	n/a	4/17/2014	Treatment of non-cystic fibrosis bronchiectasis	Bayer HealthCare Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
842	cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate	n/a	1/19/2010	Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae	Medicines for Malaria Venture (MMV)
843	Cisplatin ChemoThin Wafer	n/a	11/3/2015	Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)	Privo Technologies
844	Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/2007	Treatment of osteosarcoma	Eleison Pharmaceuticals LLC
845	Cisplatin/epinephrine	Intradose	9/7/2000	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc.
846	Cisplatin/epinephrine	Intradose	4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc.
847	Citric acid, glucono-delta-lactone and magnesium carbonate	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc.
848	civamide	n/a	2/17/2009	Treatment of postherpetic neuralgia.	Winston Laboratories, Inc.
849	civamide	Zucapsaicin	12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc.
850	Cladribine	Mylinax	4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Johnson & Johnson Pharmaceutical R & D, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
851	cladribine	n/a	3/19/2015	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chord Therapeutics S.a.r.l.
852	Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute
853	clarithromycin, rifabutin, clofazimine	n/a	4/26/2011	Treatment of pediatric Crohn's disease.	RedHill Biopharma Ltd.
854	Clazosentan	Erajet	2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Actelion Pharmaceuticals Ltd.
855	clenbuterol	Spiropent, Ventipulmin	10/27/2014	Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease	Duke University Medical Center
856	Clindamycin	Cleocin	10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc.
857	Clindamycin	Cleocin	10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn
858	Clindamycin hydrochloride	n/a	8/9/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
859	clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Lundbeck, Inc.
860	clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Genzyme Corporation
861	clofarabine	Clofarex	3/14/2002	Treatment of acute myelogenous leukemia	Genzyme Corp (Ilex Products, Inc.)

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
862	clofazimine	Lamprene	6/25/2014	Treatment of active tuberculosis	Novartis Pharmaceuticals Corp.
863	Clofazimine	Lamprene	6/11/1984	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation
864	Clonazepam	Klonopin	8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc.
865	Clonazepam Intranasal Spray	n/a	12/19/2007	Treatment of recurrent acute repetitive seizures	Jazz Pharmaceuticals, Inc.
866	Clonidine	Duraclon	1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc.
867	Clotrimazole	n/a	4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D.
868	Clotrimazole	n/a	3/13/2006	Treatment of Huntington's disease	EnVivo Pharmaceuticals, Inc.
869	Clotrimazole	n/a	6/14/2005	Topical treatment of children and adults with pouchitis	AesRx, LLC
870	clotrimazole otic solution	n/a	5/10/2016	Treatment of fungal otitis externa (otomycosis).	Laboratorios SALVAT S.A.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
871	CNDO-109-activated allogeneic natural killer cells	n/a	6/18/2012	Treatment of acute myeloid leukemia	Coronado Biosciences, Inc.
872	Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company
873	Coagulation Factor IX (human)	Alphanine	7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation
874	Coagulation Factor IX (recombinant)	Benefix	10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc.
875	coagulation factor IX (recombinant)	Rixubis	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Baxalta US, Inc.
876	Coagulation factor IX (recombinant), Fc fusion protein	Alprolix	10/30/2008	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Biogen Idec Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
877	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Novo Nordisk, Inc.
878	Coagulation factor VIIa (recombinant)	Novoseven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk, Inc.
879	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
880	Coagulation factor VIIa (recombinant)	Novoseven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
881	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Novo Nordisk, Inc.
882	coagulation factor VIIa (recombinant)	Novoseven Rt	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk Inc.
883	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors	Novo Nordisk, Inc.
884	Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
885	coagulation factor XIII A-subunit (recombinant)	Tretten	11/6/2003	Prophylaxis of bleeding associated with congential factor XIII deficiency	Novo Nordisk, Inc.
886	cobimetinib	n/a	1/31/2014	Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation	Genentech, Inc.
887	coccidioidin SD Skin Test Antigen	n/a	12/19/2007	For the diagnosis of Coccidioidomycosis	Allermed Labortories, Inc.
888	Coenzyme Q10	n/a	3/5/2001	Treatment of Huntington's disease	Integrative Therapeutics, Inc.
889	coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/2011	Treatment of Friedreich's Ataxia.	NBI Pharmaceuticals, Inc.
890	Colchicine	n/a	9/25/2007	Treatment of Behcet's Syndrome	AR Scientific, Inc.
891	colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	AR Holding Company, Inc.
892	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages.	Glaxo Wellcome Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
893	collagenase clostridium histolyticum	Xiaflex	3/12/1996	Treatment of Peyronie's disease.	Auxilium Pharmaceuticals, Inc.
894	collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Auxilium Pharmaceuticals, Inc.
895	combination of disulfiram and copper gluconate	n/a	5/18/2016	Treatment of glioblastoma multiforme.	Cantex Pharmaceuticals, Inc.
896	Combination of nivolumab and ipilimumab	n/a	10/9/2014	Treatment of Stage IIb to Stage IV melanoma	Bristol-Myers Squibb Company
897	combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE)	n/a	5/2/2016	Treatment of soft tissue sarcoma	Immune Design Corp.
898	combretastatin A 1 diphosphate	n/a	11/19/2012	Treatment of acute myelogenous leukemia	OXiGENE, Inc.
899	Combretastatin A4 Phosphate	n/a	7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc
900	Combretastatin A4 phosphate	n/a	5/8/2006	Treatment of ovarian cancer	OXiGENE, Inc.
901	competetive small molecule inhibitor of the enzyme O-GlcNAcase	n/a	3/10/2016	Treatment of progressive supranuclear palsy.	Merck & Company, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
902	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	NanoViricides Incorporated
903	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/2001	Treatment of malignant tumors of the central nervous system	Xenova Biomedix Limited
904	conjugated bile acids	Cobartin	7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc.
905	Contulakin-G	n/a	7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Cognetix, Inc.
906	copanlisib	n/a	2/5/2015	Treatment of follicular lymphoma	Bayer HealthCare Pharmaceuticals, Inc.
907	Copper 64-DOTA-TATE	Netmedix (Tm)	5/18/2016	Diagnostic for the management of neuroendocrine tumors.	RadioMedix, Inc.
908	copper histidine	n/a	5/14/2012	Treatment of Menkes disease	Stephen G. Kaler, M.D.
909	Cordycepin	n/a	7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	OncoVista, Inc.
910	corifungin	n/a	7/6/2011	Treatment of visceral leishmaniasis	Sandler Center for Drug Discovery
911	corifungin	n/a	8/22/2011	Treatment of amebic meningoencephalitis.	Ctr for Discovery & Innovation in Parasitic Diseas

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
912	Corticorelin ovine triflutate	Acthrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc.
913	Corticotropin-releasing factor, human	Xerecept	4/6/1998	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc.
914	Coumarin	Onkolox	12/22/1994	Treatment of renal cell carcinoma.	Drossapharm LTD
915	Coxsackievirus A21	Cavatak	12/15/2005	Treatment of stage II (T4), stage III, and stage IV melanoma	Viralytics Limited
916	creatine	Creapure	2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc.
917	Creatine	Creapure	10/11/2005	Treatment of Huntington's disease	Marathon Pharmaceuticals, LLC
918	crenolanib	n/a	10/31/2012	Treatment of acute myelogenous leukemia	AROG Pharmaceuticals, LLC
919	crenolanib	n/a	3/18/2011	Treatment of soft tissue sarcoma	AROG Pharmaceuticals, LLC
920	crenolanib besylate	n/a	12/20/2010	Treatment of malignant glioma	AROG Pharmaceuticals, LLC
921	cridanimod	n/a	1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Kevelt Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
922	crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Pfizer, Inc.
923	crizotinib	Xalkori	9/13/2010	Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer	Pfizer, Inc.
924	crizotinib	Xalkori	10/31/2012	Treatment of neuroblastoma	Pfizer, Inc.
925	Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Fisons Corporation
926	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Fisons Corporation
927	cromolyn sodium for inhalation	n/a	12/9/2015	Treatment of mastocytosis.	Patara Pharma, LLC
928	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation
929	cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	n/a	8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center
930	cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD)	Alexion Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
931	Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}	n/a	12/20/2006	Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis	Lux Biosciences, Inc.
932	cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonly-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt	n/a	6/24/2013	Treatment of acromegaly	Aspireo Pharmaceuticals Limited
933	cyclocreatine	n/a	6/18/2012	Treatment of creatine transporter deficiency	Lumos Pharma
934	cyclophosphamide	Cyrevia(Tm)	6/7/2011	Treatment of systemic sclerosis.	Accentia Biopharmaceuticals, Inc.
935	cyclophosphamide	Cyrevia(Tm)	6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Accentia Biopharmaceuticals, Inc.
936	Cyclosporin A	Mitogard	10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Maas Biolab,LLC
937	cyclosporine	n/a	2/17/2009	Prophylaxis of graft-versus-host disease	Sigmoid Pharma Limited

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
938	Cyclosporine	Pluminiq	11/25/2003	Treatment of acute rejection in patients requiring allogenic lung transplants	APT Pharmaceuticals, Inc.
939	cyclosporine	n/a	2/17/2009	Treatment of graft-versus-host disease	Sigmoid Pharma Limited
940	Cyclosporine	n/a	11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	APT Pharmaceuticals, Inc.
941	cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer	Allergan, Inc.
942	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty	Allergan, Inc.
943	cyclosporine A	n/a	9/30/2008	Prevention of corneal graft rejection	Santen SAS
944	cyclosporine A	Nova22007	4/9/2008	Treatment of herpes simplex virus stromal keratitis	Santen SAS
945	Cyclosporine A	n/a	5/4/2007	Treatment of vernal keratoconjunctivitis	Santen SAS
946	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/2000	Prevention of solid organ graft rejection.	RTP Pharma Corporation
947	Cyclosporine ophthalmic	Optimmune	11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
948	cyclosporine; ciclosporin	Neurostat(R)/Ciclomulsion (R)	11/23/2010	Treatment of moderate to severe traumatic brain injury.	NeuroVive Pharmaceutical AB
949	Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III)	n/a	12/29/2015	Treatment of invasive aspergillosis.	Vical Incorporated
950	Cys-His-Ala-Val-Cys	n/a	2/14/2008	For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV	Adherex Technologies, Inc.
951	Cysteamine	Lynovex	9/11/2014	Treatment of cystic fibrosis	NovaBiotics Ltd.
952	cysteamine	n/a	9/11/2013	Treatment of pancreatic cancer	Raptor Pharmaceuticals, Inc.
953	cysteamine	n/a	5/9/2008	Treatment of Huntington's disease	Raptor Therapeutics
954	Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc.
955	cysteamine	n/a	8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Raptor Pharmaceuticals, Inc.
956	Cysteamine	n/a	5/1/1986	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D.
957	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics, Inc.
958	Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
959	Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcftr.10	3/9/1995	Treatment of cystic fibrosis.	GenVec, Inc.
960	Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/1993	Treatment of cystic fibrosis.	Genetic Therapy, Inc.
961	Cytarabine liposomal	Depocyt	6/2/1993	Treatment of neoplastic meningitis.	Pacira Pharmaceuticals, Inc.
962	cytarabine liposome	Depocyt	1/30/2007	Treatment of gliomas	Bruce Frankel, MD
963	Cytarabine:daunorubicin liposome injection	n/a	8/22/2008	Treatment of acute myeloid leukemia	Celator Pharmaceuticals, Inc.
964	cytochrome C, flavin mononucleotide and thiamin diphosphate	n/a	6/17/2011	Treatment of mitochondrial disorders	NBI Pharmaceuticals, Inc.
965	cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate	n/a	12/17/2014	Treatment of pancreatic cancer in combination with ifosfamide	Nuvilex, Inc.
966	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/2006	For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations	Vical Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
967	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/2005	Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations	Astellas Pharma Global Development, Inc.
968	Cytomegalovirus immune globulin (human)	Cytogam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	CSL Behring LLC
969	Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation
970	D-mannitol and L-proline	Prodarsan	4/20/2009	Treatment of Cockayne syndrome	DNage B.V.
971	D-peptide	Nerofe	2/4/2011	Treatment of acute myelogenous leukemia	Immune System Key, Ltd
972	D-peptide of the sequence AKRHHGYKRKFH - NH2	Pulmadex	10/23/2002	Treatment of cystic fibrosis	Demegen, Inc.
973	d6-tetrabenazine, deutetrabenazine	n/a	11/5/2014	Treatment of Huntington's Disease	Teva Pharmaceuticals, Inc.
974	dabrafenib	Tafinlar	2/8/2016	Treatment of malignant glioma with BRAF V600 mutation	Novartis Pharmaceuticals Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
975	dabrafenib	Tafinlar	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	Novartis Pharmaceuticals Corp.
976	dabrafenib	Tafinler	10/20/2014	Treatment of patients with BRAF mutation positive non-small cell lung cancer	Novartis Pharmaceuticals Corp
977	dabrafenib and trametinib	n/a	10/29/2015	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	Novartis Pharmaceuticals Corp.
978	dacetuzumab	n/a	8/13/2004	Treatment of multiple myeloma.	Seattle Genetics, Inc.
979	dacetuzumab	n/a	10/6/2005	Treatment of chronic lymphocytic leukemia	Seattle Genetics, Inc.
980	Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc.
981	dacomitinib	n/a	3/3/2015	Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.	Pfizer, Inc.
982	dalbavancin	Dalvance	3/30/2015	Treatment of acute osteomyelitis in children (0 through 16 years of age)	Durata Therapeutics International B.V.
983	dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Acorda Therapeutics
984	dantrolene sodium	n/a	9/25/2012	Treatment of heat stroke	Eagle Pharmaceuticals, Inc.
985	dantrolene sodium	n/a	2/17/2016	Treatment of Wolfram Syndrome	Washington University in St. Louis
986	dantrolene sodium suspension for injection	Ryanodex	8/16/2013	Treatment of malignant hyperthermia syndrome	Eagle Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
987	Dapsone	n/a	11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc.
988	Dapsone USP	Dapsone	12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company
989	Dapsone USP	Dapsone	1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company
990	daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma.	Janssen Research & Development, LLC
991	daratumumab	n/a	8/20/2015	Treatment of mantle cell lymphoma.	Janssen Research & Development, LLC
992	daratumumab	n/a	8/6/2015	Treatment of follicular lymphoma	Janssen Research & Development, LLC
993	daratumumab	Humax (R) - Cd38	11/9/2015	Treatment of diffuse large B-cell lymphoma.	Janssen Research and Development, LLC
994	Darinaparsin	n/a	9/13/2010	Treatment of peripheral T-cell lymphoma.	Solasia Pharma K.K.
995	Dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
996	Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Bristol-Myers Squibb Company

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
997	dasiprotimut-T	Biovax Id	6/17/2010	Treatment of mantle cell lymphoma	Biovest International, Inc.
998	dasiprotimut-T	Biovaxid	10/28/2009	Treatment of follicular lymphoma	Biovest International, Inc.
999	Daunorubicin citrate liposome injection	Daunoxome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc.
1000	Daunorubicin liposomal	n/a	9/5/2008	Treatment of acute myeloid leukemia	Diatos USA, LLC
1001	davunetide	n/a	12/7/2009	Treatment of progressive supranuclear palsy.	Allon Therapeutics, Inc.
1002	DCVAC OvCa	n/a	5/14/2013	Treatment of ovarian cancer	SOTIOS a.s.
1003	DEAE-rebeccamycin	n/a	3/1/2004	Treatment of bile duct tumors	Helsinn Healthcare SA
1004	debrase	Debridase	8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd.
1005	decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Otsuka Pharmaceutical Development
1006	defactinib	n/a	2/12/2015	Treatment of ovarian cancer	Verastem, Inc.
1007	deferasirox	Exjade	2/24/2015	Treatment of chronic iron overload in alpha-thalassemia	Novartis Pharmaceuticals Corporation
1008	Deferasirox	Exjade	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation
1009	deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	ApoPharma, Inc. A Division of

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1010	deferiprone	n/a	9/1/2011	Treatment of superficial siderosis	ApoPharma, Inc.
1011	deferiprone	n/a	7/31/2008	Treatment of Friedreich's ataxia	ApoPharma, Inc.
1012	deferoxamine starch conjugate	n/a	1/28/2005	Treatment of acute iron poisoning	Biomedical Frontiers, Inc.
1013	deferoxamine starch conjugate	n/a	12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc.
1014	Defibrotide	n/a	7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Crinos International
1015	defibrotide	n/a	1/8/2007	For the prevention of hepatic veno-occlusive disease.	Gentium SpA
1016	defibrotide	Defitelio	5/21/2003	For the treatment of hepatic veno-occlusive disease	Gentium S.r.L.
1017	deflazacort	n/a	8/16/2013	Treatment of Duchenne muscular dystrophy	Marathon Pharmaceuticals, LLC
1018	deflazacort	Calcort	9/16/2010	Treatment of Duchenne muscular dystrophy	University of Rochester Medical Center
1019	deflazacort	n/a	10/22/2015	Treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.	Marathon Pharmaceuticals, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1020	dehydrated alcohol	n/a	3/16/2012	Treatment of trigeminal neuralgia	Luitpold Pharmaceuticals, Inc.
1021	dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Belcher Pharmaceuticals, LLC
1022	Dehydroepiandrosterone (DHEA)	Fidelin	8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc.
1023	Dehydroepiandrosterone sulfate sodium	n/a	1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc.
1024	Dehydroepiandrosterone sulfate sodium	n/a	1/29/1997	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc.
1025	delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione	n/a	12/2/2011	Treatment of Duchenne muscular dystrophy	ReveraGen Biopharma
1026	delta-9-tetrahydrocannibinol and cannabidiol	n/a	12/3/2015	Treatment of glioma.	GW Research Ltd.
1027	demcizumab	n/a	4/30/2014	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1028	dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha	n/a	6/7/2010	Treatment of glioblastoma or brain stem glioma	ImmunoCellular Therapeutics Ltd.
1029	dendritic hybrid cell vaccine	Neuroblaxin	9/23/2011	Treatment of neuroblastoma	Orbis Health Solutions, LLC
1030	dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene	n/a	1/6/2016	Treatment of soft tissue sarcoma.	Immune Design Corp.
1031	denileukin diftitox	n/a	6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Eisai, Inc.
1032	denileukin diftitox	Ontak	4/30/2010	Treatment of peripheral T-cell lymphoma	Eisai, Inc.
1033	denileukin diftitox	n/a	7/12/2013	Treatment of cutaneous T-cell lymphoma	Eisai Inc.
1034	denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Eisai, Inc.
1035	denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Amgen, Inc.
1036	denosumab	Xgeva	9/11/2013	Treatment of hypercalcemia in malignancy	Amgen, Inc.
1037	Dermagraft	n/a	12/13/2010	Treatment of epidermolysis bullosa	Shire Regenerative Medicine, Inc.
1038	Deslorelin	Somagard	11/5/1987		Roberts Pharmaceutical Corp.
1039	Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/2004	Treatment of pemphigus vulgaris	Peptimmune, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1040	Desmopressin acetate	n/a	1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C.
1041	deutetrabenazine	n/a	1/13/2015	Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)	TEVA Pharmaceuticals
1042	dexamethasone intravitreal implant	Ozurdex	9/11/1998	Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis	Allergan
1043	dexamethasone phosphate	n/a	12/2/2008	Treatment of corneal graft rejection.	EyeGate Pharmaceuticals, Inc.
1044	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/2012	Treatment of ataxia-telangiectasia	EryDel S.p.A.
1045	dexanabinol	n/a	8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Pharmos Corporation
1046	dexpramipexole	n/a	10/11/2007	Treatment of amyotrophic lateral sclerosis	Knopp Biosciences LLC
1047	Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1048	dexrazoxane	Totect(R)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Clinigen Healthcare Ltd.
1049	dexrazoxane hydrochloride	n/a	8/19/2014	Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines	Satiscor, LLC
1050	dextran 1	n/a	3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc.
1051	Dextran 70	Dehydrex	3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc.
1052	Dextran and deferoxamine	Bio-Rescue	3/8/1991	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc.
1053	Dextran sulfate (inhaled, aerosolized)	Uendex	10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
1054	Dextran sulfate sodium	n/a	11/19/1987	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd.
1055	diacerein	n/a	10/15/2014	Treatment of epidermolysis bullosa	TWI Biotechnology, Inc.
1056	Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1057	diannexin	n/a	10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Astellas Pharma Global Development, Inc.
1058	diazepam (intranasal)	n/a	11/16/2015	Management of acute repetitive seizures.	Neurelis Pharmaceuticals, Inc.
1059	diazepam (intranasal)	n/a	7/31/2012	Management of patients with acute repetitive seizures	Acorda Therapeutics, Inc.
1060	diazepam auto-injector	n/a	5/30/2013	Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity	Meridian Medical Technologies-a Pfizer subsidiary
1061	diazepam subcutaneous injection	Diazepen(Tm)	5/26/2016	Treatment of acute repetitive seizures.	Xeris Pharmaceuticals, Inc.
1062	Diazepam viscous solution for rectal administration	n/a	2/25/1992	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Valeant Pharmaceuticals
1063	diazoxide	n/a	12/3/2012	Treatment of Prader Willi Syndrome	Sedogen, LLC
1064	diazoxide choline	n/a	5/13/2014	Treatment of Prader-Willi Syndrome	Essentialis, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1065	dichlorphenamide	n/a	9/2/2010	Treatment of primary periodic paralyses	Taro Pharmaceuticals
1066	Diethyldithiocarbamate	Imuthiol	4/3/1986	Treatment of AIDS.	Connaught Laboratories
1067	diethylenetriaminepentaacetate (DPTA)	n/a	4/14/2004	For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.	CIS-US
1068	Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.	Hameln Pharmaceuticals gmbh
1069	diferuloylmethane	n/a	6/13/2003	Treatment of cystic fibrosis	Allertein Therapeutics, LLC
1070	difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Alcon Pharmaceuticals. Ltd.
1071	digitoxin	n/a	10/18/2001	Treatment of soft tissue sarcomas	SimRx Advisors LLC
1072	digitoxin	n/a	5/27/2005	Treatment of cystic fibrosis	Silver Pharmaceuticals
1073	digitoxin	n/a	11/2/2001	Treatment of ovarian cancer	SimRx Advisors LLC
1074	digoxin immune fab (ovine)	n/a	2/3/2012	Treatment of severe preeclampsia and eclampsia	Velo Bio, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1075	Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc.
1076	Digoxin immune fab(ovine)	Digidote	3/11/1985	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp.
1077	dihydroartemisinin and piperaquine	Eurartesim	1/8/2007	Treatment of uncomplicated malaria caused by "Plasmodium falciparum," Plasmodium vivax," Plasmodium malariae," or "Plasmodium ovale."	Sigma-Tau Pharmaceuticals, Inc.
1078	Dihydrotestosterone	Androgel -Dht	2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Besins Internaitonal, US Inc.
1079	dimebon	n/a	5/12/2009	Treatment of Huntington's Disease.	Medivation, Inc.
1080	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Bellicum Pharmaceuticals, Inc.
1081	dimethyl fumarate	n/a	9/11/2013	Treatment of Friedreich's Ataxia	Gino Cortopassi

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1082	Dimethyl sulfoxide	n/a	11/22/1994	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Abela Pharmaceuticals, Inc.
1083	dimethyl sulfoxide	n/a	5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Abela Pharmaceuticals, Inc.
1084	Dimethylsulfoxide	n/a	4/15/1997	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc.
1085	Dimethylsulfoxide	n/a	4/6/1998	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc.
1086	dinaciclib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Merck Sharp & Dohme Ltd.
1087	dinutuximab	Unituxin	12/20/2010	Treatment of neuroblastoma	United Therapeutics Corporation
1088	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc.
1089	diphenylcyclopenone	n/a	6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1090	Diphenylcyclopropenone gel	Samcyprone (Tm)	4/15/2015	Treatment of malignant melanoma stage IIB to IV	RXi Pharmaceuticals Corp.
1091	dipraglurant	n/a	12/29/2015	Treatment of levodopa-induced dyskinesias	Addex Pharma SA
1092	Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc.
1093	Disodium clodronate	n/a	6/16/1993	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc.
1094	Disodium clodronate tetrahydrate	Bonefos	3/5/1990	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc.
1095	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/2009	Treatment of ovarian cancer	BioCancell Therapeutics Ltd.
1096	DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	n/a	2/6/2014	Treatment of amyotrophic lateral sclerosis	ViroMed Co., Ltd.
1097	DNA plasmid vector expressing eIF5Ak50	n/a	12/13/2010	Treatment of multiple myeloma.	Senesco Technologies, Inc.
1098	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the nastive eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of diffuse large B cell lymphoma	Senesco Technologies, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1099	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of mantle cell lymphoma	Senesco Technologies, Inc.
1100	DNA plasmid vector expressing human IL-12 gene	n/a	4/4/2005	Treatment of ovarian cancer.	Celsion Corporation
1101	DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Leuvectin	4/28/2000	Treatment of renal cell carcinoma.	Vical Incorporated
1102	DNP-Modified autologous tumor vaccine	O-Vax	9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc.
1103	docosahexaenoic acid	n/a	4/27/2015	Treatment of sickle cell disease	Sancilio & Company, Inc.
1104	docosahexaenoic acid	n/a	6/1/2015	Treatment of short bowel syndrome	Sancilio and Company, Inc.
1105	docosahexaenoic acid, DHA	n/a	12/17/2014	Treatment of primary sclerosing cholangitis	Sancilio and Company, Inc.
1106	dodecafluoropentane emulsion	n/a	2/11/2016	Treatment of sickle cell disease	NuvOx Pharma
1107	dodecafluoropentane emulsion (DDFPe)	n/a	12/2/2015	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme (GBM).	NuvOx Pharma

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1108	domperidone	n/a	9/2/2011	Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding	Thomas W. Hale, RPh, PhD
1109	Doripenem	n/a	7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Shionogi, Inc.
1110	Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc.
1111	double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic	n/a	6/9/2015	Treatment of Alpha-1 Antitrypsin deficiency	Arrowhead Research Corporation
1112	double stranded RNA which targets the mutated KRAS oncogene	n/a	1/26/2015	Treatment of pancreatic cancer	Silenseed Ltd
1113	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/2010	Treatment of pancreatic cancer	BioCancell Therapeutics Israel Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1114	dovitinib	n/a	9/26/2013	Treatment of adenoid cystic carcinoma	Novartis Pharmaceuticals Corporation
1115	DOXO-EMCH	n/a	4/18/2011	Treatment of adenocarcinoma of the pancreas.	CytRx Corporation
1116	doxofylline	n/a	2/14/2014	Treatment of bronchiectasis	Alitair Pharmaceuticals, Inc.
1117	doxorubicin	n/a	8/25/2009	Treatment of hepatocellular carcinoma.	Delcath Systems, Inc.
1118	doxorubicin	n/a	4/6/2015	Treatment of cutaneous T-cell lymphoma	Louis D. Falo, Jr.
1119	doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Johnson & Johnson Pharmaceutical Research & Dev.
1120	Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/2005	Treatment of esophageal carcinoma	Supratek Pharma Inc.
1121	Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Alza Corporation
1122	doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/2005	Treatment of hepatocellular carcinoma	BioAlliance Pharma
1123	doxorubicin with pluronics F-127 and L-61	n/a	2/20/2008	Treatment of gastric cancer	Supratek Pharma, Inc.
1124	DPX-Survivac	n/a	7/14/2015	Treatment of ovarian cancer.	Immunovaccine Technologies, Inc.
1125	Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1126	droxidopa	Northera	1/17/2007	Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.	Lundbeck LLC
1127	dry extract from Betulae Cortex (birch bark)	n/a	8/7/2014	Treatment of epidermolysis bullosa	Birken AG
1128	Duramycin	n/a	12/11/1997	Treatment of cystic fibrosis.	Lantibio, Inc.
1129	duvelisib	n/a	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Infinity Pharmaceuticals
1130	duvoglustat hydrochloride	n/a	6/18/2007	Treatment of Pompe disease	Amicus Therapeutics, Inc
1131	Dynamine	n/a	2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation
1132	Dynamine	n/a	10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation
1133	E-selectin antagonist	n/a	5/13/2015	Treatment of acute myeloid leukemia (AML)	GlycoMimetics, Inc.
1134	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1135	Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]	n/a	2/8/2016	Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.	Cidara Therapeutics, Inc.
1136	echinomycin	n/a	5/21/2015	Treatment of acute myeloid leukemia.	OncoImmune, Inc.
1137	echothiophate iodide	n/a	6/2/2014	Treatment of Stargardt's disease	Makindus, Inc.
1138	ecopipam hydrochloride	n/a	9/29/2010	Treatment of Tourette's syndrome in children 0-16 years old.	Psyadon Pharmaceuticals, Inc.
1139	ecopipam hydrochloride	n/a	7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Psyadon Pharmaceuticals, Inc.
1140	Eculizumab	n/a	9/21/2000	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc.
1141	eculizumab	n/a	3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc.
1142	eculizumab	Soliris	10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1143	eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.
1144	eculizumab	Soliris	1/10/2014	Prevention of delayed graft function after renal transplantation	Alexion Pharmaceuticals, Inc.
1145	eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Alexion Pharmaceuticals, Inc.
1146	eculizumab	n/a	6/12/2014	Treatment of Myasthenia Gravis.	Alexion Pharmaceuticals, Inc.
1147	eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1148	Edaravone	n/a	5/12/2015	Treatment of amyotrophic lateral sclerosis	Mitsubishi Tanabe Pharma Corporation
1149	edaravone	n/a	3/12/2015	Treatment of amyotrophic lateral sclerosis	Treeway B.V.
1150	Edotreotide	Onalta(Tm)	7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)
1151	efaproxiral	n/a	7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Allos Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1152	Efdispo (tm)	Efdispo (Tm)	1/15/2013	Treatment of Ewings Sarcoma.	TDP Biotherapeutics, Inc.
1153	Eflornithine	n/a	9/29/2006	Treatment of anaplastic glioma	Orbus Therapeutics, Inc.
1154	eflornithine	n/a	2/4/2011	Treatment of Familial Adenomatous Polyposis	Cancer Prevention Pharmaceuticals
1155	eflornithine	n/a	11/23/2010	Treatment of neuroblastoma	Cancer Prevention Pharmaceutical, Inc.
1156	eflornithine HCL	n/a	4/7/2015	Treatment of gastric cancer	Cancer Prevention Pharmaceuticals, Inc.
1157	Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel
1158	eflornithine plus sulindac	n/a	1/22/2013	Treatment of familial adenomatous polyposis	Cancer Prevention Pharmaceuticals, Inc.
1159	eicosapentaenoic acid	n/a	3/8/2011	Treatment of familial adenomatous polyposis	S.L.A. Pharma Ltd. (UK)
1160	elacytarabine	n/a	6/18/2008	Treatment of acute myeloid leukemia (AML)	Clavis Pharma ASA
1161	Elcatonin	n/a	9/25/1995	Intrathecal treatment of intractable pain.	Innapharma, Inc.
1162	Elesclomol	n/a	12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Synta Pharmaceuticals Corporation
1163	eliglustat	Cerdelga	9/17/2008	Treatment of Type I Gaucher disease	Genzyme Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1164	elosulfase alfa	Vimizim	5/15/2009	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	BioMarin Pharmaceutical Inc.
1165	elotuzumab	n/a	9/1/2011	Treatment of multiple myeloma	Bristol-Myers Squibb Company
1166	eltoprazine HCl	n/a	2/8/2016	Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.	Amarantus BioScience Holdings, Inc.
1167	eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	Novartis Pharmaceuticals Corp.
1168	eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	Novartis Pharmaceuticals Corp.
1169	emricasan	n/a	11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Conatus Pharmaceuticals Inc.
1170	Enadoline hydrochloride	n/a	1/28/1997	Treatment of severe head injury.	Warner-Lambert Company
1171	Encapsulated porcine islet preparation	Betarx	7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx
1172	encapsulated spores from fecal microbiota	n/a	8/19/2015	Treatment of recurrent Clostridium difficile infection (CDI)	Seres Health, Inc.
1173	enchochleate amphotericin B	n/a	1/10/2014	Treatment of visceral leishmaniasis	Aquarius Biotechnologies, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1174	encochleated amikacin	n/a	3/3/2016	Treatment of non-tuberculous mycobacteria (NTM) infections	Aquarius Biotechnologies, Inc.
1175	encorafenib	n/a	11/19/2013	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Array BioPharmas, Inc.
1176	encorafenib + binimetinib	n/a	11/19/2013	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Array BioPharma, Inc.
1177	Endothelin receptor B antagonist	n/a	1/21/2016	Treatment of malignant melanoma Stages IIB to IV.	ENB Therapeutics, LLC
1178	enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor	n/a	5/10/2016	Treatment of invasive Candida infections, including candidemia	SCYNEXIS, Inc.
1179	Engineered variant of recombinant human fibroblast growth factor 19	n/a	2/6/2014	Treatment of primary biliary cirrhosis	NGM Biopharmaceuticals, Inc.
1180	eniluracil	n/a	12/15/2005	Treatment of hepatocellular carcinoma.	Adherex Technologies, Inc.
1181	ensituximab	n/a	10/21/2010	Treatment of pancreatic cancer.	Neogenix Oncology, Inc.
1182	entrectinib;N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	12/22/2014	Treatment of neuroblastoma	Ignyta, Inc.
1183	enzastaurin	n/a	3/4/2009	Treatment of diffuse large B-cell lymphoma	Denovo Biopharma LLC
1184	Enzastaurin	n/a	9/19/2005	Treatment of glioblastoma multiforme	Denovo Biopharma LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1185	epacadostat	n/a	2/11/2016	Treatment of stage IIB-IV melanoma.	Incyte Corporation
1186	Epidermal growth factor (human)	n/a	10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision
1187	Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company
1188	Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Amgen, Inc.
1189	Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc.
1190	Epoetin alfa	n/a	12/20/1993	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev.,
1191	Epoetin alpha	Procrit	3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute
1192	Epoetin alpha	Procrit	8/27/1987	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute
1193	Epoetin beta	Marogen	10/22/1987	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc.
1194	Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1195	epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline
1196	epratuzumab	Lymphocide	7/13/1998	Treatment of non-Hodgkin's lymphoma	Immunomedics, Inc.
1197	epratuzumab	n/a	9/30/2008	Treatment of acute lymphoblastic leukemia	Immunomedics, Inc.
1198	Eprodisate	Kiacta(Tm)	4/6/1999	Treatment of secondary amyloidosis	C. T. Development America, Inc.
1199	Epstein-Barr virus-specific autologous cytotoxic T lymphocytes	n/a	6/12/2014	Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma)	FFCanVac Pte Ltd
1200	eptifibatide and iloprost	n/a	4/20/2012	Treatment of purpura fulminans	Thrombologic
1201	erdosteine	n/a	12/20/2013	Treatment of bronchiectasis.	Alitair Pharmaceuticals, Inc.
1202	eribulin mesylate	Halaven	5/14/2012	Treatment of soft tissue sarcoma	Eisai Inc.
1203	Erlotinib Hydrochloride	Tarceva	7/18/2003	Treatment of malignant gliomas	Genentech, Inc
1204	Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Jazz Pharmaceuticals, Inc.
1205	Erythropoietin (recombinant human)	n/a	8/19/1987	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp
1206	estradiol Gel	n/a	10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Ascend Therapeutics US, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1207	etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation
1208	etarfolatide	n/a	2/16/2000	For the identification of ovarian carcinomas	Endocyte, Inc.
1209	eteplirsen	n/a	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Sarepta Therapeutics, Inc.
1210	ethanolamine	Ethamolin	1/17/2014	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	QOL Medical, LLC
1211	Ethanolamine oleate	Ethamolin	3/22/1984	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	QOL Medical
1212	ethiodized oil injection	Lipiodol	9/26/2013	Management of patients with known hepatocellular carcinoma (HCC)	Guerbet LLC
1213	Ethyl eicosapentaenoate	n/a	4/6/2000	Treatment of Huntington's disease.	Laxdale Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1214	Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc.
1215	Etiocholanedione	n/a	11/3/1995	Treatment of aplastic anemia.	SuperGen, Inc.
1216	Etiocholanedione	n/a	5/7/1996	Treatment of Prader-Willi syndrome.	SuperGen, Inc.
1217	etirinotecan pegol	n/a	4/18/2011	Treatment of ovarian cancer.	Nektar Therapeutics
1218	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
1219	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
1220	everolimus	Afinitor	7/23/2012	Treatment of hepatocellular carcinoma	Novartis Pharmaceuticals Corporation
1221	everolimus	n/a	6/2/2014	Treatment of diffuse large B-cell lymphoma	Novartis Pharmaceuticals Corp.
1222	everolimus ointment	n/a	9/10/2015	Topical treatment of Tuberous Sclerosis Complex-related skin lesions	Aucta Pharmaceuticals, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1223	evinacumab	n/a	2/8/2016	Treat of homozygous familial hypercholesterolemia.	Regeneron Pharmaceuticals, Inc.
1224	evolocumab	Repatha	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Amgen Inc.
1225	Ex vivo cultured adult human mesenchymal stem cells	Prochymal(R)	12/14/2005	Treatment of acute graft versus host disease	Mesoblast, Inc.
1226	ex vivo cultured human mesenchymal stromal cells	n/a	5/8/2014	Prevention of graft rejection following solid organ transplantation	iCell Science AB
1227	ex-vivo cultered adult human mesenchymal stem cells	Prochymal(R)	4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Mesoblast, Inc.
1228	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	TCA Cellular Therapy, LLC
1229	Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn
1230	exendin-(9-39)	n/a	6/1/2011	Treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children	The Children's Hospital of Philadelphia

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1231	Exisulind	n/a	2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	OSI Pharmaceuticals, Inc.
1232	Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	BioMarin Pharmaceutical, Inc.
1233	Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	BioMarin Pharmaceutical, Inc.
1234	Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/2009	Treatment of Duchenne Muscular Dystrophy.	BioMarin Pharmaceutical, Inc.
1235	Exon 52 specific phosphorothiate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	BioMarin Pharmaceutical, Inc.
1236	exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	BioMarin Pharmaceutical, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1237	Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	BioMarin Pharmaceutical, Inc.
1238	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Intercytex Ltd.
1239	expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/2013	Treatment of retinitis pigmentosa	ReNeuron Ltd
1240	Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass	n/a	5/14/2012	Treatment of multiple myeloma	Unicorn Pacific Corporation
1241	extract of sorghum bicolor extract	n/a	11/19/2012	Treatment of sickle cell disease	Invenux, LLC
1242	ezatiostat hydrochloride	Telintra	1/9/2013	Treatment of myelodysplastic syndrome	Telik, Inc.
1243	Facilitated DNA Plasmid Vaccine	n/a	3/8/1995	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics
1244	factor VIII mimetic bispecific antibody	n/a	1/10/2014	Treatment of hemophilia A	Genentech
1245	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
1246	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	5/21/2003	Treatment of congenital FXIII deficiency	Novo Nordisk Pharmaceuticals, INc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1247	Fampridine	Neurelan	6/2/1997	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc.
1248	Fancalen (lentiviral vector containing the Fanconi anemia-A (FANCA) gene	n/a	5/2/2016	Treatment of Fanconi anemia type A patients.	Centro de Investigacion Biomedica en Red (CIBER)
1249	farletuzumab	n/a	6/16/2006	Treatment of ovarian cancer	Morphotek, Inc.
1250	fecal microbiota	n/a	3/10/2014	Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease)	Rebiotx, Inc.
1251	Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories
1252	fenfluramine HCl	Brabafen	12/20/2013	For the Treatment of Dravet Syndrome	Zogenix, Inc.
1253	Fenobam hydrochloride	n/a	11/20/2006	Treatment of fragile X syndrome	Neuropharm, Ltd.
1254	Fenretinide	n/a	4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	McGill University
1255	fenretinide	n/a	2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Cancer Research UK
1256	Fenretinide	n/a	10/5/2005	Treatment of neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
1257	fenretinide	n/a	9/4/2013	Treatment of peripheral T-cell lymphoma	CerRx, Inc.
1258	fenretinide	n/a	9/4/2013	Treatment of cutaneous T-cell lymphoma	CerRx, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1259	ferric hexacyanoferrate (II) "Prussian Blue"	n/a	6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG
1260	ferumoxytol	n/a	4/6/2012	For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)	ArsNova Partners, LLC
1261	ferumoxytol	n/a	10/7/2011	For use in magnetic resonance imaging in brain metastases	Oregon Health & Science University
1262	ferumoxytol	Feraheme	4/29/2011	For use in MR imaging for the mangement of brain tumors	Edward A. Neuwelt, MD
1263	fexinidazole	n/a	4/4/2016	Treatment of human African trypanosomiasis (HAT) or sleeping sickness	Sanofi US Services, Inc.
1264	fialuridine	n/a	7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc.
1265	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34	n/a	2/1/2007	Treatment of solitary (unicameral) bone cysts	Kuros Biosurgery AG

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1266	Fibrinogen (human)	n/a	8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation
1267	Fibronectin (human plasma derived)	n/a	9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc.
1268	Fibronectin Peptide	n/a	6/29/2011	Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.	NeoMatrix Formulations, Inc.
1269	fidaxomicin	Dificid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Optimer Pharmaceuticals, Inc.
1270	filanesib	n/a	5/6/2014	Treatment of multiple myeloma.	Array BioPharma, Inc.
1271	Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc.
1272	filgrastim	Neupogen	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1273	Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Amgen, Inc.
1274	filgrastim	n/a	1/27/2015	Treatment of amyotrophic lateral sclerosis (ALS)	Neurovision Pharma GmbH
1275	Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc.
1276	Filgrastim	Neupogen	11/7/1996	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc.
1277	filociclovir	n/a	11/29/2010	Treatment of active cytomegalovirus infections	Microbiotix, Inc.
1278	fingolimod	n/a	4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Novartis Pharmaceutical Corporation
1279	firtecan pegol	n/a	4/18/2011	Treatment of neuroblastoma.	Enzon Pharmaceuticals, Inc.
1280	FliC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Cleveland BioLabs, Inc.
1281	florilglutamic acid	n/a	5/11/2016	Diagnostic for the management of glioma	Piramal Imaging S.A.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1282	Floxuridine, FUDR	n/a	12/22/2004	Intraperitoneal treatment of gastric cancer.	Franco Muggia, M.D.
1283	flubendazole	n/a	10/25/2013	Treatment of onchocerciasis caused by Onchocerca volvulus	Janssen Research & Development, LLC
1284	flubendazole	n/a	1/23/2014	Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.	Janssen Research and Development, LLC
1285	fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)	n/a	4/7/2015	For the diagnosis of glioma	Blue Earth Diagnostics Ltd.
1286	Fludarabine phosphate	Fludara	4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc.
1287	Fludarabine phosphate	Fludara	4/18/1989	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc.
1288	Fludarabine phosphate oral tablets	n/a	12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Sanofi-Aventis U.S., Inc.
1289	Flunarizine	Sibelium	1/6/1986	Treatment of alternating hemiplegia.	Janssen Research Foundation
1290	flunarizine hydrochloride	n/a	6/24/2013	Treatment of alternating hemiplegia	Marathon Pharmaceuticals, LLC
1291	Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1292	Fluorouracil	n/a	4/18/1990	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc.
1293	Fluorouracil	n/a	6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA
1294	Fluorouracil	n/a	10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
1295	Fluoxetine	Prozac	4/30/1999	Treatment of autism.	Neuropharm, Ltd.
1296	Fluoxetine	Prozac	4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Hollander, Eric MD
1297	fluticasone propionate	n/a	1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Adare Pharmaceuticals, Inc.
1298	fluticasone propionate	n/a	12/29/2015	Treatment of eosinophilic esophagitis	Banner Life Sciences, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1299	Follitropin alfa, recombinant	Gonal-F	12/21/1998	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	EMD Serono, Inc.
1300	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals
1301	fosbretabulin tromethamine	n/a	12/29/2015	Treatment of neuroendocrine tumors	OXiGENE, Inc.
1302	fosfomycin/tobramycin	n/a	11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	CURx Pharmaceuticals, Inc.
1303	Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company
1304	fostamatinib disodium	n/a	8/25/2015	Treatment of immune thrombocytopenic purpura	Rigel Pharmaceuticals, INc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1305	FTV1+GDP-fucose	n/a	3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	America Stem Cell, Inc.
1306	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
1307	Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	NovImmune S.A.
1308	fully human IgG2 monoclonal antibody that binds insulin receptors	n/a	6/9/2015	Treatment of congenital hyperinsulinism	XOMA (US) LLC
1309	fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/2013	Treatment of growth hormone deficiency	Versartis, Inc.
1310	Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Edimer Pharmaceuticals, Inc.
1311	G17DT Immunogen	Gastrimmune(Tm)	7/18/2002	Treatment of gastric cancer	Cancer Advances, Inc.
1312	G17DT Immunogen	Gastrimmune(Tm)	7/10/2002	Treatment of adenocarcinoma of the pancreas	Cancer Advances, Inc.
1313	gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Depomed, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1314	gabapentin	Neurontin	7/5/1995	Treatment of amyotrophic lateral sclerosis	Warner-Lambert Company
1315	gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	XenoPort, Inc.
1316	Gallium (68Ga) edotreotide	n/a	7/1/2015	Diagnostic for the clinical management of neuroendocrine tumors.	Advanced Accelerator Applications, USA
1317	Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide	Netspot	12/31/2013	Diagnostic for the clinical management of neuroendocrine tumors	Advanced Accelerator Applications, USA
1318	Gallium-68 (DOTA0-Phel-Tyr3)octreotide	n/a	10/25/2013	The management of neuroendocrine tumors	University of Iowa Hospital & Clinics
1319	Gamma hydroxybutyrate	n/a	12/3/1987	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc.
1320	Gammalinolenic acid	n/a	7/27/1994	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D.
1321	ganaxolone	n/a	4/14/2016	Treatment of status epilepticus.	Marinus Pharmaceuticals, Inc.
1322	Ganaxolone	n/a	5/25/1994	Treatment of infantile spasms.	Marinus Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1323	ganaxolone	n/a	3/24/2015	Treatment of Protocadherin 19 (PCDH19) female epilepsy.	Marinus Pharmaceuticals, Inc.
1324	ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Sirion Therapeutics, Inc.
1325	Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products
1326	ganitumab	n/a	11/23/2010	Treatment of pancreatic cancer.	Nantcell
1327	Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/2009	Treatment of pancreatic cancer	Astrimmune Ltd.
1328	gefitinib	Iressa	8/26/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	AstraZeneca Pharmaceuticals LP
1329	gemcabene	n/a	2/6/2014	Treatment of homozygous familial hypercholesterolemia	Gemphire Therapeutics, Inc.
1330	gemcitabine	n/a	12/30/2015	Treatment of upper tract urothelial carcinoma	TARIS Biomedical LLC
1331	gemcitabine	n/a	1/11/2016	Treatment of cholangiocarcinoma.	InnoPharmax, Inc.
1332	gemcitabine ready-to-use	n/a	6/24/2015	Treatment of pancreatic cancer	Sun Pharmaceutical Industries Ltd.
1333	gemcitabine ready-to-use	n/a	6/24/2015	Treatment of ovarian cancer	Sun Pharmaceutical Industries Ltd.
1334	Gemtuzumab zogamicin	Mylotarg	11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1335	gene encoding chimeric CD40 ligand	n/a	2/4/2009	Treatment of chronic lymphocytic leukemia	Memgen, LLC
1336	genetically engineered herpes simplex virus (G207)	n/a	4/29/2002	Treatment of malignant glioma	Aettis, Inc.
1337	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/1997	Treatment of Crohn's disease.	Celltech Chiroscience Limited
1338	Geneticin	n/a	6/6/2005	Treatment of amoebiasis.	ProcesScience, Inc (PSI)
1339	gentamicin	n/a	9/18/2015	For use in conjunction with fracture fixation plates to reduce the rate of deep surgical site infection following trauma plating procedures in adult patients at an increased risk of infection	AbbVie, Inc.
1340	gentamicin C2 congener	n/a	3/29/2016	Treatment of cystic fibrosis	La Jolla Pharmaceuticals Company
1341	Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc.
1342	Gentamicin liposome injection	Maitec	7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc.
1343	gevokizumab	n/a	7/27/2010	Treatment of Behcet's disease	XOMA (US) LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1344	gevokizumab	n/a	2/21/2014	Treatment of pyoderma gangrenosum	XOMA (US) LLC
1345	gevokizumab	n/a	8/20/2012	Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis	XOMA (US) LLC
1346	givinostat	n/a	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Italfarmaco SpA
1347	Glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA
1348	glatiramer acetate	Copaxone	11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Teva Neurosciences, Inc.
1349	Glatiramer acetate for injection	Copaxone	6/5/2001	Treatment of primary-progressive multiple sclerosis	Teva Pharmaceuticals USA
1350	glioma derived cell lysates and irradiated cells	n/a	1/12/2011	Treatment of glioma.	Epitopoietic Research Corp.
1351	glucagon	n/a	12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Biodel, Inc.
1352	glucagon infusion	G-Pump (Tm)	9/25/2014	Prevention of chronic, severe hypoglycemia related to congential hyperinsulinism	Xeris Pharmaceuticals, Inc.
1353	glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	BTG International Inc.
1354	glufosfamide	n/a	9/18/2006	For treatment of pancreatic cancer.	Eleison Pharmaceuticals LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1355	Glutamine	Nutrestore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Emmaus Medical, Inc.
1356	Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/2010	Treatment of glioma	to-BBB technologies BV
1357	glyburide	n/a	2/8/2016	Treatment of acute subarachnoid hemorrhage	Remedy Pharmaceuticals, Inc.
1358	glyburide	n/a	9/29/2015	Treatment of acute spinal cord injury	Remedy Pharmaceuticals, Inc.
1359	glycafilin	n/a	8/22/2008	Prevention of delayed graft function after solid organ transplantation	ProtAffin Biotechnologie AG
1360	glycerol phenylbutyrate	Ravicti	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Horizon Pharma, Inc.
1361	Glyceryl tri (4-phenylbutyrate)	n/a	5/24/2005	Treatment of spinal muscular atrophy	Ucyclyd Pharma, Inc
1362	Glyceryl trioleate and glyceryl trierucate	n/a	2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D.
1363	glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Shionogi, Inc.
1364	glycopyrrolate 2%	n/a	6/17/2010	Treatment of Frey's syndrome	Wellesley Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1365	glycosylated recombinant human interleukin-7	n/a	9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Cytheris, Inc.
1366	glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/2013	Treatment of Fragile X Syndrome	Neuren Pharmaceuticals, Ltd.
1367	glycyl-L-2-methylpropyl-L-glutamic acid	n/a	2/11/2015	Treatment of Rett syndrome	Neuren Pharmaceuticals, Ltd.
1368	Glyeraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/2010	Treatment of pediatric multiple sclerosis	BPT Pharmaceuticals, Inc.
1369	GNE Lipoplex	n/a	11/13/2008	Treatment of hereditary inclusion body myopathy-2	Gradalis, Inc.
1370	GNE plasmid(H001)	n/a	3/26/2010	Treatment of hereditary inclusion body myopathy type 2	HIBM Research Group
1371	golimumab	Simponi	3/16/2012	Treatment of pediatric ulcerative colitis	Janssen Biotech, Inc.
1372	golimumab	Simponi Aria	4/2/2015	Treatment of polyarticular juvenile idiopathic arthritis in pediatric patients (o through 16 years of age)	Janssen Research & Development, LLC
1373	golnerminogene pradenovec	Tnferade(Tm) Biologic	10/28/2009	Treatment of pancreatic cancer.	GenVec, Inc.
1374	Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1375	Gossypol	n/a	10/22/1990	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D.
1376	Gp100 adenoviral gene therapy	n/a	3/25/1997	Treatment of metastatic melanoma.	Genzyme Corporation
1377	granulocyte macrophage colony stimuling factor	n/a	8/27/2008	Treatment of cystic fibrosis	DrugRecure Aps
1378	granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF	n/a	7/24/2013	Treatment of soft tissue sarcoma	Oncos Therapeutics
1379	Growth hormone releasing factor	n/a	8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Valeant Pharmaceuticals North America
1380	growth hormone releasing hormone, 1-44 human amide	n/a	2/23/2016	Treatment of growth hormone deficiency	Hollenbeck Pharmaceuticals, Inc.
1381	guadecitabine	n/a	9/29/2015	Treatment of acute myeloid leukemia.	Astex Pharmaceuticals, Inc.
1382	guanfacine	Tenex	8/5/1999	Treatment of fragile X syndrome.	Watson Laboratories, Inc.
1383	guanfacine and amphetamine	n/a	3/17/2016	Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age)	Genco Sciences, LLC
1384	gusperimus trihydrochloride	n/a	6/29/2011	Treatment of Wegener's granulomatosis	Nordic Group B.V.
1385	GVAX melanoma	n/a	12/23/2010	Treatment of stage IIb to IV melanoma	Aduro BioTech, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1386	gylceryl tri (4-pheynlybutyrate)	n/a	9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Hyperion Therapeutics, Inc.
1387	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt	n/a	12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	CanBas Company, Ltd.
1388	H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/2012	Treatment of Kaposi sarcoma	Immuno Tech, Inc.
1389	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/2013	Treatment of subarachnoid hemorrhage	NoNO, Inc.
1390	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH	n/a	4/11/2014	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	NoNO, Inc.
1391	Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals
1392	Halofuginone	Stenorol	2/7/2000	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd.
1393	halofuginone hydrobromide	n/a	10/13/2011	Treatment of Duchenne Muscular Dystrophy	Halo Theraeputics, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1394	Hanferon	Hanferon	3/9/2012	Treatment of Behcet's disease	HanAll BioPharma Co., Ltd.
1395	Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Surgeon General of the U. S. Army
1396	HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex	n/a	4/19/2016	Treatment of localized scleroderma.	Fibrocell Technologies, Inc.
1397	heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/2004	Active tuberculosis	Cadila Pharmaceuticals Limited, Inc.
1398	heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc.
1399	heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Cadila Pharmaceuticals Limited
1400	heat killed whole cell mycobacterium obuense	n/a	9/23/2014	Treatment of pancreatic cancer	Immodulon Therapeutics Limited
1401	Heat Shock Protein (hsp60) antigen	Diapep277	5/21/2012	For use in type 1 diabetic mellitus patients with residual beta-cell function	AndromedA Biotech, LTD
1402	Heat Shock Protein 70	n/a	3/18/2011	Treatment of amyotrophic lateral sclerosis	ALS Biopharma, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1403	hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist	n/a	8/27/2014	Hematopoietic support in patients with acute lymphoblastic leukemia (ALL)	Novartis Pharmaceuticals Corporation
1404	Heme arginate	Normosang	3/1/1994	Treatment of myelodysplastic syndromes.	Orphan Europe
1405	Heme arginate	Normosang	3/10/1988	Treatment of symptomatic stage of acute porphyria.	Orphan Europe SARL
1406	Hemin	Panhematin	3/16/1984	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.	Abbott Laboratories
1407	Hemin and zinc mesoporphyrin	Hemex	12/20/1993	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D.
1408	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/2007	Treatment of cardiogenic shock	Apex Bioscience, Inc.
1409	heparan sulfate mimetic	n/a	5/29/2014	Treatment of pancreatic cancer	Momenta Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1410	heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	n/a	10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	BioArctic Neuroscience AB
1411	Heparin sodium	n/a	6/29/2006	Treatment of cystic fibrosis	Ockham Biotech Limited
1412	Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/2006	Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams	Trillium Therapeutics, Inc.
1413	hepatitis B immune globulin (human)	Hepagam	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Cangene Corporation
1414	Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Biotest Pharmaceuticals Corporation
1415	hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Green Cross Corp.
1416	Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Biotest Pharmaceuticals Corporation
1417	hepcortespenlisimut-L	n/a	12/17/2014	Treatment of hepatocellular carcinoma	Immunitor, Inc.
1418	Heptadecasodium salt of an 18-base residue phosphorothioate oligonucleotide	n/a	4/18/2011	Treatment of spinal muscular atrophy	Isis Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1419	herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter	n/a	12/23/2014	Treatment of pancreatic cancer	Karcinolys S.A.S.
1420	Herpes simplex virus gene	n/a	10/16/1992	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc.
1421	heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/2012	Treatment of urea cycle disorders	Promethera Biosciences
1422	heterologous human liver derived progenitor cells	n/a	3/9/2012	Treatment of Crigler-Najjar syndrome	Promethera Biosciences
1423	hexasodium phytate	n/a	12/2/2012	Treatment of calciphylaxis	Laboratoris Sanifit, S.L.
1424	HIRMAb-IDS	n/a	5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	ArmaGen Technologies, Inc.
1425	His-His- Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2	n/a	1/13/2016	Treatment of retinal detachment	ONL Therapeutics, Inc
1426	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/2013	Treatment of retinal detachment	ONL Therapeutics, Inc
1427	Histamine	Ceplene	12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	EpiCept Corporation
1428	Histamine	Maxamine	2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	EpiCept Corporation
1429	Histrelin	n/a	5/3/1991	Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.	Anderson, Karl E., M.D.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1430	Histrelin	Supprelin La	11/18/2005	Treatment of central precocious puberty	Endo Pharmaceuticals Solutions, Inc.
1431	Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
1432	HLA-A2-selective gp100-specific T cell redirector	n/a	1/21/2016	Treatment of uveal melanoma.	Immunocore Ltd
1433	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/1999	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated
1434	homoharringtonine	n/a	2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc.
1435	HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Gliknik, Inc.
1436	HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	ISA Therapeutics BV
1437	Hu1D10, humanized monoclonal antibody	Remitogen	11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	PDL BioPharma, Inc.
1438	human allogeneic bone marrow derived osteoblastic cells	Allob	1/10/2014	Treatment of osteonecrosis	Bone Therapeutics SA
1439	human allogeneic bone marrow derived osteoblastic cells	n/a	11/9/2015	Treatment of osteogenesis imperfecta.	Bone Therapeutics SA

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1440	Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells	n/a	9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Mesoblast, Inc.
1441	Human alpha 2,6 sialyltransferase adenoviral gene therapy	n/a	4/4/2005	Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.	Falk Center for Molecular Therapeutics
1442	Human anti-CD30 monoclonal antibody	n/a	9/27/2004	Treatment of Hodgkin's disease	Bristol-Myers Squibb, Inc.
1443	human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/2004	Treatment of mycosis fungoides	Emergent Product Development Seattle, LLC
1444	human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/2008	Treatment of multiple myeloma	BioInvent International AB
1445	Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/2008	Treatment of osteonecrosis	Bone Therapeutics S.A.
1446	human coagulation factor VIII	Octanate	12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	OCTAPHARMA USA, Inc.
1447	human coagulation factor XI	Hemoleven	11/8/2007	Treatment of severe congential Factor XI deficiency.	Laboratoire francais du Fractionnement et des Biot

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1448	human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI)	n/a	11/3/2015	Treatment of patients with cystic fibrosis.	Shire
1449	Human cytomegalovirus immunoglobulin	n/a	12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Biotest Pharmaceuticals Corporation
1450	Human factor X	Coagadex	11/8/2007	Treatment of hereditary factor X deficiency	Bio Products Laboratory
1451	human fibrinogen concentrate, pasteurized	Riastap	3/13/2008	Treatment of fibrinogen deficient patients.	CSL Behring, LLC
1452	human fully IgG1 antibody specific for CD33	n/a	6/19/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
1453	human gammaglobulin	Oralgam	11/14/2003	Treatment of idiopathic inflammatory myopathies	Latona Life Sciences, Inc.
1454	human gammaglobulin	Oralgam	9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Latona Life Sciences, Inc.
1455	human gammaglobulin	Oralgam	5/25/2001	Treatment for juvenile rheumatoid arthritis	Latona Life Sciences, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1456	human glial restricted progenitor cells and their progeny	Q-Cells	9/11/2013	Treatment of amyotrophic lateral sclerosis	Q Therapeutics, Inc.
1457	human haptoglobin	n/a	11/19/2013	Treatment of sickle cell disease	BioProducts Laboratory Limited
1458	Human Hemin	n/a	8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Borders Technology Management Ltd
1459	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/2011	Treatment of acute liver failure	Alfact Innovation SAS
1460	human heterologous liver cells	n/a	2/14/2011	Treatment of urea cycle disorders	Promethera Biosciences S.A./N.V.
1461	human IgG1k monoclonal antibody	n/a	10/16/2013	Treatment of systemic sclerosis	MedImmune
1462	Human immune globulin	Flebogamma(R) 5% Dif	3/29/2006	Treatment of post-polio syndrome	Instituto Grifols, S.A.
1463	Human immunoglobin anti-CD30 monoclonal antibody	n/a	1/10/2006	Treatment of CD30+ T-cell lymphoma	Bristol-Myers Squibb
1464	human insulin (rDNA)	n/a	4/6/2015	Treatment of short bowel syndrome (SBS).	Nutrinia, Ltd.
1465	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Orban Biotech, LLC
1466	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/2011	Treatment of acute myeloid leukemia.	Stemline Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1467	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Stemline Therapeutics, Inc.
1468	human laminin-111	n/a	9/23/2011	Treatment of merosin (laminin-alpha2) deficient congential muscular dystrophy type 1A.	Prothelia, Inc.
1469	human leukocyte antigen-A2 restricted peptides	n/a	1/26/2015	Treatment of glioma.	Stemline Therapeutics, Inc.
1470	human leukocyte-derived cytokine mixture	n/a	7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	IRX Therapeutics, Inc.
1471	human MHC non-restricted cytotoxic T-cell line	n/a	7/6/2012	Treatment of ovarian cancer	Galileo Research srl
1472	human monoclonal anti-PA antibody	Yervoy	10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Emergent Product Development Gaithersburg, Inc.
1473	Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F	n/a	5/29/2014	Treatment of glioblastoma multiforme	AbbVie, Inc.
1474	Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CuraGen Corporation
1475	human monoclonal antibody againt human interleukin 13 (IL-13)	n/a	10/15/2013	Treatment of eosinophilic esophagitis	Novartis Pharmaceuticals Corporaton

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1476	human monoclonal antibody directed against active plasma kallikrein	n/a	11/26/2013	Treatment of hereditary angioedema (HAE)	Dyax Corporation
1477	Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa	Aerumab 11	9/18/2006	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Kenta Biotech Limited
1478	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Kenta Biotech Limited
1479	human monoclonal antibody directed against tissue factor pathway inhibitor	n/a	5/18/2016	Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients.	Pfizer, Inc.
1480	Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	n/a	12/16/2013	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Omeros Corporation
1481	Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/2010	Treatment of ovarian cancer	Ortho Biotech
1482	human monoclonal antibody targeting human sclerostin	n/a	2/29/2016	Treatment of osteogenesis imperfecta.	Mereo Biopharma 3 Limited

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1483	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Octapharma USA, Inc.
1484	Human plasma derived conagulation protein-Factor XI	n/a	4/30/2014	For the treatment of congenital Factor XI deficiency	Cambryn Biologics
1485	human plasminogen	n/a	6/7/2010	Treatment of ligneous conjunctivitis	Kedrion, S.p.A.
1486	human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Prophylix Pharma AS
1487	Human prothrombin complex concentrate	Octaplex	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Octapharma USA, Inc.
1488	human recombinant bone morphogenetic protein 4	n/a	5/4/2016	Treatment of glioblastoma multiforme.	HyperStem Therapeutics, Inc.
1489	human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor	n/a	7/6/2012	Treatment of idiopathic pulmonary fibrosis	FibroGen, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1490	human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A	n/a	2/4/2016	Treatment of pediatric patients 0 to	AbbVie, Inc.
1491	human recombinant mesencephalic, astrocyte derived neurotrophic factor	n/a	12/22/2014	Treatment of retinitis pigmentosa	Amarantus BioScience Holdings, Inc.
1492	human retinal progenitor cells	n/a	7/23/2012	Treatment of retinitis pigmentosa	jCyte, Inc.
1493	human soluble receptor-Fc fusion protein that targets human activin A	n/a	10/14/2015	Treatment of ovarian cancer.	Atara Biotherapeutics
1494	human spinal cord derived neural stem cells	n/a	2/4/2011	Treatment of amyotrophic lateral sclerosis	Neuralstem, Inc.
1495	Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/1989	Treatment of AIDS.	MicroGeneSys, Inc.
1496	Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/2006	Treatment of pancreatic cancer	GemVax A/S

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1497	human trtravalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3)	n/a	10/22/2014	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
1498	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/2009	Treatment of liver cancer	Molecular Medicine S.p.A. (Molmed)
1499	human umbilical cord blood-derived mesenchymal stem cells	Pneumostem	11/26/2013	Prevention of bronchopulmonary dysplasia	MEDIPOST America, Inc.
1500	Human Wilms tumor protein 1 peptides	n/a	12/23/2015	Treatment of acute myeloid leukemia	SELLAS Life Sciences Group
1501	Human wilms tumor protein 1 peptides	n/a	2/23/2016	treatment of mesothelioma.	SELLAS Life Sciences Group
1502	Human/Murine Chimeric Monoclonal antibody to Endoglin	n/a	1/20/2016	Treatment of soft tissue sarcoma.	Tracon Pharmaceuticals, Inc.
1503	Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/2013	Treatment of neuroblastoma	Memorial Sloan-Kettering Cancer Center
1504	humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19	n/a	2/10/2016	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	MedImmune, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1505	Humanized anti-CD3 monoclonal antibody	n/a	9/29/2006	Treatment of recent-onset Type I diabetes	MacroGenics, Inc.
1506	humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	n/a	6/30/2014	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chugai Pharma USA, LLC
1507	Humanized anti-tac	Zenapax	3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc.
1508	humanized Fc engineered monoclonal antibody against CD19	n/a	4/29/2014	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	MorphoSys AG
1509	humanized Fc engineered monoclonal antibody against CD19	n/a	12/1/2014	Treatment of diffuse large B-cell lymphoma.	MorphoSys AG
1510	humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Prothena Therapeutics Limited
1511	humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/2011	Treatment of follicular lymphoma	MENTRIK Biotech, LLC
1512	humanized IgG2 antibody	n/a	7/22/2008	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Selexys Pharmaceuticals Corp.
1513	humanized IgG4 monoclonal antibody	n/a	12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ tranplantation	Opsona Theraeputics
1514	humanized immunoglobulin monoclonal antibody against CD38	n/a	5/22/2014	Treatment of multiple myeloma.	Sanofi U.S. Services, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1515	humanized monoclonal antibodies hu1B7 and hu11E6	n/a	9/11/2014	Treatment of Bordetella pertussis	Synthetic Biologics, Inc.
1516	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/2010	Treatment of idiopathic pulmonary fibrosis	Biogen Idec, Inc.
1517	humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47	n/a	8/20/2015	Treatment of acute myeloid (myelogenous) leukemia.	Forty Seven, Inc.
1518	humanized monoclonal antibody that targets the a-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473)	n/a	5/5/2015	Treatment of acute myeloid leukemia	Janssen Research & Development, LLC
1519	humanized monoclonal antibody to tissue factor	n/a	4/26/2011	Treatment of pancreatic cancer.	Morphotek, Inc.
1520	Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/2011	Treatment of soft tissue sarcoma	Morphotek
1521	humanized monocloncal antibody against human integrin alphaVbeta6	n/a	6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Stromedix, Inc.
1522	humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/2011	Treatment of chronic lymphocytic leukemia	Emergent Product Development Seattle, LLC
1523	humanized, afucosylated IgG1 kappa monoclonal antibody	n/a	12/3/2009	Treatment of scleroderma	MedImmune

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1524	hyaluronic acid	n/a	3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	CoTherix
1525	Hydralazine	n/a	4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Bioniche Pharma USA LLC
1526	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of cutaneous T-cell lymphoma.	Neolpharma S.A.DE C.V.
1527	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of myelodysplastic syndrome	Neolpharma S.A.DE C.V.
1528	hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO)	n/a	3/9/2015	Treatment of amyotrophic lateral sclerosis	Alsonex Pty Ltd
1529	hydrocortisone modified release capsules	Chronocort	3/18/2015	Treatment of congenital adrenal hyperpasia	Diurnal Limited
1530	hydrocortisone modified release capsules	Chronocort(R)	9/3/2015	Treatment of adrenal insufficiency.	Diurnal Ltd.
1531	hydrocortisone modified release tabs	Duocort	6/18/2008	Treatment of adrenal insufficiency	Shire ViroPharma, Inc.
1532	hydrocortisone oral granules	Infacort(R)	5/13/2015	Treatment of pediatric adrenal insufficiency (0 through 16 years of age).	Diurnal Limited
1533	Hydroxocobalamin	n/a	9/22/2000	Treatment of acute cyanide poisoning	Jazz Pharmaceuticals
1534	Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	SERB, S.A.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1535	Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/2010	Treatment of Niemann Pick Disease, Type C	Sphingo Biotech, LLC
1536	hydroxycarbamide (hydroxyurea)	Siklos	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	addmedica Laboratories
1537	hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	KV Pharmaceutical Company
1538	Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute
1539	hydroxyurea	n/a	4/15/2005	Treatment of pediatric patients with sickle cell anemia.	UPM Pharmaceuticals, Inc.
1540	hydroxyurea	Pedroxa	3/16/2015	Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.	Ebelle D'Ebelle Pharmaceuticals LLC
1541	Hypericin	n/a	2/7/2000	Treatment of cutaneous T-cell lymphoma.	Soligenix, Inc.
1542	Hypericin	n/a	8/3/2000	Treatment of glioblastoma multiforme.	HyBiopharma, Inc.
1543	Hypothiocyanite and lactoferrin	Meveol	11/5/2009	Treatment of cystic fibrosis	Alaxia Biotechnologies Sante
1544	I(131)-TM-601 (chlorotoxin)	n/a	2/14/2002	Treatment of malignant glioma	Morphotek, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1545	ibalizumab	n/a	10/20/2014	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	TaiMed Biologics, Inc.
1546	ibritumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Spectrum Pharmaceuticals, Inc.
1547	ibrutinib	Imbruvica	2/2/2016	Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)	Pharmacyclics, LLC
1548	ibrutinib	Imbruvica	2/5/2015	Treatment of nodal marginal zone lymphoma	Pharmacyclics, LLC
1549	ibrutinib	n/a	5/16/2013	Treatment of multiple myeloma	Pharmacyclics, LLC
1550	ibrutinib	Imbruvica	5/30/2013	Treatment of small lymphocytic lymphoma	Pharmacyclics, LLC
1551	ibrutinib	n/a	9/8/2014	Treatment of follicular lymphoma	Pharmacyclics, LLC
1552	ibrutinib	Imbruvica	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Pharmacyclics, LLC
1553	ibrutinib	n/a	10/23/2013	Treatment of diffuse large B-cell lymphoma	Pharmacyclics, LLC
1554	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, LLC
1555	ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma	Pharmacyclics, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1556	ibrutinib	Imbruvica	2/5/2015	Treatment of splenic marginal zone lymphoma	Pharmacyclics, LLC
1557	ibudilast	n/a	6/1/2015	Treatment of Krabbe disease.	MediciNova, Inc.
1558	Ibuprofen i.v. solution	Salprofen	10/29/1996	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC
1559	Ibuprofen lysine	Neoprofen	10/29/1996	Treatment of patent ductus arteriosus	Lundbeck, Inc.
1560	icatibant	Firazyr	11/25/2003	Treatment of angioedema	Shire Orphan Therapies
1561	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation
1562	Idarubicin HCl for injection	Idamycin	7/25/1988	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc.
1563	idarucizumab	n/a	5/28/2015	To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure	Boehringer Ingelheim Pharmaceuticals, Inc.
1564	idebenone	n/a	3/25/2004	Treatment of Friedreich's ataxia	Santhera Pharmaceuticals LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1565	idebenone	n/a	5/22/2009	Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)	Santhera Pharmaceuticals Limited
1566	idebenone	n/a	10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Santhera Pharmaceuticals Limited
1567	idebenone	n/a	2/16/2007	Treatment of Duchenne muscular dystrophy	Santhera Pharaceuticals Limited
1568	idelalisib	n/a	10/15/2013	Treatment of nodal marginal zone lymphoma.	Gilead Sciences, Inc.
1569	idelalisib	n/a	10/15/2013	Treatment of splenic marginal zone lymphoma	Gilead Sciences, Inc.
1570	idelalisib	n/a	10/15/2013	Treatment of extranodal marginal zone lymphoma	Gilead Sciences, Inc.
1571	idelalisib	n/a	9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia	Gilead Sciences, Inc.
1572	idelalisib	Zydelig	9/26/2013	Treatment of follicular lymphoma	Gilead Sciences, Inc.
1573	idelalisib	Zydelig	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Gilead Sciences, Inc.
1574	idelalisib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
1575	Idoxuridine	n/a	4/8/1996	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1576	IDUA-HIRMAb fusion protein	n/a	1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	ArmaGen Technologies, Inc.
1577	idursulfase	Elaprase	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Shire Human Genetic Therapies, Inc.
1578	idursulfase beta	n/a	2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Green Cross Corp.
1579	idursulfase IT	n/a	9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Shire Human Genetic Therapies
1580	iduvec	n/a	1/21/2011	Treatment of Mucopolysaccharidosis Type I	Zebraic Corporation
1581	iferanserin (S-MPEC)	n/a	12/13/2010	For use in pulmonary arterial hypertension.	Sam Amer & Company, Inc.
1582	Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute
1583	ifosfamide	n/a	8/7/1985	Treatment of soft tissue and bone sarcomas	Bristol-Myers Squibb Company
1584	IgG1 chimeric monoclonal antibody	n/a	6/22/2011	Treatment of multiple myeloma.	Immune System Therapeutics Ltd
1585	IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/2013	Treatment of malignant glioma	Activartis Biotech GmbH

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1586	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/2000	Treatment of astrocytic glioma.	Medicenna Therapeutics, Inc.
1587	iloprost	n/a	4/6/2012	Treatment of pulmonary arterial hypertension	Algorithum Sciences, LLC
1588	Iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	CoTherix, Inc.
1589	Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals Corporation
1590	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
1591	Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Novartis Pharmaceuticals Corporation
1592	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
1593	Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Novartis Pharmaceuticals Corporation
1594	Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Novartis Pharmaceuticals Corporation
1595	imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Novartis Pharmaceuticals Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1596	imatinib mesylate	n/a	5/6/2014	Treatment of progressive multifocal leukencephalopathy	Inhibikase Therapeutics, Inc.
1597	Imciromab pentetate	Myoscint	1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
1598	imetelstat	n/a	12/23/2015	Treatment of myelodysplastic syndrome	Janssen Research & Development, LLC
1599	imetelstat	n/a	6/11/2015	Treatment of myelofibrosis	Janssen Research & Development, LLC
1600	Imexon	n/a	11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation
1601	imexon	Amplimexon	8/12/2005	Treatment of ovarian cancer.	AmpliMed Corporation
1602	Imiglucerase	Cerezyme	11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation
1603	Imiquimod	n/a	12/3/2014	Treatment of carcinoma in situ (CIS) of the urinary bladder	Telormedix SA
1604	Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Vital Therapies, Inc.
1605	Immune Globulin (Human)	Gamunex(R)-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Grifols Therapeutics, Inc.
1606	immune globulin (human)	n/a	3/2/2010	Treatment of Guillain-Barre syndrome	Octapharma USA, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1607	Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/2004	Treatment of the West Nile virus infection	OMRIX Biopharmaceuticals, Ltd.
1608	immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Baxalta US, Inc.
1609	immune globulin infusion 10% (human) with recombinant human hyaluronidase)	n/a	3/31/2016	Treatment of chronic inflammatory demyelinating polyneuropathy	Baxalta US, Inc.
1610	Immune Globulin Intravenous (human)	Carimune Nf	5/4/2004	Treatment for Guillain Barre Syndrome	ZLB Bioplasma AG
1611	Immune globulin intravenous, human	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation
1612	immune globulin intraveous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Bio Products Laboratory
1613	Immune Globulin Subcutaneous (Human), 20% Liquid	Hizentra	8/18/2014	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	CSL Behring
1614	immunoglobulin G degrading enzyme of Streptococcus pyogenes	n/a	9/10/2015	Prevention of antibody mediated organ rejection in solid organ transplant patients.	Hansa Medical AB
1615	immunologically active synthetic peptides	n/a	6/1/2015	Treatment of Hemophilia A	Apitope International NV

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1616	Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation
1617	Imported fire ant venom, allergenic extract	n/a	5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.
1618	Inalimarev and falimarev	n/a	1/10/2006	Treatment of adenocarcinoma of the pancreas	Therion Biologics Corporation
1619	inBreath airway transplant system	n/a	9/4/2014	To restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection	Harvard Apparatus Regenerative Technology, Inc.
1620	Indium-111 pentetreotide	Neuroendomedix	6/16/2006	Treatment of neuroendocrine tumors	RadioIsotope Therapy of America (RITA) Foundation
1621	Inecalcitol	n/a	5/14/2014	Treatment of chronic lymphocytic leukemia	Hybrigenics, S.A.
1622	inecalcitol	n/a	8/3/2015	Treatment of acute myeloid leukemia.	Hybrigenics, S.A.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1623	Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc.
1624	infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Centocor, Inc.
1625	infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Janssen Biotech Inc.
1626	infliximab	Remicade	10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
1627	Infliximab	Remicade	5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc.
1628	inhibitor of microRNA-451	n/a	2/4/2011	Treatment of polycythemia vera	miRagen Therapeutics, Inc.
1629	Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST	n/a	10/2/2014	Treatment of gastrointestinal stromal tumors (GIST)	Deciphera Pharmaceuticals, LLC
1630	Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/2010	Treatment of hemophilia A and hemophilia B.	Baxter Healthcare Corporation, Baxter BioScience
1631	inolimomab	Leukotac	10/23/2002	Treatment of graft versus host disease	Jazz Pharmaceuticals
1632	Inosine pranobex	Isoprinosine	9/20/1988	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals
1633	inotuzumab ozogamicin	n/a	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Pfizer, Inc.
1634	insecticidal toxin derived from Bacillus thuringiensis	n/a	9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	University of California, San Diego
1635	Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1636	Interferon alfa-2a (recombinant)	Roferon-A	4/18/1988	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc.
1637	Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc.
1638	Interferon alfa-2a (recombinant)	Roferon-A	5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc.
1639	Interferon alfa-2a (recombinant)	Roferon-A	10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
1640	Interferon alfa-2a (recombinant)	Roferon-A	5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc.
1641	Interferon alfa-2a (recombinant)	Roferon-A	5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1642	Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation
1643	Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Biogen, Inc.
1644	Interferon beta-1a	Rebif	3/11/1996	Treatment of patients with secondary progressive multiple sclerosis.	EMD Serono, Inc.
1645	Interferon beta-1a (recombinant human)	n/a	7/24/1992	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1646	Interferon beta-1a (recombinant)	Rebif	12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
1647	Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories
1648	Interferon gamma	n/a	10/11/2007	Treatment of idiopathic pulmonary fibrosis	mondoBIOTECH Laboratories AG
1649	interferon gamma	n/a	11/4/2011	Treatment of Friedreich's ataxia	Roberto Testi, MD
1650	Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Horizon Pharma Ireland Limited
1651	Interferon gamma-1b	Actimmune	9/30/1996	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	Horizon Pharma Ireland Limited
1652	Interferon gamma-1b	Actimmune	12/4/1995	Treatment of renal cell carcinoma.	Horizon Pharma Ireland Limited
1653	interferon gamma-1b	Actimmune	10/1/2014	Treatment of Friedreich's Ataxia	Horizon Pharma Ireland Limited
1654	Interferon-alfa-1b	n/a	4/17/2001	Treatment of multiple myeloma	Ernest C.Borden
1655	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/2012	Treatment of chronic hepatitis D	Medgenics, Inc.
1656	interleukin-1 receptor antagonist anakinra	Kineret	9/15/2015	Treatment of Still's disease including systemic juvenile idiopathic arithritis and adult-onset Still's disease.	Swedish Orphan Biovitrum AB

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1657	Interleukin-1 receptor antagonist, human recombinant	Antril	10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1658	Interleukin-1 receptor antagonist, human recombinant	Antril	9/23/1991	Treatment of juvenile rheumatoid arthritis.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1659	Interleukin-1 Trap	n/a	4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Regeneron Pharmaceuticals, Inc.
1660	Interleukin-2	Teceleukin	2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1661	Interleukin-2	Teceleukin	5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1662	Interleukin-2	Teceleukin	5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
1663	Interleukin-2	Teleleukin	2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
1664	Intraoral fluoride releasing system	Ifrs	7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc.
1665	intravenous carbamazepine	n/a	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Lundbeck LLC
1666	Intravenous immune globulin	Vitigam	7/26/2007	Treatment of Stage IIB to IV malignant melanoma	GammaCan Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1667	Intravenous immune globulin (human) 10%	Octagam(R)	7/31/2008	Treatment of stiff-person syndrome	Octapharma USA, Inc.
1668	intraventricular nimodipine	n/a	5/28/2015	Treatment of subarachnoid hemorrhage	Edge Therapeutics, Inc.
1669	Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	GE Healthcare, Inc.
1670	Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of pheochromocytomas	GE Healthcare, Inc.
1671	Iobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Molecular Insight Pharmaceuticals
1672	iobenguane I 131	n/a	7/5/2007	Treatment of neuroendocrine tumors	Jubilant DraxImage, Inc.
1673	Iobenguane Sulfate I-123	Omaclear	10/17/2005	For scintigraphic detection, localization and staging of neuroblastoma.	Brogan Pharmaceuticals, LLC
1674	iobenguane sulfate I-123	Omaclear	10/21/2005	For the detection, localization, and staging of pheochromocytomas.	Brogan Pharmaceuticals, Inc.
1675	Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/1984	For use in adrenal cortical imaging.	David E. Kuhl, M.D.
1676	Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc.
1677	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody	Pentacea	2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1678	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	131ichtnt-1	2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc.
1679	ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Company
1680	iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG
1681	isavuconazonium sulfate	Cresemba	5/6/2013	Treatment of invasive aspergillosis	Astellas Pharma Global Development Inc.
1682	isavuconazonium sulfate	Cresemba	10/25/2013	Treatment of zygomycosis	Astellas Pharma Global Development Inc.
1683	isavuconazonium sulfate	n/a	10/20/2014	Treatment of invasive candidiasis/candidemia	Astellas Pharma Global Development, Inc.
1684	Isobutyramide	n/a	5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation
1685	Isobutyramide	Isobutyramide Oral Solution	12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D.
1686	isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor	n/a	6/9/2015	Treatment of acute myeloid leukemia (AML)	Agios Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1687	isocitrate dehydrogenase 2-mutant inhibitor	n/a	6/12/2014	Treatment of acute myelogenous leukemia	Celgene Corporation
1688	isofagomine tartrate	n/a	1/10/2006	Treatment of Gaucher disease	Amicus Therapeutics, Inc.
1689	isotretinoin	n/a	4/10/2014	Treatment of congenital ichthyosis	Patagonia Pharmaceuticals, LLC
1690	Itraconazole	n/a	5/19/2016	Treatment of basal cell carcinoma nevus syndrome.	HedgePath Pharmaceuticals, Inc
1691	Itraconazole suspension	n/a	10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Fairfield Clinical Trials, LLC
1692	ivabradine	n/a	3/23/2016	Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.	Amgen, Inc.,
1693	ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Vertex Pharmaceuticals, Inc.
1694	ixazomib citrate	Ninlaro	2/18/2011	Treatment of multiple myeloma	Millennium Pharmaceuticals
1695	Japanese encephalitis vaccine (live, attenuated)	n/a	5/19/1999	Prevention of Japanese encephalitis.	Glovax Co., Ltd.
1696	Japanese encephalitis vaccine, inactivated, adsorbed	Ixiaro	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Intercell AG
1697	ketotifen	n/a	2/25/2015	Treatment of mastocytosis	Melbourne Laboratories LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1698	Kre-Celazine	n/a	4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	All American Pharmaceutical & Natural Foods Corpor
1699	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/1996	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc.
1700	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/1994	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc.
1701	L-5 Hydroxytrytophan	n/a	11/1/1984	Treatment of postanoxic intention myoclonus.	Watson Laboratories, Inc.
1702	L-5-hydroxytryptophan	n/a	1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc.
1703	L-amino acids, vitamins and minerals combined with omega-3 fatty acids	n/a	1/12/2011	Treatment of patients with pediatric Crohn's disease	Immunopath Profile, Inc.
1704	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	n/a	1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	CepTor Corporation
1705	L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/2013	Treatment of acute radiation syndrome	Soligenix, Inc.
1706	L-asparaginase	n/a	3/27/2014	Treatment of acute myeloid leukemia	ERYTECH Pharma S.A.
1707	L-asparaginase encapsulated in red blood cells	Graspa	1/6/2010	Treatment of acute lymphoblastic leukemia	Erytech Pharma
1708	L-asparaginase encapsulated in red blood cells	Graspa	7/6/2012	Treatment of pancreatic cancer.	ERYTECH Pharma

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1709	L-baclofen	Neuralgon	1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Osmotica Pharmaceutical Corp.
1710	L-baclofen	n/a	1/6/1998	Treatment of trigeminal neuralgia	Osmotica Pharmaceutical Corp.
1711	L-baclofen	n/a	7/13/1990	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D.
1712	L-baclofen	n/a	12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Osmotica Pharmaceutical Corp.
1713	L-cycloserine	n/a	8/1/1989	Treatment of Gaucher's disease.	Lev, Meir M.D.
1714	L-cysteine	n/a	5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Brigham and Women's Hospital
1715	L-glutamine	n/a	8/1/2001	Treatment of sickle cell disease	Emmaus Medical, Inc.
1716	L-glutamyl-L-tryptophan	n/a	10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Implicit Bioscience Pty Ltd
1717	L-ornithine phenylacetate	n/a	4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase	Ocera Therapeutics, Inc.
1718	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/2009	Prevention of delayed graft function following renal transplant	Araim Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1719	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Araim Pharmaceuticals, Inc.
1720	L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Nyxis Neurotherapies, Inc.
1721	L-tyrosine-L-serine-L-leucine	Cms-024	9/10/2004	Treatment of hepatocellular carcinoma.	CMS Peptides Patent Holding Company Limited
1722	L. reuteri	n/a	8/1/2013	Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams	Infant Bacterial Therapeutics
1723	Lactic acid	Aphthaid	6/29/1999	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc.
1724	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)	n/a	1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc.
1725	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	n/a	1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc.
1726	Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis	n/a	3/24/2015	Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams	Sigma-Tau Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1727	lactobacillus brevis CD2	n/a	10/4/2011	Treatment Behcet's disease	VSL Pharmaceuticals, Inc.
1728	laminin-111 (human)	n/a	7/21/2011	Treatment of Duchenne Muscular Dystrophy	Prothelia, Inc.
1729	Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development
1730	Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	IPSEN, Inc.
1731	lanreotide acetate	n/a	9/8/2011	Treatment of symptoms associated with carcinoid syndrome	Ipsen Biopharmaceuticals, Inc.
1732	lanreotide acetate	Somatuline Depot	8/25/2011	Treatment of neuroendocrine tumors	Ipsen Biopharmaceuticals, Inc.
1733	lapatinib	Tykerb	5/29/2009	Treatment of ErbB2 positive gastric cancer	Novartis Pharmaceuticals Corp.
1734	lapatinib ditosylate hydrochloride	Tykerb	5/29/2009	Treatment of ErbB2 positive esophageal cancer	Novartis Pharmaceuticals Corp.
1735	Laromustine	Cloretazine	3/27/2014	Treatment of acute myelogenous leukemia	Nanotherapeutics, Inc.
1736	laromustine	Onrigin	10/21/2004	Treatment of acute myelogenous leukemia	Vion Pharmaceuticals, Inc.
1737	laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
1738	late stage human motor neutron progenitors	Motorgraft(Tm)	11/25/2009	Treatment of spinal muscular atrophy	California Stem Cell, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1739	Latrodectus immune F(ab)2	Analatro	6/18/2001	Treatment of black widow spider envenomations	Instituto Bioclon, S.A. de C.V.
1740	lebrikizumab	n/a	3/9/2015	Treatment of idiopathic pulmonary fibrosis	Genentech, Inc.
1741	Leflunomide	n/a	10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W.
1742	lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Celgene Corporation
1743	lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Celgene Corporation
1744	lenalidomide	Revlimid	4/29/2015	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Celgene Corporation
1745	lenalidomide	Revlimid	1/17/2007	Treatment of chronic lymphocytic leukemia	Celgene Corporation
1746	lenalidomide	Revlimid	3/28/2011	Treatment of diffuse large B-cell lymphoma	Celgene Corporation
1747	lenalidomide	Revlimid	9/20/2001	Treatment of multiple myeloma	Celgene Corporation
1748	lenalidomide	Revlimid	9/17/2013	Treatment of follicular lymphoma	Celgene Corporation
1749	Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/2010	Treatment of Stargardt disease	Sanofi US Services, Inc.
1750	lentiviral vector containing the human liver and erythroid pyruvate kinase gene	n/a	3/23/2016	Treatment of pyruvate kinase deficiency.	Centro de Investigacion Biomedica en RED (CIBER)

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1751	Lentiviral vector containing the human MY07A gene	Ushstat(Tm)	5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Sanofi US Services, Inc.
1752	Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Memorial Sloan-Kettering Cancer Center
1753	lenvatinib	n/a	3/27/2014	Treatment of hepatocellular carcinoma	Eisai, Inc.
1754	lenvatinib	Lenvima	12/27/2012	Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer	Eisai, Inc.
1755	lenvatinib	n/a	3/26/2014	Treatment of stage IIB to Stage IV melanoma	Eisai, Inc.
1756	Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel
1757	Lestaurtinib	n/a	3/24/2006	Treatment of acute myeloid leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
1758	lestaurtinib	n/a	9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Teva Branded Pharmaceutical Products R&D, Inc.
1759	letermovir	n/a	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Merck Sharpe & Dhome Corporation
1760	Leucovorin	Leucovorin Calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1761	Leucovorin	Leucovorin Calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation
1762	leukocyte interleukin	Multikine	5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	CEL-SCI Corporation
1763	leukotriene A4 hydrolase inhibitor	n/a	1/26/2015	Treatment of cystic fibrosis	Celtaxsys, Inc.
1764	Leupeptin	n/a	9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc.
1765	Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Tap Pharmaceuticals, Inc.
1766	levetiracetam	Keppra	4/30/2010	Treatment of neonatal seizures	University of California
1767	levocarnitine	Carnitor	11/15/1989	1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity	Sigma-Tau Pharmaceuticals, Inc.
1768	Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc.
1769	Levocarnitine	Carnitor	4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1770	Levocarnitine	Carnitor	11/22/1993	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc.
1771	Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc.
1772	Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc.
1773	Levodopa and carbidopa	Duodopa	1/18/2000	Treatment of late stage Parkinson's disease	AbbVie, Inc.
1774	Levofloxacin	n/a	2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Forest Research Institute, Inc.
1775	Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Spectrum Pharmaceuticals, Inc.
1776	levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Spectrum Pharmaceuticals, Inc.
1777	levomefolate calcium	n/a	2/10/2015	Treatment of megaloblastic anemia caused by folate deficiency	Cox Biosciences LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1778	Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation
1779	levothyroxine sodium	n/a	4/26/2011	The preservation of organ function in brain-dead organ donors.	Fera Pharmaceuticals, LLC
1780	Lidocaine patch 5%	Lidoderm Patch	10/24/1995	For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.	Teikoku Pharma USA, Inc.
1781	Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals
1782	liposomal amikacin	Arikace	3/25/2013	Treatment infections caused by non-tuberculous mycobacteria	Insmed, Inc.
1783	liposomal amikacin	Arikace	3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Insmed, Inc.
1784	liposomal amikacin	Arikace	8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Insmed, Inc.
1785	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc.
1786	Liposomal amphotericin B	Ambisome	12/6/1996	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc.
1787	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of histoplasmosis.	Fujisawa USA, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1788	Liposomal annamycin	n/a	6/17/2005	Treatment of acute lymphoblastic leukemia	Callisto Pharmaceuticals, Inc.
1789	Liposomal annamycin	n/a	6/17/2005	Treatment of acute myeloid leukemia	Callisto Pharmaceuticals, Inc.
1790	liposomal busulfan	Busulipo	6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogenic hematopoietic stem cell transplantation	Pharmalink AB
1791	Liposomal ciprofloxacin for inhalation	n/a	12/27/2006	Management of bronchiectasis	Aradigm Corporation
1792	Liposomal ciprofloxacin for inhalation	n/a	4/19/2006	Management of cystic fibrosis	Aradigm Corporation
1793	liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/2012	For the management of cystic fibrosis	Aradigm Corporation
1794	Liposomal cisplatin	Lipova-Pt	5/23/2006	Treatment of ovarian cancer	Eleison Pharmaceuticals LLC
1795	Liposomal cyclosporin A	Cyclospire	4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D.
1796	liposomal cyclosporine	n/a	5/11/2009	Treatment of bronchiolitis obliterans	PARI Pharma GmbH
1797	liposomal cyclosporine for inhalation	n/a	6/24/2008	Prevention of bronchiolitis obliterans.	PARI Pharma GmbH

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1798	Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/2006	Treatment of soft tissue sarcomas	GP-Pharm SA
1799	liposomal encapsulated paclitaxel	n/a	1/21/2015	Treatment of ovarian cancer	Insys Therapeutics, Inc.
1800	liposomal gadodiamide	n/a	11/12/2008	Treatment of glioma.	MedGenesis Therapeutix, Inc.
1801	liposomal glutathione	n/a	5/18/2016	Treatment of Dengue Virus infection.	Your Energy Systems, LLC
1802	Liposomal Glutathione	n/a	4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Your Energy Systems, LLC
1803	liposomal irinotecan	n/a	7/21/2011	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
1804	Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala - gylcerolidpalmitoyl	Immther	6/10/1998	Treatment of osteosarcoma.	Endorex Corp.
1805	Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala - gylcerolidpalmitoyl	Immther	6/10/1998	Treatment of Ewing's sarcoma.	Endorex Corp.
1806	Liposomal nystatin	Nyotran	6/13/2000	Treatment of invasive fungal infections.	The University of Texas
1807	liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide	n/a	4/27/2015	Treatment of acute myeloid leukemia	Bio-Path Holdings, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1808	liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/2003	Treatment of chronic myelogenous leukemia	Bio-Path, Inc.
1809	liposomal topotecan hydrochloride	n/a	10/30/2008	Treatment of gliomas	MedGenesis Therapeutix, Inc.
1810	liposomal Ã}Â±-galactosylceramide	Lip. Alpha Galactosylceramide	9/28/2012	Prevention of graft-versus-host disease	REGiMMUNE Corporation
1811	liposome encapsulated paclitaxel	n/a	12/3/2014	Treatment of gastric cancer	Insys Therapeutics, Inc.
1812	Liposome encapsulated recombinant interleukin-2	n/a	6/20/1994	Treatment of cancers of the kidney and renal pelvis	Oncothyreon Canada, Inc.
1813	Liposome encapsulated recombinant interleukin-2	n/a	11/25/1991	Treatment of brain and CNS tumors.	Oncothyreon Canada, Inc.
1814	Lisofylline	n/a	6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc.
1815	listeria monocytogenes	n/a	9/5/2013	Treatment of pancreatic cancer	Aduro BioTech, Inc.
1816	lisuride	n/a	1/17/2013	Treatment of pulmonary arterial hypertension	Sinoxa Pharma GmbH
1817	lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/2010	Treatment of Huntington's disease.	Medesis Pharma
1818	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Advaxis, Inc.
1819	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	5/21/2014	Treatment of osteosarcoma.	Advaxis, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1820	live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/2010	Treatment of Familial Adenomatous Polyposis	Marina Biotech
1821	Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38	Not Determined	3/24/2015	Treatment of mesothelioma.	Aduro BioTech, Inc.
1822	LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL	n/a	5/4/2015	Treatment of pancreatic cancer	Lokon Pharma AB
1823	Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc.
1824	lomitapide	n/a	3/3/2011	Treatment of Familial Chylomicronemia	Aegerion Pharmaceuticals, Inc.
1825	lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Aegerion Pharmaceuticals, Inc.
1826	Lonafarnib	n/a	11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Eiger Biopharmaceuticals, Inc.
1827	lonafarnib	n/a	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome	The Progeria Research Foundation, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1828	long acting recombinantFactor VIIa-CTP3	n/a	2/27/2014	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	PROLOR Biotech, Ltd
1829	losartan	n/a	12/12/2011	Treatment of Marfan Syndrome	National Marfan Foundation
1830	low molecular weight dextran sulfate	Ibsolvmir(R)	7/6/2011	Treatment to mobilze progenitor cells prior to stem cell transplantation	TikoMed AB
1831	low molecular weight dextran sulfate	Ibsolvmir	10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	TikoMed AB
1832	lucerastat	n/a	10/29/2015	Treatment of Fabry Disease.	Actelion Pharmaceuticals Ltd
1833	Lucinactant	Surfaxin	5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Windtree Therapeutics, Inc.
1834	Lucinactant	Surfaxin(R), Aerosurf(R)	10/21/2010	Treatment of cystic fibrosis.	Windtree Therapeutics, Inc.
1835	Lucinactant	Surfaxin	7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Windtree Therapeutics, Inc.
1836	Lucinactant	Surfaxin	10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Windtree Therapeutics, Inc.
1837	Lucinactant	Surfaxin	10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Windtree Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1838	lumacaftor/ivacaftor	Orkambi	6/30/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
1839	lurbinectedin	n/a	8/20/2012	Treatment of ovarian cancer	PharmaMar USA, Inc.
1840	lutetium (177Lu)-edotreotide	n/a	5/21/2015	Treatment of gastro-entero-pancreatic neuroendocrine tumors	ITG Isotope Technologies Garching GmbH
1841	lyso-thermosensitive lipsomal doxorubicin	Thermodox (R)	3/17/2009	Treatment of hepatocellular carcinoma	Celsion Corporation
1842	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Vivendy Therapeutics LTD
1843	MA09-hRPE cells	n/a	2/2/2010	Treatment of Stargardt's macular dystrophy.	Advanced Cell Technology, Inc.
1844	macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Actelion Pharmaceuticals Ltd
1845	Mafenide acetate solution	Sulfamylon Solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc.
1846	Mafosfamide	n/a	1/21/2003	Treatment of neoplastic meningitis	Baxter Healthcare Corporation
1847	MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Gliknik, Inc.
1848	magnesium lysinate bis eicosapentaenoate	n/a	12/23/2015	Treatment of familial adenomatous polyposis.	Thetis Pharmaceuticals

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1849	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be administered	CMC Contrast AB
1850	Manganese superoxide dismutase mimetic	n/a	2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Galera Therapeutics, LLC
1851	Mannitol	Bronchitol	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Pharmaxis Ltd.
1852	mannopentaose phosphate sulfate	n/a	4/27/2004	Treatment of high-risk Stage II, Stage III, and Stage IV melanoma	Medigen Biotechnology Corp.
1853	maribavir	n/a	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	Shire ViroPharma, Inc.
1854	maribavir	n/a	2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	Shire ViroPharma, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1855	Marijuana	n/a	5/25/1999	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc.
1856	marizomib	n/a	9/21/2015	Treatment of malignant glioma.	Triphase Research & Development I Corp.
1857	Marizomib	n/a	12/13/2013	Treatment of multiple myeloma	Triphase Research and Development I Corp.
1858	masitinib	n/a	7/21/2009	Treatment of patients with pancreatic cancer	AB Science
1859	masitinib	n/a	4/20/2005	Treatment of malignant gastrointestinal stromal tumors	AB Science
1860	masitinib	n/a	9/14/2005	Treatment of mastocytosis	AB Science
1861	masitinib mesylate	n/a	9/14/2015	Treatment of gastric cancer including cancer of the gastroesophageal junction	AB Science
1862	masitinib mesylate	n/a	3/18/2015	Treatment of amyotrophic lateral sclerosis.	AB Science
1863	Matrix metalloproteinase inhibitor	Galardin	12/5/1991	Treatment of corneal ulcers.	Glycomed, Inc
1864	MaxAdFVIII	n/a	3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics Corporation
1865	maytansinoid conjugated humanized monoclonal antibody against FOLRI	n/a	7/14/2014	Treatment of ovarian cancer	ImmunoGen, Inc.
1866	maytansinoid-conjugated humanized monoclonal antibody against CD37	n/a	5/12/2016	Treatment of diffuse large B-cell lymphoma	ImmunoGen, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1867	Mazindol	Sanorex	12/8/1986	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D.
1868	mebendazole	Vermox 500 Mg Chewable Tablets	9/3/2014	Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).	Janssen Pharmaceutical Research & Development, LLC
1869	Mecamylamine	Inversine	10/14/1998	Treatment of Tourette's syndrome.	Targacept, Inc.
1870	Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Ipsen Biopharmaceuticals, Inc.
1871	mecasermin	Iplex	12/3/2007	Treatment of myotonic dystrophy	Insmed, Inc.
1872	mecasermin rinfabate	n/a	9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Premacure AB
1873	mecasermin rinfabate	Iplex	7/23/2012	Treatment of amyotropic lateral sclerosis	PCUT BioPartners, Inc.
1874	mecasermin rinfabate	Iplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Insmed, Inc.
1875	mecasermin, recombinant human insulin-like growth factor-1	Increlex	9/21/2015	Treatment of Rett Syndrome.	Keck Graduate Institute of Applied Life Sciences

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1876	meclorethamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Actelion Pharmaceuticals Ltd.
1877	Medroxyprogesterone acetate	Hematrol	2/22/2001	Treatment of immune thrombocytopenic purpura.	ZaBeCor Pharmaceutical Company, LLC
1878	Mefloquine HCl	Mephaquin	7/22/1987	Treatment and prevention of chloroquine-resistant Falciparummalaria	Mepha AG
1879	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.
1880	Megestrol acetate	Megace	4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute
1881	Melanoma autologous dendritic cell vaccine	n/a	9/6/2006	Treatment of stage IIIb through IV metastatic melanoma	Caladrius Biosciences
1882	Melanoma cell vaccine	Canvaxin	10/13/1994	Treatment of invasive melanoma.	CancerVax Corporation
1883	Melanoma peptide vaccine	n/a	3/29/2005	Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma	Bristol-Myers Squibb Research Inst

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1884	Melanoma vaccine	Melacine	12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc.
1885	melarsoprol-hydroxypropylbetadex	n/a	9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,
1886	melatonin	n/a	4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Scharper S.p.A.
1887	Melatonin	Circadin	7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Neurim Pharmaceuticals, Ltd.
1888	Melatonin	n/a	11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D.
1889	meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc.
1890	Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc.
1891	melphalan	n/a	11/19/2012	Treatment of retinoblastoma	Icon Bioscience, Inc.
1892	melphalan	n/a	7/14/2015	Treatment of cholangiocarcinoma.	Delcath Systems, Inc.
1893	melphalan	n/a	11/19/2012	Treatment of Stage IIB through IV melanoma	OncoTx, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1894	melphalan	Evomela	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Spectrum Pharmaceuticals, INc.
1895	melphalan flufenamide hydrochloride	n/a	3/16/2015	Treatment of plasma cell myeloma, also referred to as multiple myeloma	Oncopeptides AB
1896	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with cutaneous melanoma.	Delcath Systems, Inc.
1897	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Delcath Systems, Inc.
1898	melphalan hydrochloride	n/a	5/22/2009	Treatment of neuroendocrine tumors	Delcath Systems, Inc.
1899	melphalan hydrochloride	n/a	9/26/2013	Treatment of patients with hepatocellular carcinoma	Delcath Systems, Inc.
1900	menadione sodium bisulfite	n/a	5/14/2014	Treatment of autosomal dominant polycystic liver disease	IC-MedTech Corporation
1901	Menadione Sodium Bisulfite	n/a	5/14/2014	For the treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
1902	menaquinone	Menaquinonegold	9/4/2012	Treatment of calciphylaxis	Nu Science Trading, LLC
1903	menatetrenone	Mk4(R)	2/4/2011	Treatment of myelodysplastic syndrome.	NBI Pharmaceuticals, Inc.
1904	menatetrenone	Mk4	3/17/2011	Treatment of acute myeloid leukemia	NBI Pharmaceuticals, Inc.
1905	menatetrenone	Mk4(R)	11/2/2010	Treatment of hepatocellular carcinoma (HCC).	NBI Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1906	menatetrenone	Mk4(R)	11/2/2010	Treatment of acute promyelocytic leukemia.	NBI Pharmaceuticals, Inc.
1907	menatetrenone and Vitamin D3	n/a	8/22/2011	Treatment of myelodysplastic syndrome	NBI Pharmaceuticals, Inc.
1908	mepivacaine	n/a	1/8/2007	Treatment of postherpetic neuralgia	Relmada Therapeutics, Inc.
1909	mepivacaine	n/a	10/18/2006	Treatment of painful HIV-associated neuropathy	Relmada Therapeutics, Inc.
1910	mepolizumab	n/a	5/28/2004	For first-line treatment in patients with hypereosinophilic syndrome	GlaxoSmithKline LLC
1911	mepolizumab	n/a	7/14/2011	Treatment of Churg-Strauss Syndrome.	GlaxoSmithKline LLC
1912	mercaptopurine oral solution	Purixan	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Nova Laboratories Limited
1913	mesalamine	Canasa	1/19/2010	Treatment of pediatric ulcerative colitis	Aptalis Pharma US, Inc.
1914	mesalamine and N-acetycysteine	n/a	9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Altheus Therapeutics, Inc.
1915	mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Shire
1916	mesencephalic, astrocyte-derived neurotrophic factor	n/a	9/10/2015	Treatment of retinal artery occlusion.	Amarantus BioScience Holdings, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1917	mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	BrainStorm Cell Therapeutics Ltd.
1918	Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation
1919	met-enkephalin; Met-N	n/a	2/18/2011	Treatment of pancreatic cancer.	NBI Pharmaceuticals, Inc.
1920	metadoxine	n/a	12/16/2013	Treatment of Fragile X Syndrome	Alcobra, Inc.
1921	metformin	n/a	5/29/2014	Treatment of pediatric polycystic ovary syndrome	EffRx Pharmaceuticals SA
1922	Methionine/L-methionine	n/a	8/21/1996	Treatment of AIDS myelopathy.	Genopia USA, Inc.
1923	Methotrexate	Amethopterin	8/28/2014	Treatment of Myasthenia Gravis	The Universtiy of Kanasa Medical Center
1924	methotrexate	n/a	8/20/2009	Treatment of acute lymphoblastic leukemia	Orbona Pharma Ltd
1925	methotrexate oral liquid formulation	n/a	3/18/2015	Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.	Chesapeake Therapeutics
1926	methotrexate oral solution	n/a	5/28/2015	Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)	Silvergate Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1927	methotrexate oral solution	n/a	8/27/2015	Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age	Silvergate Pharmaeuticals, Inc.
1928	Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Lederle Laboratories
1929	Methotrexate with laurocapram	Methotrexate/Azone	10/15/1990	Topical treatment of mycosis fungoides.	Echo Therapeutics, Ltd.
1930	methoxsalen	Uvadex	5/12/1994	For the prevention of acute rejection of cardiac allografts	Therakos, Inc.
1931	Methoxsalen	Uvadex	10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1932	Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-asparagyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[	n/a	4/18/2011	Prevention of ischemia reperfusion injury associated wth solid organ transplantation	Endotis Pharma
1933	methylene blue	n/a	7/24/2012	Treatment of methemoglobinemia	Fera Pharmaceuticals, LLC
1934	methylene blue injection	n/a	8/11/2012	Treatment of congenital and acquired methemoglobinemia	Luitpold Pharmaceuticals, Inc.
1935	methylene blue0.5%	Provayblue	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Provepharm SAS
1936	methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/2013	Treatment of cutaneous T-cell lymphoma	TetraLogic Pharmaceuticals
1937	metreleptin	Myalept	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Aegerion Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1938	metreleptin	n/a	8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Aegerion Pharnaceuticals, Inc.
1939	metronidazole	n/a	9/17/2008	Treatment of pouchitis	Avivia Project BV
1940	metronidazole	n/a	4/26/2011	Treatment of pouchitis.	S.L.A. Pharma Limited (UK)
1941	Metronidazole	Metrogel	10/24/1991	Treatment of perioral dermatitis.	Galderma Laboratories, Inc.
1942	metronidazole	n/a	4/5/2016	Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).	Appili Therapeutics, Inc.
1943	Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Galderma Laboratories, Inc.
1944	Metronidazole 10% ointment	n/a	11/8/2007	Topical treatment of active perianal Crohn's disease	SLA Pharma (UK) Ltd
1945	metyrapone	n/a	9/25/2012	Treatment of Cushing's syndrome	Laboratoire HRA Pharma
1946	metyrosine	Demser	7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Cerberus Princeton, LLC
1947	mexiletine	n/a	9/2/2010	Treatment of nondystrophic myotonia	University of Rochester Medical Center
1948	mibefradil	n/a	8/25/2009	Treatment of glioblastoma multiforme.	Cavion, LLC
1949	mibefradil	n/a	10/16/2008	Treatment of pancreatic cancer.	Cavion, LLC
1950	mibefradil	n/a	6/15/2007	Treatment of ovarian cancer	Cavion, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1951	miconazole	n/a	5/22/2014	Treatment of fungal otitis externa (otomycosis)	Hill Dermaceuticals, Inc.
1952	Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc.
1953	Microvesiculated modified glycosylated tissue factor	n/a	10/11/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.	Thrombotargets Corp.
1954	Microvesiculated modified glycosylated tissue factor	n/a	1/25/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients	Thrombotargets Corp.
1955	midazolam	n/a	7/24/2012	Treatment of nerve agent-induced seizures	Meridian Medical Technologies, Inc.
1956	midazolam	n/a	10/20/2009	Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)	Upsher-Smith Laboratories, Inc.
1957	midazolam	n/a	2/8/2016	Treatment of seizures induced by organophosporous insecticide poisoning.	Meridian Medical Technologies, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1958	midazolam	n/a	5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	UCB, Inc
1959	midazolam	n/a	2/18/2016	Treatment of status epilepticus	Shire Development LLC
1960	midazolam	n/a	2/4/2016	Treatment of status epilepticus	Meridian Medical Technologies, Inc.
1961	Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Shire
1962	Midostaurin	n/a	7/7/2009	Treatment of acute myeloid leukemia	Novartis Pharmaceuticals Corporation
1963	Midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Novartis Oncology
1964	mifamuritide	Junovan	6/5/2001	Treatment of osteosarcoma	Millennium Pharmaceuticals, Inc.
1965	mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrone	Corcept Therapeutics, Inc.
1966	Mifepristone	n/a	2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	HRA Pharma
1967	mifepristone	Korlym	1/14/2016	Treatment of ovarian cancer.	Corcept Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1968	migalastat hydrochloride	n/a	2/25/2004	Treatment of Fabry Disease	Amicus Therapeutics, Inc.
1969	miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd
1970	miglustat	Zavesca (R)	11/12/2008	Treatment of the neurological manifestations of Niemann-Pick disease,type C.	Actelion Pharmaceuticals Ltd
1971	milatuzumab	n/a	3/10/2008	Treatment of multiple myeloma	Immunomedics, Inc.
1972	milatuzumab	n/a	6/24/2008	Treatment of chronic lymphocytic leukemia.	Immunomedics, Inc.
1973	milciclib maleate	n/a	9/20/2012	Treatment of thymic epithelial tumors.	Tiziana Life Sciences PLC
1974	miltefosine	Impavido	10/10/2006	Treatment of leishmaniasis.	Knight Therapeutics (USA)
1975	miltefosine	Miltex/Impavido	3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	ExperGen Drug Development GmbH
1976	Minnelide	Minnelide (Tm)	2/18/2013	Treatment of pancreatic cancer	Minneamrita Therapeutics, LLC
1977	Minocycline hydrochloride	n/a	3/28/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
1978	mipomersen	Kynamro	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Kastle Therapeutics, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1979	misoprostol	Gymiso	1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Gynuity Health Projects, LLC
1980	Mitoguazone	Apep	3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc.
1981	Mitolactol	n/a	7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Targent, Inc.
1982	Mitolactol	n/a	1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Targent, Inc..
1983	mitomycin	n/a	1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Mobius Therapeutics, LLC
1984	mitomycin	n/a	6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Mobius Therapeutics, LLC
1985	mitomycin	Mitogel	9/8/2014	Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)	TheraCoat, Ltd.
1986	Mitomycin-C	n/a	8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1987	mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mobius Therapeutics, LLC
1988	Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Serono
1989	Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Serono, Inc.
1990	Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Serono, Inc.
1991	Mitoxantrone HCl	Novantrone	7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories
1992	Mixture of 2 anti-rabies humanized monoclonal immunoglobulin (Ig)G1k antibodies	n/a	10/7/2015	Post-exposure prophylaxis against rabies virus infection	Synermore Biologics Co., Ltd
1993	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of acute myelogenous leukemia.	Millennium Pharmaceuticals
1994	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of Myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.
1995	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/1998	Treatment of small cell lung cancer	Immunomedics, Inc.
1996	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc.
1997	Mocetinostat	n/a	6/12/2014	Treatment of myelodysplastic syndrome	Mirati Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1998	mocetinostat	n/a	8/7/2014	Treatment of diffuse large B-cell lymphoma	Mirati Therapeutics, Inc.
1999	MOD-423 hGH analogue	n/a	9/29/2010	Treatment of growth hormone deficiency	OPKO Biologics Ltd.
2000	Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc.
2001	modified a-cobratoxin	n/a	9/1/2015	Treatment of pediatric multiple sclerosis (0 through 16 years of age).	Nutra Pharma Corporation
2002	modified human papillomavirus capsid protein conjugated to a near infrared dye	n/a	4/8/2015	Treatment of uveal melanoma	Aura Biosciences, Inc.
2003	modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/2013	Treatment of achondroplasia	BioMarin Pharmaceutical, Inc.
2004	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Gencia Corporation
2005	mogamulizumab	n/a	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Kyowa Kirin Pharmaceutical Development Inc.
2006	mogamulizumab	n/a	11/2/2010	Treatment of peripheral T-cell lymphoma.	Kyowa Kirin Pharmaceutical Development, Inc.
2007	mogamulizumab	n/a	7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Kyowa Kirin Pharmaceutical Development, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2008	monarsen	n/a	11/14/2003	Treatment of myasthenia gravis	Bioline Rx, Ltd.
2009	mongersen	n/a	7/20/2015	Treatment of pediatric Crohn's disease	Celgene Corporation
2010	monoclonal antibody 11-1F4	n/a	12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Alan Solomon, M.D.
2011	monoclonal antibody 11-1F4	n/a	12/7/2009	For use as a radioimmaging agent in amyloidosis	Alan Solomon, M.D.
2012	monoclonal antibody 3F8	n/a	10/16/2008	Treatment of neuroblastoma	United Therapeutics Corporation
2013	monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus	n/a	8/25/2014	Treatment of Ebola virus infection	LeafBio, Inc.
2014	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	MassBiologics-University of MA Medical School
2015	Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/1993	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc.
2016	monoclonal antibody Hu3F8	n/a	1/10/2014	Treatment of osteosarcoma	Memorial Sloan-Kettering Cancer Center
2017	monoclonal antibody targeting eotaxin-2	n/a	1/6/2015	Treatment of systemic sclerosis	ChemomAb, Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2018	monoclonal antibody targeting eotaxin-2	n/a	10/29/2015	Treatment of idiopathic pulmonary fibrosis.	ChemomAb, Ltd.
2019	Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/1996	Treatment of epithelial ovarian cancer.	Quest PharmaTech, Inc.
2020	Monolaurin	Glylorin	4/29/1993	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc.
2021	monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C	n/a	7/29/2014	Treatment of pancreatic cancer.	Millennium Pharmaceuticals, Inc.
2022	Mononuclear enriched fraction of human umbilical cord blood	U-Cord-Cell(R)	9/15/2015	Treatment of amyotrophic lateral sclerosis (ALS).	Saneron CCEL Therapeutics, Inc.
2023	Monooctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc.
2024	Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc.
2025	motexafin gadolinium	Xcytrin	1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, LLC
2026	mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37	n/a	3/24/2015	Treatment of chronic lymphocytic leukemia (CLL).	Boehringer Ingelheim Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2027	mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/2012	Treatment of neuroblastoma.	APEIRON Biologics AG
2028	moxetumomab pasudotox	n/a	11/15/2007	Treatment of hairy cell leukemia	MedImmune, LLC
2029	moxetumomab pasudotox	n/a	6/28/2013	Treatment of acute lymphoblastic leukemia	MedImmune, LLC
2030	moxetumomab pasudotox	n/a	11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	MedImmune, LLC
2031	moxidectin	n/a	9/29/2010	Treatment of onchocerciasis volvulus in children and adults.	Medicines Development Limited
2032	mPEG-r-crisantaspase	Asparec(Tm)	2/1/2010	Treatment of acute lymphoblastic leukemia.	Jazz Pharmaceuticals, Inc.
2033	MTC-DOX for Injection	n/a	1/3/2001	Treatment of hepatocellular carcinoma	FeRx Incorporated
2034	mTOR kinase inhibitor (CC-223)	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Celgene Corporation
2035	multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200)	n/a	12/7/2015	Treatment of ovarian cancer.	Tapimmune, Inc.
2036	Multi-ligand somatostatin analog	n/a	7/27/2004	Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.	Novartis Pharmaceuticals Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2037	Multi-peptide cancer vaccine	n/a	6/23/2013	Treatment of multiple myeloma	OncoPep, Inc.
2038	Multi-vitamin infusion (neonatal formula)	n/a	12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P.
2039	multi-vitamin infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Mayne Pharma (USA) Inc.
2040	Multistem(r)	n/a	9/15/2010	Prophylaxis of graft vs host disease	Athersys, Inc.
2041	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc.
2042	Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	Theragyn	3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc
2043	murine monoclonal antibody against CD26	Begedina	2/18/2011	Treatment of graft versus host disease	Adienne S.A.
2044	MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin	n/a	9/23/2014	Treatment of Neuroblastoma	MabVax Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2045	Mx-dnG1	Rexin-G	6/24/2008	Treatment of osteosarcoma.	Epeius Biotechnologies Corporation
2046	Mx-dnG1	Rexin-G(R)	6/24/2008	Treatment of soft tissue sarcoma	Epeius Biotechnologies Corporation
2047	Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies Corporation
2048	Mycobacterium avium sensitin RS-10	n/a	10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut
2049	mycobacterium vaccae	n/a	8/20/2010	Treatment of tuberculosis	Immodulon Therapeutics Ltd
2050	myo-inositol	n/a	4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Abbott Nutrition
2051	N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine	n/a	10/29/2015	Treatment of malaria.	Donald J. Krogstad, MD
2052	N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)	n/a	4/6/2012	Treatment of mercury toxicity	CTI Science Limited
2053	N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide	n/a	11/17/2014	Treatment of Duchenne muscular dystrophy	Catabasis Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2054	N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide	n/a	11/17/2014	Treatment of optic neuritis	Bionure Farma SL
2055	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/2008	Treatment of acute myeloid leukemia	Mirati Therapeutics, Inc.
2056	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/2007	Treatment of Hodgkin's lymphoma	Mirati Therapeutics, Inc.
2057	N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide	n/a	10/15/2014	Treatment of AL Amyloidosis	ProteoTech, Inc.
2058	N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	n/a	11/26/2013	Treatment of gliomas	Kinex Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2059	N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl]-L-cysteinyl-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteinyl-L-aginine amide, cyclic (4-13)-disulfide	n/a	7/6/2012	For use to mobilize hematopoietic stem cells (HSCs) from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	BioLineRx, Ltd.
2060	N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine	n/a	2/18/2016	Treatment of glioma.	Flag Therapeutics, Inc.
2061	N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate	n/a	10/21/2014	Treatment of ovarian cancer	Amgen, Inc.
2062	N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt	n/a	3/18/2009	Treatment of acute myeloid leukemia	Ambit Biosciences Corporation
2063	N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride	n/a	11/17/2014	Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)	Emergent Virology, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2064	N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl(phenyl]amino}pyrimidin-4-yl)benzamide	n/a	8/5/2010	Treatment of myelofibrosis	Gilead Sciences, Inc.
2065	N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	n/a	10/17/2005	Treatment of multiple myeloma.	AB Science
2066	N-acetyl cysteine amide	n/a	12/31/2013	Treatment of retinitis pigmentosa	Brighton Biotech, Inc.
2067	N-acetyl-glucosamine thiazoline	n/a	2/6/2006	Treatment of adult Tay-Sachs disease	ExSAR Corporation
2068	N-acetyl-procainamide	n/a	12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas
2069	N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/2000	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc.
2070	N-acetylcysteine	n/a	9/9/2002	Treatment of acute liver failure	Cumberland Pharmaceuticals, Inc.
2071	N-acetylcysteine	n/a	7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Edward A. Neuwelt, MD

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2072	N-acetylcysteine and sodium thiosulfate	n/a	8/31/2015	Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).	Edward A. Neuwelt, MD
2073	N-acetylgalactosamine-4-sulfatase, recombinant human	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc.
2074	N-Acetylmannosamine (ManNAc)	n/a	4/5/2010	Treatment of hereditary inclusion body myopathy type 2	Escala Therapeutics, Inc.
2075	N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/2007	Treatment of tuberculosis.	Sequella, Inc.
2076	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/2012	Treatment of Schwannoma of the central nervous system	Arno Therapeutics, Inc.
2077	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/2012	Treatment of meningioma	Arno Therapeutics, Inc.
2078	N-Methanocarbathymidine	n/a	10/15/2014	Treatment of neonatal herpes	N & N Pharmaceuticals, Inc.
2079	N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride	n/a	7/18/2013	Treatment of mesothelioma	Verastem, Inc.
2080	N-t-butylhydroxylamine	n/a	5/12/2015	Treatment of infantile neuronal ceroid lipofuscinosis.	Andrew Lim

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2081	N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/2013	Treatment of polycythemia vera	sanofi-aventis U.S. LLC
2082	N-tert-butyl-3-[5-methyl-2-{[4-(2-pryyolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/2009	Treatment of secondary and primary myelofibrosis	Sanofi-Aventis US, LLC a Sanofi company
2083	N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride	n/a	1/12/2011	Treatment of acute myeloid leukemia (AML).	EMD Serono, Inc.
2084	N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride	n/a	1/29/2010	Treatment of pancreatic cancer	EMD Serono, Inc.
2085	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	1/7/2015	For the treatment of Cushing's Syndrome	Atterocor, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2086	N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide	n/a	12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	CytRx Corporation
2087	N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	n/a	5/25/1995	Treatment of malignant glioma.	Sugen, Inc.
2088	N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/1996	Treatment of ovarian cancer.	Sugen, Inc.
2089	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/12/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer	Ignyta, Inc.
2090	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/3/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer	Ignyta, Inc.
2091	N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide	n/a	2/4/2011	Treatment of tuberculosis.	Sequella, Inc.
2092	N1,N14,-diethyl-3,12,-dihydroxyhomospermine	n/a	8/7/2014	Treatment of pancreatic cancer	Sun BioPharma, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2093	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/2000	For pancreatic cancer	SmithKline Beecham Pharmaceuticals
2094	N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/2008	Treatment of multiple myeloma	Biotest Pharmaceuticals Corporation
2095	nabumetone	n/a	5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Cook Pharma
2096	Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Syntex (USA), Inc.
2097	naloxone	n/a	11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Elorac, Inc.
2098	naltrexone	n/a	2/23/2015	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC
2099	naltrexone	n/a	1/19/2010	Treatment of Crohn's disease in pediatric patients	TNI BioTech, Inc.
2100	naltrexone	n/a	1/13/2015	Treatment of autoimmune hepatitis	TaiwanJ Pharmaceuticals Co., Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2101	Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals
2102	naltrexone/clonidine combination	n/a	4/14/2014	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC
2103	nano-diamino-tetraiodothyroacetic acid	n/a	10/28/2015	Treatment of pancreatic cancer	NanoPharmaceuticals, LLC
2104	nano-diamino-tetraiodothyroacetic acid	n/a	7/9/2015	Treatment of glioblastoma multiforme (GBM)	NanoPharmaceuticals, LLC
2105	Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.	n/a	5/23/2016	Treatment of ovarian cancer.	PeptiMed
2106	NanoDTPA(tm)	n/a	6/17/2011	Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium	Nanotherapeutics, Inc.
2107	nanoparticulate paclitaxel	Nanotax(R)	10/6/2015	Treatment of ovarian cancer.	NanOlogy, LLC
2108	naproxcinod	n/a	3/16/2015	Treatment of Duchenne muscular dystrophy.	Nicox SA
2109	Natural human lymphoblastoid interferon-alpha	n/a	8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2110	Natural human lymphoblastoid interferon-alpha	n/a	1/18/2000	Treatment of Behcet's disease	Amarillo Biosciences, Inc.
2111	natural human lymphoblastoid interferon-alpha	n/a	11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.
2112	NDX-peptides	n/a	12/14/2010	Treatment of amyotrophic lateral sclerosis	NeoDiagnostic Research Ltd
2113	Nebacumab	Centoxin	10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc.
2114	necitumumab	n/a	11/20/2015	Treatment of squamous non-small cell lung cancer	Eli Lilly and Company
2115	nelarabine	n/a	9/2/1999	Treatment of chronic lymphocytic leukemia.	Novartis Pharmaceuticals Corp.
2116	nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Novartis Pharmaceuticals Corp.
2117	neostigmine	n/a	3/18/2013	Treatment of acute colonic pseudo-obstruction	Luitpold Pharmaceuticals, Inc.
2118	neostigmine methylsulfate	n/a	2/17/2012	Treatment of Myasthenia Gravis	Luitpold Pharmaceuticals, Inc.
2119	neridronate	n/a	3/25/2013	Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)	Grunenthal USA, Inc.
2120	Neurotrophin-1	n/a	9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2121	Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation
2122	nevirapine	n/a	11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Auritec Pharmaceuticals
2123	Nifedipine	n/a	6/13/1991	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D.
2124	nifurtimox	n/a	12/31/2013	Treatment of Chagas disease	MetronomX Therapeutics, LLC
2125	nifurtimox	Lampit	8/5/2010	Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi	Bayer HealthCare Pharmaceuticals, Inc.
2126	Nikkomycin Z	n/a	2/14/2006	Treatment of coccidioidomycosis	Valley Fever Center for Excellence (1-111 INF)
2127	nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Novartis Pharmaceutical Corporation
2128	nimodipine	Nymalize	9/16/2011	Treatment of subarachnoid hemorrhage.	Arbor Pharmaceuticals, Inc.
2129	nimotuzumab	n/a	9/8/2015	Treatment of pancreatic cancer.	InnoCIMab Pte Ltd
2130	Nimotuzumab	n/a	11/17/2004	Treatment of glioma	InnoKeys PTE Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2131	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	The Vaccine Company
2132	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of acute myelogenous leukemia	The Vaccine Company
2133	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of chronic myelogenous leukemia.	The Vaccine Company
2134	nintedanib	Ofev	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Boehringer Ingelheim Pharmaceuticals, Inc.
2135	niprisan	Hemoxin	8/15/2003	Treatment of sickle cell disease	Xechem International, Inc.
2136	niraparib	n/a	4/30/2010	Treatment of ovarian cancer	TESARO, Inc.
2137	nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C.
2138	Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Romark Laboratories, L.C.
2139	nitazoxanide	Cryptaz	10/23/2001	Treatment for intestinal amebiasis	Romark Laboratories, L.C.
2140	Nitisinone	Orfadin	10/19/2001	Treatment of alkaptonuria	Swedish Orphan AB
2141	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB
2142	Nitric oxide	n/a	2/16/2005	Diagnosis of sarcoidosis	SensorMedics Corporation
2143	Nitric oxide	n/a	7/10/1995	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2144	Nitric oxide	Inomax	9/27/2004	To reduce the risk of chronic lung disease in premature neonates	INO Therapeutics
2145	nitric oxide	Inomax	12/28/2011	Treatment of pulmonary arterial hypertension	Bellerophon Therapeutics
2146	Nitric oxide	n/a	9/11/2013	Treatment of cystic fibrosis	Novoteris, LLC
2147	nitric oxide	n/a	9/23/2014	Treatment of cystic fibrosis	Advanced Inhalation Therapies Ltd.
2148	nitric oxide	Inomax (R)	9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	INO Therapeutics
2149	Nitric oxide	Inomax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc.
2150	nitric oxide	n/a	6/18/2012	Treatment of persistent pulmonary hypertension in newborns	GeNO, LLC
2151	Nitroprusside	n/a	2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan
2152	nivolumab	n/a	9/15/2015	Treatment of small cell lung cancer.	Bristol-Myers Squibb Company
2153	nivolumab	n/a	1/23/2013	Treatment of Stage IIb to IV melanoma	Bristol-Myers Squibb Co.
2154	nivolumab	Opdivo	8/7/2014	Treatment of Hodgkin lymphoma	Bristol-Myers Squibb Co.
2155	nivolumab	n/a	8/27/2015	Treatment of glioblastoma	Bristol-Myers Squibb Co

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2156	nivolumab	Opdivo(R)	9/2/2015	Treatment of hepatocellular carcinoma.	Bristol-Myers Squibb Company
2157	non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I	n/a	12/15/2014	Treatment of hypoparathyroidism	Chugai Pharma USA, LLC
2158	non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene	At001	12/3/2014	Treatment of x-linked myotubular myopathy	Audentes Therapeutics, Inc.
2159	non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene	n/a	5/24/2016	Treatment of Crigler Najjar syndrome.	Audentes Therapeutics, Inc.
2160	non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase	n/a	12/8/2015	Treatment of Mucopolysaccharidosis Type II	REGENXBIO, Inc.
2161	non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein	n/a	10/20/2014	Treatment of retinitis pigmentosa	RetroSense Therapeutics, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2162	NorLeu3-Angiontensin(1-7)) [NorLeu3-A(1-7)]	n/a	12/31/2013	Treatment of leakage from the surgical site following penetrating keratoplasty	US Biotest, Inc.
2163	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	1/31/2014	Treatment of dermal injury due to nuclear/radiation incident	US Biotest, Inc.
2164	noscapine	n/a	12/29/2015	Treatment of amyotrophic lateral sclerosis.	KineMed Inc.
2165	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/2004	Treatment of pancreatic cancer	Antisoma Research Ltd.
2166	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/2009	Treatment of acute myeloid leukemia	Antisoma, Inc.
2167	Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/2005	Treatment of renal cell carcinoma	Antisoma Inc.
2168	O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/2013	Treatment of Duchenne Muscular Dystrophy	Vudbenk Life Sciences
2169	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate	n/a	3/16/2012	Treatment of acute myeloid leukemia	JSK Therapeutics, Inc.
2170	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate	n/a	12/13/2013	Treatment of multiple myeloma	JSK Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2171	obeticholic acid	Ocaliva	4/9/2008	Treatment of primary biliary cirrhosis	Intercept Pharmaceuticals, Inc.
2172	obiltoxaximab	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Elusys Therapeutics, Inc.
2173	obinutuzumab	Gazyva	6/11/2015	Treatment of splenic marginal zone lymphoma	Genentech, Inc.
2174	obinutuzumab	Gazyva	2/17/2012	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2175	obinutuzumab	Gazyva	4/15/2015	Treatment of follicular lymphoma	Genentech, Inc.
2176	obinutuzumab	n/a	2/17/2012	Treatment of diffuse large B cell lymphoma	Genentech, Inc.
2177	oblimersen	Genasense	7/31/2000	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc.
2178	oblimersen	Genasense	8/28/2001	Treatment of chronic lymphocytic leukemia	Genta, Inc.
2179	oblimersen	Genasense	8/28/2001	Treatment of multiple myeloma	Genta, Inc.
2180	oblimersen	Genasense	8/28/2001	Treatment of acute myelocytic leukemia	Genta, Inc.
2181	Octreotide	Sandostatin Lar	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation
2182	octreotide	Sandostatin Lar	8/5/2010	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
2183	Octreotide	Sandostatin Lar	8/24/1998	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2184	Octreotide	Sandostatin Lar	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation
2185	octreotide (oral)	Octreolin(Tm)	6/17/2010	For the oral treatment of acromegaly	Chiasma, Inc.
2186	octreotide acetate subcutaneous implant	n/a	12/7/2009	Treatment of acromegaly	Endo Pharmaceuticals Solutions, Inc.
2187	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corp.
2188	Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Allergan, Inc.
2189	oglufanide disodium	n/a	9/24/2001	Treatment of ovarian cancer	Implicit Bioscience Pty Ltd
2190	olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	AstraZeneca Pharmaceuticals LP
2191	olaptesed pegol	n/a	8/19/2014	Treatment of glioblastoma in conjunction with radiotherapy.	Noxxon Pharma AG
2192	olaratumab	n/a	10/9/2014	Treatment of soft tissue sarcoma	Eli Lilly and Company
2193	oleylphosphocholine	n/a	10/25/2013	Treatment of leishmaniasis	Dafra Pharma International nv
2194	oligodendrocyte progenitor cells	n/a	2/2/2016	Treatment of acute spinal cord injury	Asterias Biotherapeutics
2195	oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	n/a	2/27/2014	Treatment of amyotrophic lateral sclerosis	Genervon Biopharmaceuticals, LLC
2196	olipudase alfa	n/a	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Genzyme Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2197	omacetaine mepesuccinate	n/a	1/12/2009	Treatment of myelodysplastic syndromes	IVAX International GmbH
2198	omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	IVAX International GmbH
2199	Ombitasvir/Paritaprevir/Ritonavir	Technivie® Tablets	2/24/2016	Treatment of pediatric patients with chronic hepatitis C virus infection	AbbVie Inc.
2200	ombitasvir/paritaprevir/ritonavir and dasabuvir	Viekira Pak	7/16/2015	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	Abbvie, Inc.
2201	ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethozyphenyl)vinyl]phenyl}-L-serinamide hydrochloride	n/a	3/3/2011	Treatment of soft tissue sarcoma	Sanofi-Aventis U.S., Inc.
2202	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/1995	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals
2203	Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/2000	Treatment of IgA nephropathy.	Pronova Biocare, AS
2204	Omegaven emulsion	Omegaven	2/27/2008	Treatment of parenteral nutrition-associated liver disease	Fresenius Kabi Deutschland GmbH
2205	omeprazole-lansoprazole with buffer	n/a	2/10/2015	Treatment of esophageal ulcers	Effexus Pharmaceuticals, LLC
2206	omigapil	n/a	6/24/2008	Treatment of congenital muscular dystrophy.	Santhera Pharmaceuticals Limited

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2207	Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)	n/a	12/22/2014	Treatment of malignant mesothelioma	Oncos Therapeutics
2208	oncophage	n/a	4/14/2009	Treatment of glioma	Agenus, Inc.
2209	ondansetron inhalation powder	n/a	10/14/2015	Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .	Luxena Pharmaceuticals, Inc.
2210	opioid growth factor	n/a	4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
2211	opium tincture	n/a	12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Valeant Pharmaceuticals International, Inc.
2212	Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc.
2213	oprozomib	n/a	10/28/2014	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
2214	oprozomib	n/a	8/25/2014	Treatment of Waldenstrom's macroglobulinemia	Onyx Therapeutics, Inc.
2215	optically pure phenylalanine derivative	n/a	8/20/2012	Treatment of narcolepsy	Jazz Pharmaceuticals International III Limited
2216	oral unfractionated heparin	n/a	1/29/2004	Treatment of sickle cell disease	TRF Technologies, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2217	osilodrostat	n/a	9/13/2013	Treatment of Cushing's disease	Novartis Pharmaceuticals corporation
2218	osimertinib	Tagrisso	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	AstraZeneca Pharmaceuticals LP
2219	otelixizumab	n/a	2/6/2006	Treatment of new-onset type I diabetes mellitus	GlaxoSmithKline
2220	OTL38; conjugate of pteroi acid and S0456 near infrared dye	n/a	12/23/2014	Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)	On Target Laboratories, LLC
2221	Oxaliplatin	n/a	10/6/1992	Treatment of ovarian cancer.	Debio Pharm S.A.
2222	oxaloacetate	n/a	7/24/2012	Treatment of gliomas	Terra Biological LLC
2223	Oxaloacetic acid	n/a	11/18/2015	Treatment of amyotrophic lateral sclerosis	Terra Biological LLC
2224	Oxalobacter formigenes	n/a	3/29/2006	Treatment of primary hyperoxaluria	OxThera, Inc.
2225	Oxandrolone	Oxandrin	9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp.
2226	Oxandrolone	Oxandrin	4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Savient Pharmaceuticals, Inc.
2227	oxfendazole	n/a	7/14/2014	Treatment of cysticercosis (including neurocysticercosis)	Robert H. Gilman, MD, DTMH and

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2228	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals
2229	Oxymorphone	Numorphan H.P.	3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company
2230	Oxypurinol	n/a	11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp.
2231	oxytocin	n/a	11/24/2014	Treatment of Prader-Willi syndrome	Pr Maithe Tauber
2232	ozanimod	n/a	12/29/2015	Treatment of pediatric (0 through 16 years of age) ulcerative colitis	Receptos Services, LLC
2233	p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt	n/a	3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc.
2234	P140K MGMT transduced human CD34 cells	n/a	1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Lentigen Corporation
2235	p38 mitogen-activated kinase inhibitor	n/a	5/27/2014	Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations	Array BioPharma, Inc.
2236	paclitaxel	n/a	5/1/2009	Treatment of pancreatic cancer	SynCore Biotechnology Co., Ltd.
2237	Paclitaxel	Paxene	4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2238	Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
2239	paclitaxel aqueous gel	Oncogel(Tm)	2/1/2008	Treatment of esophageal cancer	BTG International, Inc.
2240	paclitaxel aqueous gel	Oncogel (Tm)	12/23/2008	Treatment of brain cancer.	BTG International Inc.
2241	paclitaxel nanoparticles	n/a	1/2/2013	Treatment of pancreatic cancer	CIRJ Co., Ltd.
2242	paclitaxel poliglumex	Opaxio	9/20/2012	Treatment of glioblastoma multiforme	CTI BioPharma Corporation
2243	paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Abraxis BioScience, LLC
2244	paclitaxel, micellar	Paclical	4/3/2009	Treatment of ovarian cancer	Oasmia Pharmaceutical AB
2245	paclitaxel-coated buttress	n/a	7/15/2014	For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.	AcuityBio, Inc.
2246	pacritinib	n/a	3/13/2008	Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF	CTI BioPharma Corporation
2247	pafuramidine maleate	n/a	11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Immtech Pharmaceuticals, Inc.
2248	Pafuramidine maleate	n/a	8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Immtech Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2249	Pafuramidine maleate	n/a	5/14/2007	Treatment of malaria	Immtech Pharmaceuticsl, Inc.
2250	palovarotene	n/a	7/21/2014	Treatment of fibrodysplasia ossificans progressiva	Clementia Pharmaceuticals, Inc.
2251	panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Novartis Pharmaceuticals Corporation
2252	pantothenate phosphate	n/a	5/4/2015	Treatment of pantothenate kinase associated neurodegeneration (PKAN).	Retrophin, Inc.
2253	Papain, trypsin, and chymotrypsin	Wobe-Mugos	12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc.
2254	paquinimod	n/a	1/17/2014	Treatment of systemic sclerosis	Active Biotech AB
2255	parathyroid hormone	Natpara	8/31/2007	Treatment of hypoparathyroidism	NPS Pharmaceuticals, Inc.
2256	paricalcitol	Zemplar	10/27/2015	Treatment of pediatric hyperparathyroidism	Abbvie, inc.
2257	paromomycin	n/a	2/11/2015	Treatment of cutaneous leishmaniasis (Old World and New World)	The Surgeon General, Dept. of the Army
2258	paromomycin sulfate/gentamicin sulfate	n/a	1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Office of the Surgeon General
2259	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2260	pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Novartis Pharmaceuticals Corporation
2261	pasireotide	n/a	8/25/2009	Treatment of acromegaly	Novartis Pharmaceuticals Corporation
2262	pazopanib	n/a	5/6/2013	Treatment of ovarian cancer.	Novartis Pharmaceuticals Corp.
2263	pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	Novartis Pharmaceuticals Corp
2264	PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)	n/a	4/2/2015	Treatment of angiosarcoma	Co-D Therapeutics, Inc.
2265	PEG-glucocerebrosidase	Lysodase	12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, NIH
2266	PEG-interleukin-2	n/a	2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation
2267	Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Sigma-tau Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2268	pegargiminase	n/a	7/21/2014	Treatment of mesothelioma.	Polaris Group
2269	Pegaspargase	Oncaspar	10/20/1989	Treatment of acute lymphocytic leukemia.	Baxalta US, Inc.
2270	Pegfilgrastim	Neulasta	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
2271	Peginterferon alfa-2a	Pegasys	7/13/1998	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc.
2272	Peginterferon alfa-2a	Pegasys	9/30/1999	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc.
2273	peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Schering-Plough Corporation
2274	pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Horizon Pharma Rheumatology, LLC
2275	pegsitacase	Uricase-Peg 20	12/3/2009	Treatment of Lesch-Nyhan syndrome.	EnzymeRx, LLC
2276	Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Sensus Corporation
2277	pegylated arginine deiminase	Hepacid	3/26/1999	Treatment of hepatocellular carcinoma	Polaris Pharmaceuticals, Inc.
2278	Pegylated arginine deiminase	Melanocid	4/12/1999	Treatment of invasive malignant melanoma.	Polaris Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2279	pegylated carboxyhemoglobin	n/a	10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Sangart, Inc.
2280	pegylated carboxyhemoglobin bovine	Sanguinate	1/15/2015	Treatment of the comorbidities associated with Sickle Cell Disease	Prolong Pharmaceuticals, LLC
2281	pegylated granulocyte colony stimulating factor	n/a	4/30/2014	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	PharmaEssentia
2282	pegylated human recombinant arginase I	n/a	3/16/2015	Treatment of arginase I deficiency (hyperargininemia).	AERase, Inc.
2283	pegylated proline interferon alpha-2b	n/a	4/11/2014	Treatment of essential thrombocythemia	PharmaEssentia, Corporation
2284	pegylated proline interferon alpha-2b	n/a	4/10/2014	Treatment of myelofibrosis	PharmaEssentia, Corporation
2285	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/2012	Treatment of polycythemia vera	PharmaEssentia Corporation
2286	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	KaloBios Pharmaceuticals, Inc.
2287	PEGylated recombinant human hyaluronidase PH20	n/a	10/1/2014	Treatment of pancreatic cancer	Halozyme Therapeutics, Inc.
2288	pelareorep	Reolysin(R)	2/24/2015	Treatment of primary peritoneal cancer	Oncolytics Biotech, Inc.
2289	pelareorep	Reolysin(R)	2/10/2015	Treatment of ovarian cancer	Oncolytics Biotech, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2290	pelareorep	Reolysin(R)	2/11/2015	Treatment of pancreatic cancer	Oncolytics Biotech, Inc.
2291	pelareorep	Reolysin	5/4/2015	Treatment of gastric cancer	Oncolytics Biotech, Inc.
2292	pelareorep	Reolysin	4/15/2015	Treatment of malignant glioma	Oncolytics Biotech, Inc.
2293	pelareorep	Reolysin	2/24/2015	Treatment of fallopian tube cancer	Oncolytics Biotech, Inc.
2294	Peldesine	n/a	10/5/1993	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc.
2295	pembrolizumab	Keytruda	12/30/2015	Treatment of Hodgkin lymphoma.	Merck, Sharp & Dohme Corp.
2296	pembrolizumab	Ketruda	1/14/2016	Treatment of primary mediastinal B cell lymphoma.	Merck, Sharp & Dohme Corp.
2297	pembrolizumab	Keytruda	6/16/2015	Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma	Merck, Sharp & Dohme
2298	pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
2299	pembrolizumab	Keytruda	2/17/2016	Treatment of multiple myeloma.	Merck, Sharp & Dohme Corp.
2300	pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Eli Lilly and Company
2301	pentagastrin	n/a	5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Medical Defense Technologies, LLC
2302	Pentamidine isethionate	Nebupent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2303	Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc.
2304	Pentamidine isethionate	n/a	10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C.
2305	Pentamidine isethionate (inhalation)	Pneumopent	10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease	Fisons Corporation
2306	pentapeptide with sequence Ac-VSRRR-NH2	n/a	1/13/2015	Treatment of intracerebral hemorrhage	CereNOva, LLC
2307	Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit	Cylexin	7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation
2308	Pentastarch	Pentaspan	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	DuPont Pharmaceuticals
2309	pentetate trisodium	Diethylenetriaminepentaacetate	4/12/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
2310	pentetrazol	n/a	9/9/2015	Treatment of idiopathic hypersomnia.	Balance Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2311	pentosan polysulfate sodium	n/a	9/16/2011	Treatment of sickle cell disease.	Vanguard Therapeutics, Inc.
2312	pentosan polysulfate sodium	n/a	11/21/2008	Treatment of sickle cell disease.	TRF Pharma, Inc.
2313	Pentosan polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Alza Corporation
2314	pentosan polysulfate sodium	Lysosan (Tm)	1/5/2015	Treatment of mucopolysaccharidosis (MPS) type VI	Plexcera Therapeutics, LLC
2315	Pentostatin	Nipent	11/24/1999	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc.
2316	Pentostatin	Nipent	1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc.
2317	Pentostatin	Nipent	3/27/1998	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc.
2318	Pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia.	SuperGen, Inc.
2319	pentoxifylline	n/a	6/14/2012	Treatment of Behcet's disease	Keck Graduate Institute of Applied Life Sciences
2320	Peptide 144 TGF beta-1 inhibitor	n/a	4/27/2006	Treatment of systemic sclerosis	Digna Biotech, S.L.
2321	Peptide 144 TGF beta-1-inhibitor	n/a	4/26/2006	Treatment of localized scleroderma	Digna Biotech, S.L.
2322	Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Rose Pharmaceuticals
2323	peptide YY	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Mondobiotech Laboratories AG

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2324	peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	VAXON-Biotech
2325	peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)	n/a	9/3/2009	Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).	Sarepta Therapeutics, Inc.
2326	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/2011	Treatment of myasthenia gravis	CuraVac Europe SPRL
2327	Peptidomimetic analog of hexarelin	n/a	5/14/2007	Diagnosis of growth hormone deficiency	Aeterna Zentaris GmbH
2328	perampanel	Fycompa	12/7/2012	Treatment of Lennox-Gastaut Syndrome	Eisai, Inc.
2329	peretinoin	n/a	9/23/2011	Treatment of hepatocellular carcinoma.	Kowa Pharmaceutical Europe Co. Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2330	Perflubron	Liquivent(Tm)	4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	PFC Development/New Alliance Pharmaceutical
2331	perhexiline maleate	n/a	6/14/2012	Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy	Heart Metabolics, Limited.
2332	perifosine	n/a	7/9/2010	Treatment of neuroblastoma	Aeterna Zentaris GmbH
2333	perillyl alcohol	n/a	4/18/2011	Treatment of glioma	NeOnc Technologies, Inc.
2334	pertuzumab	n/a	6/8/2009	Treatment of ovarian cancer	Genentech, Inc.
2335	pertuzumab	n/a	7/12/2013	Treatment of gastric cancer	Genentech, Inc.
2336	pexastimogene devacirepvec	n/a	5/6/2013	Treatment of hepatocellular carcinoma	SillaJen Biotherapeutics, Inc.
2337	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/2012	Treatment of idiopathic thrombocytopenic purpura	PhytoHealth Corporation
2338	PGC-C12E-terlipressin	n/a	12/27/2012	Treatment of ascites due to all etiologies except for cancer	PharmaIN Corporation
2339	phenobarbitol sodium injection	n/a	10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent siezures in neonates	Fera Pharmaceuticals, LLC
2340	phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride	n/a	3/16/2015	Treatment of Huntington's disease.	Ipsen Biopharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2341	Phenylacetate	n/a	3/6/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
2342	Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/1995	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical
2343	Phenylbutyrate	n/a	1/19/2000	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc.
2344	phenylephrine	n/a	2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma
2345	phenylephrine	n/a	1/31/2012	Treatment of Tetralogy of Fallot	Luitpold Pharmaceuticals, Inc.
2346	Phosphatidylinositol 3-Kinase "PI3K" Inhibitor	n/a	11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Semafore Pharmaceuticals
2347	phosphorothioate antisense olignucleotide against EWS-Fli-1	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
2348	phoxilium	n/a	2/14/2014	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Gambro Renal Products, Inc.
2349	picibanil	n/a	5/15/2009	Treatment of patients with lymphatic malformations	Royds Pharmaceuticals, Inc.
2350	picibanil	n/a	3/17/2011	Treatment of lymphatic malformations	Richard Smith, M.D.
2351	Picoplatin	n/a	11/2/2005	Treatment of small cell lung cancer	Poniard Pharmaceuticals

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2352	Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc.
2353	Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc.
2354	pirfenidone	n/a	7/31/2014	Treatment of idiopathic pulmonary fibrosis	Genoa Pharmaceuticals, Inc.
2355	pirfenidone	Esbriet	3/5/2004	Treatment of idiopathic pulmonary fibrosis	Genentech
2356	pirfenidone	n/a	11/19/2013	Treatment of systemic sclerosis (including the associated interstitial lung disease)	Genentech, Inc.
2357	plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent	n/a	6/30/2014	Treatment of cystic fibrosis	Imperial Innovations Limited
2358	Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/2005	Treatment of cystic fibrosis	Copernicus Therapeutics, Inc.
2359	plasmin (human)	n/a	3/30/2009	Treatment of acute peripheral arterial occlusion	Grifols Therapeutics, Inc.
2360	plasminogen (human)	n/a	3/5/2013	Treatment of hypoplasminogenemia, or type I plasminogen deficiency	ProMetic Biotherapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2361	pleconaril	n/a	12/22/2014	Treatment of symptomatic enteroviral infection in the neonate	AntiVirus Therapeutics, Inc.
2362	plerixafor	Mozobil (R)	7/10/2003	For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Genzyme Corporation
2363	Plitidepsin	Aplidin	9/30/2004	Treatment of multiple myeloma	PharmaMar USA, Inc.
2364	polidocanol	n/a	2/19/2015	Treatment of congenital venous malformations	Provensis Ltd
2365	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
2366	Poloxamer 188	Florcor	2/22/1990	Treatment of severe burns requiring hospitalization.	CytRx Corporation
2367	Poloxamer 188	n/a	8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation
2368	poloxamer 188	n/a	11/8/2013	Treatment of Acute Limb Ischemia	Mast Therapeutics Inc.
2369	poloxamer 188 (purified)	n/a	6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Mast Therapeutics Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2370	Poloxamer 331	Protox	3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation
2371	poloxamer-188 NF	n/a	1/19/2010	Treatment of Duchenne muscular dystrophy	Phrixus Pharmaceuticals, Inc.
2372	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc.
2373	Poly I: poly C12U	Ampligen	5/20/1991	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc.
2374	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc.
2375	poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/2013	Treatment of acute encephalitis syndrome	Cour Pharmaceutical Development Company, Inc.
2376	poly-CD-PEG-camptothecin	n/a	5/21/2015	Treatment of ovarian cancer.	Cerulean Pharma, Inc.
2377	Poly-ICLC	Hiltonol	3/17/1997	Treatment of primary brain tumors.	Oncovir
2378	poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine	n/a	4/5/2016	Treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,Burkholderia cepacia and other bacteria	TGV-Inhalonix, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2379	polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase	n/a	3/17/2015	Treatment of homocystinuria	Orphan Technologies Limited
2380	Polyethylene glycol-modified uricase	Zurase	9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	EnzymeRx, LLC
2381	Polyethylene glycol-modified uricase	Zurase	12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	EnzymeRx, LLC
2382	Polyethylene glycol-modified uricase	n/a	6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	EnzymeRx, LLC
2383	polyinosinic-polycytidilic acid	Poly-Iclc	8/2/2002	As an adjuvant to smallpox vaccination	Oncovir
2384	polyinosinic-polycytidilic acid	Poly-Iclc	3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir
2385	polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/2002	Treatment for orthopox virus infections	Oncovir
2386	Polymeric oxygen	n/a	3/25/1992	Treatment of sickle cell anemia.	Capmed USA

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2387	polyphenon E	n/a	7/17/2008	Treatment of chronic lymphocytic leukemia	Mitsui Norin Co., Ltd
2388	Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/1988	Treatment of AIDS.	Hemispherx Biopharma, Inc.
2389	Polyvalent, shed-antigen melanoma vaccine	n/a	6/9/2006	Treatment of stage IIb to stage IV melanoma	Polynoma LLC
2390	pomalidomide	n/a	9/21/2010	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	Celgene Corporation
2391	pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Celgene Corporation
2392	ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ARIAD Pharmaceuticals Inc.
2393	ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	ARIAD Pharmaceuticals Inc.
2394	ponatinib	Iclusig(R)	3/12/2015	Treatment of gastrointestinal stromal tumors (GIST).	ARIAD Pharmaceuticals, Inc.
2395	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2396	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
2397	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
2398	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
2399	porcine GM1 ganglioside	n/a	12/3/2012	Treatment of acute spinal cord injury	TRB Chemedica International S.A.
2400	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc.
2401	porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2402	Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc.
2403	Porfimer sodium	Photofrin	11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc.
2404	Porfimer sodium	Photofrin	11/18/2004	Treatment of cholangiocarcinoma	Concordia Laboratories, Inc.
2405	Porfiromycin	Promycin	9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
2406	Porfiromycin	Promycin	3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
2407	Posaconazole	Posoril	7/16/2004	Treatment of zygomycosis	Schering-Plough Corporation
2408	Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas
2409	Potassium citrate	Urocit-K	11/1/1984	1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2410	Potassium Iodide Oral Solution	Thyroshield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	Fleming & Company, Pharmaceuticals
2411	potassium sodium aluminosilicate	n/a	1/8/2007	For treatment of poisoning by or exposure to cesium.	Castle Creek Pharmaceuticals, LLC
2412	pracinostat	n/a	2/27/2014	Treatment of acute myeloid leulemia	MEI Pharma Inc.
2413	pralatrexate	n/a	5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Allos Therapeutics, Inc.
2414	pralatrexate	n/a	10/20/2008	Treatment of follicular lymphoma	Allos Therapeutics, Inc.
2415	pralatrexate	n/a	10/20/2008	Treatment of diffuse large B-cell lymphoma	Allos Therapeutics, Inc.
2416	pralatrexate	Folotyn	7/20/2006	Treatment of T-cell lymphoma	Allos Therapeutics, Inc.
2417	pralmorelin hydrochloride	n/a	10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Sella Pharmaceuticals, Inc.
2418	pramipexole	Mirapex	1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Boehringer-Ingelheim Pharmaceuticals, Inc.
2419	prasugrel hydrochloride	Effient	5/26/2015	Treatment of sickle cell disease	Eli Lilly

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2420	Primaquine phosphate	n/a	7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc.
2421	pritumumab	n/a	10/28/2014	Treatment of glioma	Nascent Biotech, Inc.
2422	pritumumab	n/a	4/6/2016	Treatment of pancreatic cancer.	Nascent Biotech, Inc.
2423	Procarbazine HCl	Matulane	8/8/2006	Treatment of malignant glioma	Sigma-Tau Pharmaceuticals, Inc.
2424	procaspase-activating compound 1	n/a	7/23/2015	Treatment of malignant glioma	Vanquish Oncology, Inc.
2425	profimer sodium	Photofrin(R)	12/2/2011	Treatment of malignant mesothelioma	Concordia Laboratories, Inc.
2426	progesterone	n/a	12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc.
2427	prolactin receptor antagonist	Prolanta	4/15/2013	Treatment of ovarian cancer	Oncolix, Inc.
2428	propagermanium and irbesartan	n/a	12/9/2015	Treatment of focal segmental glomerulosclerosis.	Dimerix Bioscience Ltd.
2429	propranolol	Hemangeol	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Pierre Fabre Dermatologie
2430	propranolol and etodolac	n/a	4/27/2015	Treatment of pancreatic cancer.	Vicus Therapeutics, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2431	propranolol and etodolac	n/a	7/8/2015	Treatment of malignant glioma.	Vicus Therapeutics, LLC
2432	propranolol hydrochloride and etodolac	n/a	2/24/2015	Treatment of hepatocellular carcinoma	Vicus Therapeutics, LLC
2433	Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	LTT Baio-Pharma Co., Ltd
2434	Protaxel	n/a	5/21/2003	Treatment of ovarian cancer	Biophysica, Inc.
2435	Protein C concentrate	Ceprotin	6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxalta US, Inc.
2436	Protein C concentrate	Protein C Concentrate (Human) Vapor Heated, Immuno	6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp.
2437	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
2438	Pulmonary surfactant replacement, porcine	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Chiesi USA, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2439	purified autologous type 1 regulatory T lymphocytes specific for human type II collagen	n/a	9/1/2015	Treatment of chronic non-infectious uveitis	TxCell SA
2440	purified bovine type collagen	n/a	4/27/2009	Treatment of idiopathic pulmonary fibrosis	ImmuneWorks, Inc.
2441	Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Able Laboratories, Inc.
2442	Purified type II collagen	Colloral	2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc.
2443	PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCATTTTGTCATT 3'	Imt504	11/24/2014	Treatment of rabies virus infections	Mid-Atlantic BioTherapeutics, Inc.
2444	pyridoxine; vitamin B6	n/a	3/3/2011	Treatment of pyridoxine dependent seizures.	NBI Pharmaceuticals, Inc.
2445	pyrimethamine	n/a	8/16/2011	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	ExSAR Corporation
2446	Pyruvate	n/a	2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc
2447	pyrvinium	n/a	1/5/2015	Treatment of familial adenomatous polyposis	StemSynergy Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2448	quinacrine	n/a	9/28/2012	Treatment of hepatocellular carcinoma	Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur
2449	quinine Sulfate	n/a	6/3/2004	Treatment of malaria	AR Holding Company, Inc.
2450	quinine sulfate	n/a	12/2/2008	Treatment of malaria excluding Plasmodium faliparum	Zydus Pharmaceuticals, Inc.
2451	R-(-)-gossypol	n/a	10/24/2006	Treatment of chronic lymphocytic leukemia.	Ascenta Therapeutics, Inc.
2452	R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepine -3-yl]-3-(3-methylaminophenyl)urea	n/a	9/10/2009	Treatment of gastric carcinoids	Trio Medicines Ltd.
2453	R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/2008	Treatment of the behavorial abnormalities associated with fragile X syndrome	Seaside Therapeutics, Inc.
2454	rAAV2-CB-hRPE65	n/a	2/11/2005	Treatment of type II Leber's Congential Amaurosis	Applied Genetic Technologies Corp.
2455	Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosupression in pediatric liver transplant recipients	Children's Hospital of Pittsburgh
2456	radiolabeled somastatin analog	Galiomedix(Tm)	12/31/2013	Diagnostic for the management of neuroendocrine tumors	RadioMedix, Inc.
2457	raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Eli Lilly and Company

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2458	raloxifene hydrochloride	Evista	8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Consejo Superior de Investigaciones Cientificas
2459	ramucirumab	n/a	11/4/2011	Treatment of hepatocellular carcinoma	Eli Lilly and Company
2460	ramucirumab	Cyramza	2/16/2012	Treatment of gastric cancer	Eli Lilly and Company
2461	ranagengliotucel-L	Glionix(Tm)	5/29/2009	Treatment of astrocytic tumors	NovaRx Corporation
2462	ranprinase	Onconase	1/25/2007	Treatment of malignant mesothelioma	Alfacell Corporation
2463	rapamycin	n/a	2/24/2016	Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).	DSLP
2464	Rapamycin	n/a	3/20/2007	Treatment of tuberous sclerosis complex	OncoImmune, Inc.
2465	rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2466	raxibacumab	Abthraxtm	11/12/2003	Treatment of anthrax	Human Genome Sciences, Inc.
2467	Re188 P2045 somatostatin analog	n/a	2/6/2014	Treatment of small cell lung cancer	Andarix Pharmaceuticals
2468	Re188 P2045 somatostatin peptide analogue	n/a	6/19/2014	Treatment of pancreatic cancer.	Andarix Pharmaceuticals, Inc.
2469	recilisib sodium	Ex-Rad(R)	6/1/2012	Prevention of acute radiation syndrome	Onconova Therapeutics, Inc.
2470	recilisib sodium	Ex-Rad(R)	9/4/2012	Treatment of acute radiation syndrome	Onconova Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2471	Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase	n/a	4/30/2014	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Abeona Therapeutics LLC
2472	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	n/a	4/29/2014	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	Abeona Therapeutics
2473	recombinant activated Factor X variant	n/a	3/3/2015	Treatment of intracerebral hemorrhage	Pfizer, Inc.
2474	recombinant adeno-associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/2013	For the treatment of Sandhoff disease	Nat'l Tay-Sachs & Allied Diseases Association
2475	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/2009	Treatment of Leber's congential amaurosis	AmpliPhi Biosciences Corporation
2476	recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp.
2477	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/2009	Treatment of Huntington's disease.	Neurologix, Inc.
2478	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Spark Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2479	recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP	n/a	10/29/2015	Treatment of Angelman Syndrome.	Agilis Biotherapeutics, LLC
2480	recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase	n/a	12/29/2015	Treatment of ornithine transcarbamylase deficiency	Dimension Therapeutics
2481	recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter	n/a	6/16/2015	Treatment of Duchenne muscular dystrophy	Nationwide Children's Hospital
2482	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3)	n/a	11/16/2015	Treatment of achromatopsia caused by mutations in the CNGA3 gene	Applied Genetic Technologies Corp.
2483	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Applied Genetic Technologies Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2484	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/2013	Treatment of Tay-Sachs disease	Na't Tay-Sachs & Allied Diseases Association
2485	Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/2009	Treatment of Hodgkin lymphoma	Affimed Therapeutics AG
2486	Recombinant coagulation factor VIIa	n/a	4/26/2006	Treatment of diffuse alveolar hemorrhage	PharmaOrigin ApS
2487	recombinant deriative of C3 transferase	Cethrin	11/18/2005	Treatment of acute spinal cord injury	Vertex Pharmaceuticals, Inc.
2488	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Treatment of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic, and secondary forms.	Baxalta US Inc.
2489	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms.	Baxalta US Inc.
2490	recombinant DNA plasmid	n/a	1/31/2014	Treatment of stage IIb, IIc, III and IV melanoma.	Scancell Ltd.
2491	recombinant elafin	n/a	3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Proteo Biotech AG

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2492	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Henogen S.A.
2493	Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/2006	Treatment of anthrax infection	PharmAthene, Inc.
2494	Recombinant Fusion Protein	n/a	7/24/2012	Treatment of Myelodysplastic Syndrome	Apogenix GmbH
2495	recombinant fusion protein comprising exenatide and XTEN	n/a	10/7/2015	Treatment of short bowel syndrome.	NAIA Pharmaceuticals, Inc.
2496	recombinant fusion protein consisiting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/2013	Treatment of myelodysplastic syndrome	Celgene Corporation
2497	recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/2013	Treatment of B-thalassemia	Celgene Corporation
2498	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	Idelvion	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	CSL Behring, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2499	recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL Behring
2500	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. is now Nventa
2501	recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Viventia Biotech, Inc.
2502	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/2009	Treatment of glioblastoma multiforme	Apogenix GmbH
2503	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/2010	Treatment of Pompe disease.	BioMarin Pharmaceutical, Inc.
2504	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
2505	recombinant human acid ceramidase	Plexcerase(Tm)	12/24/2013	Treatment of Faber disease	Plexcera Therapeutics, LLC
2506	recombinant human alkaline phosphatase	n/a	5/13/2015	Treatment of hypophosphatasia.	AM-Pharma BV

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2507	Recombinant human alpha 1-antitrypsin	n/a	4/28/2005	Prevention of bronchopulmonary dysplasia	Arriva Pharmaceuticals, Inc.
2508	recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/2001	Treatment of cystic fibrosis	AiroMedica LLC
2509	recombinant human alpha-1 antitrypsin	n/a	3/6/1998	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited
2510	recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	AiroMedica LLC
2511	Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/2001	Treatment of myasthenia gravis	Alpha Cancer Technologies, Inc.
2512	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/2013	Treatment of Pompe Disease	Genzyme, a Sanofi Company
2513	Recombinant human alpha-mannosidase	n/a	2/2/2006	Treatment of alpha-mannosidosis	Chiesi USA, Inc.
2514	recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Alexion Pharmaceuticals
2515	recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Pfizer, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2516	recombinant human antithrombin	Atryn	12/7/2007	Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures	GTC Biotherapeutics, Inc.
2517	Recombinant human antithrombin III	n/a	4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC
2518	recombinant human beta-glucuronidase	n/a	2/16/2012	Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)	Ultragenyx Pharmaceutical, Inc.
2519	Recombinant human C1 inhibitor	n/a	6/9/2006	Treatment of capillary leakage syndrome	Pharming Technologies B.V.
2520	Recombinant human C1 inhibitor	n/a	6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Pharming Group N.V.
2521	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming Group N.V.
2522	recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain	n/a	6/9/2015	Prevention of graft-versus-host disease	OncoImmune, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2523	Recombinant human CD4 immunoglobulin G	n/a	8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc.
2524	Recombinant human Clara Cell 10kDa protein	n/a	7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Therabron Therapeutics, Inc.
2525	recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	n/a	3/17/2014	Treatment of dystrophic epidermolysis bullosa	Shire Human Genetic Therapies, Inc.
2526	recombinant human deoxyribonuclease I	n/a	8/18/2014	Treatment of graft-vs-host disease	SciVac Ltd.
2527	recombinant human deoxyribonuclease I (DNase I)	n/a	8/18/2014	Prevention of graft-vs-host disease	SciVac Ltd.
2528	recombinant human endostatin protein	n/a	2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc.
2529	Recombinant human endostatin protein	n/a	8/13/2001	Treatment of neuroendocrine tumors	EntreMed, Inc.
2530	recombinant human erythropoietin (rHuEPO)	n/a	5/26/2011	Treatment of mutliple myeloma	XTL Biopharmaceuticals, Ltd
2531	Recombinant Human Factor VIIa Variant	n/a	11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Pfizer, Inc.
2532	Recombinant human fibrinogen	n/a	10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Pharming Technologies B.V.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2533	recombinant human fucosyltransferase VI [FTVI] + GDP-fucose	n/a	1/27/2015	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	TargaZyme, Inc.
2534	recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	ACE BioSciences A/S
2535	Recombinant human gelsolin	n/a	1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	BioAegis Therapeutics, Inc.
2536	Recombinant human gelsolin	n/a	3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	BioAgeis, Therapeutics, Inc.
2537	Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/2010	Treatment of Type I diabetes with residual beta cell function	Diamyd Therapeutics AB
2538	recombinant human GM-CSF, molgramostim	n/a	10/31/2012	Treatment of pulmonary alveolar proteinosis	Serendex ApS
2539	recombinant human gowth hormone in an ocular delivery system	n/a	12/3/2012	Treatment of persistent corneal epithelial defects	Jade Therapeutics LLC
2540	Recombinant human granulocyte colony stimulating factor	n/a	7/24/2006	Prevention of implantation failure and unexplained recurrent miscarriage	Nora Therapeutics, Inc.
2541	Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2542	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc.
2543	recombinant human histidyl tRNA synthetase	n/a	4/22/2015	Treatment of facioscapulohumeral muscular dystrophy	aTyr Pharma, Inc.
2544	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/2008	Treatment of acute myeloid leukemia	Xenetic Biosciences Plc
2545	recombinant human IgG1 monoclonal antibody	n/a	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Ultragenyx Pharmaceutical, Inc.
2546	Recombinant human insulin-like growth factor-I	Pv802	2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd.
2547	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/1999	Treatment of major burns that require hospitalization.	Insmed, Inc.
2548	Recombinant human interleukin-12	n/a	10/20/1997	Treatment of renal cell carcinoma.	Genetics Institute, Inc.
2549	Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/2005	Treatment of stage II (T4), III or IV malignant melanoma.	Zymo Genetics, Inc
2550	Recombinant human keratinocyte growth factor	n/a	12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Swedish Orphan Biovitrum AB (publ) (SOBI)

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2551	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/2010	Treatment of LCAT deficiency syndromes	AlphaCore Pharma, LLC
2552	Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	EMD Serono, Inc.
2553	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestrase	7/14/2005	Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease	Lysosomal Acid Lipase, LLC
2554	Recombinant human microplasmin	n/a	1/23/2006	Treatment of peripheral arterial occlusion	ThromboGenics Ltd
2555	recombinant human minibody against complement component	Mubodina(R)	6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Adienne S.A
2556	recombinant human minibody against complement component C5	Mubodina	2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Adienne S.A.
2557	recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Adienne S.A.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2558	recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/2012	Treatment of inclusion body myositis	Novartis Pharmaceuticals Corp.
2559	recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	n/a	8/19/2014	Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath	Novartis Pharmaceuticals Corp
2560	recombinant human monoclonal antibody to hsp90	Mycograb	9/16/2002	Treatment of invasive candidiasis	Novartis Pharmaceuticals Corp.
2561	recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (anti-PD-L1)	n/a	9/21/2015	Treatment of merkel cell carcinoma.	EMD Serono, Inc.
2562	recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/2013	Treatment of multiple myeloma	Patrys Ltd.
2563	recombinant human Naglu-insulin-like growth factor II	n/a	3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Shire Human Genetic Therapies, Inc.
2564	recombinant human nerve growth factor	n/a	8/8/2013	Treatment of retinitis pigmentosa	Dompe s.p.a.
2565	Recombinant human nerve growth factor	n/a	4/16/1999	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc.
2566	recombinant human nerve growth factor	n/a	6/23/2014	Treatment of neurotrophic keratitis	Dompe s.p.a.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2567	recombinant human neutrophil inhibitor (hNE)	n/a	12/9/2003	Treatment of cystic fibrosis	Dyax Corporation
2568	recombinant human Pentraxin-2	n/a	8/26/2014	Treatment of myelofibrosis	Promedior, Inc.
2569	recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Promedior, Inc.
2570	Recombinant human platelet derived growth factor BB	n/a	2/1/2007	Treatment of osteonecrosis of the jaws	Luitpold Pharmaceuticals, Inc.
2571	recombinant human platelet derived growth factor-BB	n/a	8/6/2010	Treatment of osteochondritis dissecans	Biomimetic Therapeutics, Inc.
2572	recombinant human porphobilinogen deaminase	Porphozyme	9/9/2002	Treatment of acute intermittent porphyria attacks	Zymenex A/S
2573	recombinant human porphobilinogen deaminase, erythropoetic form	n/a	7/11/2002	Treatment of acute intermittent porphyria preventing attacks	Zymenex A/S
2574	recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/2008	Treatment of retinitis pigmentosa	ProRetina Therapeutics, S.L.
2575	Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/2010	Treatment of idiopathic thrombocytopenic purpura	SuppreMol GmbH
2576	recombinant human surfactant protein D	n/a	6/23/2014	Prevention of bronchopulmonary dysplasia	Airway Therapeutics LLC
2577	Recombinant human thrombopoietin	n/a	9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2578	recombinant human tripeptidyl-peptidase 1 (rhTPP1)	n/a	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	BioMarin Pharmaceutical, Inc.
2579	recombinant human type I pancreatic elastase	n/a	4/3/2009	Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis	Proteon Therapeutics, Inc.
2580	recombinant human type VII collagen	n/a	6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	David T. Woodley, MD and Mei Chen, MD
2581	recombinant human vascular endothelial growth factor	n/a	6/7/2010	Treatment of amyotrophic lateral sclerosis	NeuroNova AB
2582	recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	n/a	2/11/2015	Treatment of eosinophilic esophagitis	Receptos Services, LLC
2583	recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4	n/a	7/16/2015	Treatment of gastric cancer	Gilead Sciences, Inc.
2584	recombinant humanized anti-tau antibody	n/a	1/22/2015	Treatment of progressive supranuclear palsy	AbbVie, Inc.
2585	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/2013	Treatment of sickle cell disease	NKT Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2586	recombinant humanized IgG4 monoclonal antibody that binds human colony stimulating factor 1 receptor	n/a	1/11/2016	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Five Prime Therapeutics, Inc.
2587	Recombinant humanized MAb 5c8	n/a	10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc.
2588	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc.
2589	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc.
2590	Recombinant humanized monclonal antibody 5c8	n/a	2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc.
2591	Recombinant humanized monoclonal antibody 5c8	n/a	2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc.
2592	recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	n/a	5/14/2014	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Genentech, Inc.
2593	recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/2011	Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).	Shire Human Genetics Therapies

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2594	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of epithelial ovarian cancer	National Institutes of Health
2595	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of malignant mesothelioma	National Institutes of Health
2596	recombinant kallikrein inhibitor	n/a	11/23/2010	Treatment of Netherton Syndrome.	Dermadis SA
2597	recombinant lens epithelium derived growth factor 1-326	n/a	5/19/2014	Treatment of retinitis pigmentosa	Ocugen, Inc.
2598	Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc.
2599	recombinant monoclonal antibody to human serum amyloid P component	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline
2600	recombinant multimerized human IgG1 Fc	n/a	7/14/2015	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).	Pfizer, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2601	recombinant nematode anticoagulant protein c2 (rNAPc2)	n/a	12/8/2014	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	ARCA Biopharma, Inc.
2602	recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S	n/a	11/17/2014	Treatment of patients with carbon monoxide poisoning	University of Pittsburgh
2603	recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A	n/a	1/6/2016	Treatment of soft tissue sarcoma.	Immune Design Corp.
2604	recombinant ovine interferon tau	Tauferon	1/25/2005	Treatment of pediatric multiple sclerosis	PEPGEN Corporation
2605	Recombinant P-Selectin glycoprotein ligand	n/a	3/29/2006	Prevention of delayed graft function in renal transplant patients	Y's Therapeutics, Inc.
2606	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Y's Therapeutics, Inc.
2607	Recombinant protein inhibitor of complement factor 5	n/a	5/10/2016	Treatment of Guillain-Barre Syndrome.	Akari Therapeutics Plc
2608	Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/1999	Treatment of primary ovarian cancer.	Schering Corporation
2609	Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2610	Recombinant secretory leucocyte protease inhibitor	n/a	3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc.
2611	Recombinant soluble human CD4 (rCD4)	n/a	3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc.
2612	Recombinant T-cell receptor ligand	n/a	5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Artielle ImmunoTherapeutics, Inc.
2613	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathydue to thymidine phosphorylase deficiency.	St. George's University of London
2614	Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/2005	Treatment of cystic fibrosis	Aerovance, Inc.
2615	Recombinant urate oxidase	n/a	10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2616	recombinant von Willebrand factor (rhVWF)	n/a	11/23/2010	Treatment of von Willebrand disease.	Baxalta US, Inc.
2617	recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2	n/a	5/26/2016	Treatment of glioma	Darell D. Bigner, MD, PhD

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2618	Reduced L-glutathione	Cachexon	2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation
2619	refanalin	n/a	5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Angion Biomedica Corporation
2620	regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Bayer HealthCare Pharmaceuticals, Inc.
2621	regorafenib	Stivarga	6/4/2015	Treatment of hepatocellular carcinoma.	Bayer HealthCare Pharmaceuticals, Inc.
2622	REMUNE HIV 1	n/a	2/14/2014	Treatment of pediatric HIV/AIDS (age through 16 years)	Immune Response BioPharma, Inc.
2623	reparixin	n/a	9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Dompe S.p.A.
2624	reparixin	n/a	1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe S.p.A.
2625	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2626	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	MeiraGTx, LLC
2627	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/2010	Treatment of acute myeloid leukemia	Aduro BioTech, Inc.
2628	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/2010	Treatment of chronic myeloid leukemia	Aduro BioTech, Inc.
2629	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/2010	Treatment of pancreatic cancer.	Aduro BioTech, Inc.
2630	repository corticortropin injection	H.P. Acthar Gel	6/28/2013	Treatment of amyotrophic lateral sclerosis	Questor Pharmaceuticals, Inc.
2631	repository corticotropin or adrenocorticotropic hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc.
2632	resiniferatoxin	n/a	5/13/2003	Treatment of intractable pain at end-stage disease	Sorrento Theraeputics, Inc.
2633	reslizumab	Cinquil	1/12/2011	Treatment of hypereosinophilic syndrome	Teva Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2634	reslizumab	n/a	12/19/2007	Treatment of children with eosinophilic esophagitis	Teva Respiratory, LLC
2635	resminostat	n/a	6/29/2011	Treatment of hepatocellular carcinoma	4SC AG
2636	resminostat	n/a	9/16/2011	Treatment of Hodgkin's lymphoma.	4SC AG
2637	Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachussetts Public Health Biologics Labs.
2638	Respiratory Syncytial Virus Immune Globulin (human)	Hypermune Rsv	9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc.
2639	retroviral gamma-c cDNA containing vector	n/a	4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc.
2640	Reversal agent linked to chloroquine-like moiety	n/a	3/26/2010	Treatment of malaria	DesignMedix
2641	Revimmune	n/a	2/18/2011	Treatment of autoimmune hemolytic anemia.	Accentia Biopharmaceuticals
2642	Reviparin sodium	Clivarine	6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Abbott

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2643	Reviparin sodium	Clivarine	6/18/2001	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Abbott
2644	revusiran	n/a	5/18/2015	Treatment of transthyretin amyloidosis	Alnylam Pharmaceuticals, Inc.
2645	rh-microplasmin, ocriplasmin	Jetrea	3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	ThromboGenics Inc.
2646	rhIGF-I/rhIGFBP-3	Somatokine	12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmed, Inc.
2647	Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/1993	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc.
2648	ribavirin	Virazole	4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Valeant Pharmaceuticals International
2649	ribavirin	Rebetol	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation
2650	ribavirin elaidate	n/a	9/2/2011	Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer	Translational Therapeutics, Inc.
2651	riboflavin ophthalmic solution & ultraviolet A	Photrexa Viscous	9/2/2011	Treatment of keratoconus	Avedro, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2652	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	n/a	12/2/2011	Treatment of corneal ectasia following refractive surgery	Avedro, Inc.
2653	ricin vaccine	Rivax(R)	1/7/2011	Prevention of ricin intoxication.	Soligenix, Inc.
2654	Rifabutin	n/a	12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Pfizer Inc.
2655	Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc.
2656	Rifalazil	n/a	4/13/1999	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation
2657	Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel
2658	Rifampin, isoniazid, pyrazinamide	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel
2659	Rifapentine	Priftin	6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc.
2660	Rifapentine	Priftin	3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc.
2661	Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2662	rifaximin	Normix	2/10/1998	Treatment of hepatic encephalopathy	Salix Pharmaceuticals, Inc.
2663	rigosertib	n/a	3/18/2011	Treatment of pancreatic cancer.	Onconova Therapeutics, Inc
2664	rigosertib	n/a	3/16/2012	Treatment of ovarian cancer	Onconova Therapeutics, Inc.
2665	rigosertib	n/a	9/3/2009	Treatment of myelodysplastic syndromes	Onconova Therapeutics, Inc.
2666	RII retinamide	n/a	5/6/1993	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc.
2667	rilonacept	Arcalyst	1/9/2013	Treatment of familial Mediterranean fever	Philip J Hashkes, MD, MSc.
2668	Rilonacept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Regeneron Pharmaceuticals, Inc.
2669	rilotumumab	n/a	6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Amgen, Inc.
2670	Riluzole	Rilutek	10/15/1996	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2671	Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2672	riluzole	n/a	2/23/2016	Treatment of spinocereballar ataxia.	Biohaven Pharmaceutical Holding Company, Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2673	rindopepimut	n/a	11/19/2007	Treatment of EGFRvIII-expressing glioblastoma multiforme	Celldex Therapeutics, Inc.
2674	riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Bayer HealthCare Pharmaceuticals, Inc.
2675	riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Bayer HealthCare Pharmaceuticals, Inc.
2676	riociguat	Adempas	7/24/2014	Treatment of systemic sclerosis	Bayer HealthCare Pharmaceuticals
2677	rituximab	Rituxan(R); Mabthera(R)	2/23/2015	Treatment of pemphigus vulgaris.	Genentech, Inc.
2678	rituximab	Rituxan	2/14/2006	Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)	Genentech, Inc.
2679	rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Genentech, Inc.
2680	rituximab	Rituxan	3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc.
2681	rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2682	rociletinib	n/a	5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Clovis Oncology, Inc.
2683	rofecoxib	Vioxx	3/16/2004	Treatment of juvenile rheumatoid arthritis	MERCK & Co., Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2684	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation
2685	romiplostim	n/a	10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Amgen Inc.
2686	romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Amgen, Inc.
2687	roneparstat	n/a	3/19/2015	Treatment of multiple myeloma	Sigma-Tau Research Switerland S.A.
2688	ropidoxuridine (5-iodo-2-pyrimidinone-2'-deoxyribose)	n/a	5/19/2016	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme.	EMEK, Inc.
2689	Rose Bengal Disodium	n/a	12/21/2006	Treatment of metastatic melanoma	Provectus Pharmaceuticals, Inc.
2690	Roseburia hominis	Rosburix	8/4/2014	Treatment of ulcerative colitis in pediatric patients age 0 through 16 years	4D Pharma Research Ltd
2691	Rosomidnar	n/a	3/10/2016	Treatment of diffuse large B-cell lymphoma.	ProNAi Therapeutics, Inc.
2692	rosuvastatin	Crestor	2/14/2014	For the treatment of pediatric homozygous familial hypercholesterolemia	iPR Pharmaceuticals, Inc.
2693	rovalpituzumab tesirine	n/a	12/22/2015	Treatment of small cell lung cancer	Stemcentrx, Inc.
2694	rozrolimupab	n/a	9/13/2010	Treatment of primary immune thrombocytopenia.	Symphogen A/S
2695	rsATP7A cDNA	n/a	1/10/2014	Treatment of Menkes disease	Stephen G. Kaler, MD

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2696	rSP-C lung surfactant	Venticute	4/3/2000	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals
2697	rSP-C surfactant	Venticute	9/18/2006	For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment	Altana Pharma
2698	rt-PA	Activase	10/20/2014	Treatment of plastic bronchitis	Kathleen A Stringer, PharmD, FCCP - Professor
2699	rubitecan	n/a	7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc.
2700	rucaparib	n/a	7/31/2012	Treatment of ovarian cancer	Clovis Oncology, Inc.
2701	rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Eisai, Inc.
2702	ruxolitinib	Jakafi	8/16/2013	Treatment of pancreatic cancer	Incyte Corporation
2703	ruxolitinib	Jakafi	3/26/2010	Treatment of polycythemia vera	Incyte Corporation
2704	ruxolitinib phosphate	Jakafi	3/22/2010	Treatment of essential thrombocythemia	Incyte Corporation
2705	ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Incyte Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2706	rVIIa-FP	n/a	12/22/2011	Treatment and prophyllaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	CSL Behring
2707	S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated
2708	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Intercept Blood System For	2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Cerus Corporation
2709	S-adenosylmethionine	n/a	4/30/1998	Treatment of AIDS-myelopathy.	Genopia USA, Inc.
2710	S-nitrosoglutathione	n/a	5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	N30 PHARMAceuticals, LLC
2711	S-nitrosoglutathione	n/a	12/28/2012	Treatment of severe preeclampsia	Salupont Consulting Ltd
2712	S-nitrosoglutathione reductase inhibitor	n/a	1/13/2016	Treatment of cystic fibrosis	Nivalis Therapeutics, Inc.
2713	S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinly-GNNDESNISFKEK	n/a	10/20/2009	Treatment of pancreatic cancer	MBiotec GmBH

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2714	S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide	n/a	11/16/2015	Treatment of C3 glomerulopathy.	Amyndas Pharmaceuticals
2715	S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)	n/a	10/9/2014	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Amyndas Pharmaceuticals
2716	sacituzumab govitecan	n/a	11/27/2013	Treatment of small cell lung cancer	Immunomedics, Inc.
2717	sacituzumab govitecan	n/a	5/29/2014	Treatment of pancreatic cancer.	Immunomedics, Inc.
2718	Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase-isomaltase deficiency	QOL Medical, LLC
2719	salicylic acid 6%	n/a	2/17/2012	Treatment of rare congenital ichthyoses.	Orenova Group, LLC
2720	salirasib	n/a	12/18/2006	Treatment of pancreatic cancer.	Kadmon Corporation, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2721	salmeterol xinafoate/fluticasone propionate	n/a	10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease	Lithera, Inc.
2722	saposin C	n/a	2/3/2015	Treatment of glioblastoma multiforme	Bexion Pharmaceuticals, LLC
2723	sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical, Inc.
2724	Sar9, Met(O2)11-Substance P	Homspera	3/16/2011	Treatment of idiopathic pulmonary fibrosis	ImmuneRegen BioSciences, Inc.
2725	sarcosine	n/a	10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Guochuan Emil Tsai, MD, PhD
2726	Sargramostim	Leukine	5/3/1990	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation
2727	Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation
2728	sarizotan	n/a	7/7/2015	Treatment of Rett syndrome.	Newron Pharmaceuticals US, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2729	Satumomab pendetide	Oncoscint Cr/Ov	9/25/1989	Detection of ovarian carcinoma.	Cytogen Corporation
2730	SC-1 monoclonal antibody	n/a	11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Patrys Limited
2731	SDF-1 (108) Lysine Dlmer	n/a	7/7/2005	Treatment of osteogenic sarcoma	Chemokine Therapeutics Corporation
2732	sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2733	sebelipase alfa	Kanuma	7/1/2010	Treatment of lysosomal acid lipase deficiency	Alexion Pharmaceuticals
2734	Secalciferol	Osteo-D	7/26/1993	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA
2735	Secretory leukocyte protease inhibitor	n/a	6/30/1992	Treatment of bronchopulmonary dysplasia.	Synergen, Inc.
2736	selective antagonist of the chemokine receptor type 4	n/a	9/5/2013	Treatment of acute myeloid leukemia	BioLineRx, Ltd.
2737	selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/2011	Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome	Novartis Pharmaceuticals Corporation
2738	selective inhibitor of fungal CYP51	n/a	3/3/2016	Treatment of coccidioidomycosis.	Viamet Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2739	selective inhibitor of fungal lanosterol demethylase	n/a	8/19/2014	Treatment of cryptococcal meningitis	Viamet Pharmaceuticals, Inc.
2740	Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company
2741	Selegiline HCl	Eldepryl	11/7/1984	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc.
2742	selexipag	Uptravi	4/30/2010	Treatment of pulmonary arterial hypertension	Actelion Ltd
2743	self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid	n/a	9/27/2013	Treatment of Giant Axonal Neuropathy	Hannah's Hope Fund
2744	selinexor	n/a	1/5/2015	Treatment of multiple myeloma	Karyopharm Therapeutics, Inc.
2745	Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of acute myeloid leukemia	Karyopharm Therapeutics, Inc.
2746	selisistat	n/a	12/7/2009	Treatment of Huntington's disease	Siena Biotech SpA

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2747	selumetinib	n/a	5/10/2016	Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.	AstraZeneca Pharmaceuticals LP
2748	Seneca Valley virus	n/a	8/22/2008	Treatment of neuroendocrine tumors	Neotropix, Inc.
2749	Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
2750	Serratia marcescens extract (polyribosomes)	Imuvert	9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc.
2751	setmelanotide	n/a	4/4/2016	Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene	Rhythm Pharmaceuticals, Inc.
2752	setmelanotide	n/a	9/21/2015	Treatment of Prader-Willi Syndrome.	Rhythm Metabolics, Inc.
2753	sevuparin	n/a	3/17/2015	Treatment of sickle cell disease	Dilaforette AB
2754	Short chain fatty acid enema	Colomed	8/19/1997	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D.
2755	Short chain fatty acid solution	Colomed	5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer
2756	sialic acid	n/a	9/23/2011	Treatment of hereditary inclusion body myopathy.	Ultragenyx Pharmaceutical, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2757	sildenafil	Revatio	7/28/2011	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Pfizer, Inc.
2758	silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon(R) Sil	9/11/2014	Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure	Meda Pharmaceuticals, Inc.
2759	Silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon Sil	2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Meda AB
2760	siltuximab	Sylvant	5/26/2006	Treatment of Castleman's disease	Janssen Biotech, Inc.
2761	Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/1999	Treatment of patients with severe dermal burns	Sinclair Pharmaceuticals Ltd
2762	simtuzumab	n/a	1/5/2015	Treatment of primary sclerosing cholangitis	Gilead Sciences, Inc.
2763	single chain urokinase plasminogen activator	n/a	9/11/2014	Treatment of empyema (pleural)	Lung Therapeutics, Inc.
2764	single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21	n/a	7/17/2014	Treatment of Alport syndrome	Regulus Therapeutics, Inc.
2765	siponimod	n/a	7/10/2014	Treatment of dermatomyositis	Novartis Pharmaceuticals Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2766	Siponimod	n/a	11/26/2013	Treatment of polymyositis	Novartis Pharmaceuticals Corporation
2767	sirolimus	n/a	6/25/2014	Treatment of lymphangioleiomyomatosis	LAM Therapeutics, Inc.
2768	sirolimus	Rapamune	10/31/2012	Treatment of lymphangioleiomyomatosis	Pfizer, Inc.
2769	sirolimus	n/a	11/17/2011	Treatment of lymphangioleiomyomatosis	Cote Orphan Consulting, LLC
2770	sirolimus	n/a	3/18/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2771	sirolimus	n/a	11/4/2011	Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).	Santen Inc.
2772	sirolimus in an implantable collagen matrix	Coll-R, Sirogen	5/10/2012	Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis	Vascular Therapies, LLC
2773	Sitaxsentan Sodium	n/a	11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Pfizer Global Research and Development

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2774	sitimagene ceradenovec	Cerepro	7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Gliotherapy, Ltd.
2775	skin tissue	Stratagraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Stratatech Corporation
2776	small molecule FGFR4 inhibitor	n/a	9/14/2015	Treatment of hepatocellular cancer (HCC).	Blueprint Medicines Corporation
2777	Small Molecule Inhibitor of Exon 17 mutant KIT	n/a	1/6/2016	Treatment of gastrointestinal stromal tumors (GIST).	Blueprint Medicines Corporation
2778	small molecule inhibitor of Exon 17 Mutant KIT	n/a	1/21/2016	Treatment of mastocytosis	Blueprint Medicines Corporation
2779	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/15/2013	Treatment of Acute Myeloid Leukemia	Epizyme Inc.
2780	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Epizyme Inc.
2781	small molecule inhibitor of phosphodiesterase 10	n/a	9/26/2013	Treatment of Huntington's disease	Omeros Corporation
2782	small molecule normalizing the p53 function	n/a	6/12/2014	Treatment of ovarian cancer	Critical Outcome Technologies, Inc.
2783	smilagenin	Cogane	7/21/2011	Treatment of amyotrophic lateral sclerosis	Junaxo, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2784	sobetirome	n/a	4/29/2011	Treatment of X-linked adrenoleukodystrophy	NeuroVia, Inc.
2785	sodium 2, 2 dimethylbutyrate	n/a	7/25/2008	Treatment of sickle cell disease.	HemaQuest Pharmaceuticals, Inc.
2786	sodium 2-hydroxylinoleate	n/a	8/25/2015	Treatment of neuroblastoma.	Ability Pharmaceuticals, SL
2787	sodium 4-phenylbutyrate	n/a	10/18/2011	Treatment of spinal muscular atrophy	GMP-Orphan SAS
2788	sodium alginate oligosaccharide	n/a	2/24/2016	Treatment of cystic fibrosis.	AlgiPharma AS
2789	Sodium aluminosilicate	n/a	3/4/2005	Treatment of chronic hepatic encephalopathy	Castle Creek Pharmaceuticals LLC
2790	Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	IC-MedTech Corporation
2791	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic liver disease	IC-Medtech Corporation
2792	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
2793	sodium ascorbate and menadione sodium bisulfite	Apatone	4/9/2015	Treatment of noninfected painful total joint without mechanical complication	IC-MedTech Corporation
2794	sodium benzoate and clozapine	n/a	12/22/2011	Treatment of treatment-resistant schizophrenia	Guochuan Emil Tsai, MD, PhD

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2795	sodium chlorite	n/a	8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Neuraltus Pharmaceuticals, Inc.
2796	Sodium dichloroacetate	n/a	6/11/1990	Treatment of congenital lactic acidosis	Stacpoole, Peter W. M.D., Ph.D.
2797	Sodium dichloroacetate	n/a	6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D.
2798	sodium dichloroacetate	n/a	11/29/2010	For pulmonary arterial hypertension.	Peter W. Stackpoole, PhD, MD
2799	Sodium dichloroacetate	n/a	11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D.
2800	sodium dichloroacetate	n/a	7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group
2801	sodium fusidate	n/a	10/23/2013	Treatment of patients with prosthetic joint infections	Cempra Pharmaceuticals, Inc.
2802	Sodium Monomercaptoundecahydro-closo-dodecaborate	Borocell	4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner
2803	Sodium nitrite	n/a	4/18/2007	Treatment of cyanide poisoning	Hope Pharmaceuticals
2804	sodium nitrite	n/a	9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Hope Pharmaceuticals

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2805	sodium nitrite	n/a	1/9/2012	Treatment of chlorine gas poisoning	Hope Pharmaceuticals
2806	sodium nitrite	n/a	7/8/2008	Treatment of pulmonary arterial hypertension	Airess Pharmaceuticals, Inc.
2807	Sodium nitrite	n/a	1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Hope Pharmaceuticals
2808	Sodium nitrite	n/a	4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Hope Pharmaceuticals
2809	sodium nitrite and EDTA	n/a	11/10/2015	Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis	Arch Biopartners, Inc.
2810	sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Hope Pharmaceuticals
2811	Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/2007	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
2812	Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Ucyclyd Pharma, Inc.
2813	sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Lucane Pharma SA

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2814	sodium phenylbutyrate	Buphenyl	11/22/1993	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp.
2815	Sodium phenylbutyrate	Buphenyl	1/25/2007	Treatment of spinal muscular atrophy	OrphaMed, Inc.
2816	sodium phenylbutyrate	n/a	7/2/1992	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp.
2817	Sodium phenylbutyrate	n/a	3/20/2007	Treatment of spinal muscular atrophy	Tikvah Therapeutics, Inc.
2818	sodium phenylbutyrate	n/a	1/19/2010	Treatment of urea cycle disorder.	Navinta LLC
2819	Sodium phenylbutyrate	n/a	4/24/1998	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
2820	sodium phenylbutyrate	n/a	8/19/2014	Treatment of maple syrup urine disease	Acer Therapeutics, Inc.
2821	Sodium pyruvate	n/a	3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc
2822	sodium stibogluconate	n/a	10/28/2009	Treatment of cutaneous leishmaniasis	Surgeon General of the US Army

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2823	Sodium stibogluconate	n/a	6/16/2006	Treatment of cutaneous leishmaniasis	VioQuest Pharmaceuticals, Inc.
2824	sodium sulfate, potassium sulfate, and magnesium sulfate	Suprep	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Braintree Laboratories, Inc.
2825	sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride	Suclear	9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Braintree Laboratories, Inc.
2826	Sodium tetradecyl sulfate	Sotradecol	6/10/1986	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc.
2827	sodium thiosulfate	n/a	3/3/2011	Treatment of sulfur mustard poisoning	Hope Pharmaceuticals
2828	sodium thiosulfate	n/a	12/2/2010	Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.	Hope Pharmaceuticals
2829	sodium thiosulfate	n/a	11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Hope Pharmaceuticals
2830	sodium thiosulfate	n/a	10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Hope Pharmaceuticals
2831	Sodium thiosulfate	n/a	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Fennec Pharmaceuticals, Inc.
2832	sodium thiosulfate	n/a	11/19/2012	Treatment of calciphylaxis	Edinburg BioQuarter

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2833	sodium thiosulfate	n/a	10/28/2014	Treatment of dermatomyositis	Hope Pharmaceuticals
2834	Sodium Thiosulfate	n/a	2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Luitpold Pharmaceuticals, Inc.
2835	Sodium thiosulfate and sodium nitrite	n/a	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
2836	Sodium thiosulfate, sodium nitrite, amyl nitrite	Cyanide Antidote Package	6/16/2006	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
2837	sodium valproate	n/a	8/5/2015	Treatment of Wolfram syndrome	The University of Birmingham
2838	Solasonine and solamargine	Coramsine	11/2/2005	Treatment of renal cell carcinoma	Solbec Pharmaceuticals Limited
2839	Solasonine and solamargine	Coramsine	2/6/2006	Treaatment of high risk stage II, stage III and stage IV melanoma	Solbec Pharmaceuticals Limited
2840	solnatide	n/a	2/8/2016	Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB)	Apeptico Forschung und Entwicklung GmbH
2841	solnatide	n/a	2/4/2016	Treatment of primary graft dysfunction following lung transplantation	Apeptico Forschung und Entwicklung GmbH
2842	Soluble complement receptor type 1	n/a	3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2843	Soluble recombinant human complement receptor type 1	n/a	11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc.
2844	solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Octapharma USA, Inc.
2845	somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.	n/a	2/4/2016	Prevention of organ rejection in living donor kidney transplant recipients	Novartis Pharmaceuticals Corporation
2846	somatorelin	Somatrel	8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc.
2847	Somatostatin	Zecnil	6/20/1988	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc.
2848	Somatostatin	n/a	12/22/1994	Treatment of bleeding esophageal varices.	Eumedica Pharmaceuticals A.G. (Schweiz)

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2849	Somatrem for injection	Protropin	12/9/1985	1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000).	Genentech, Inc.
2850	Somatropin	Serostim	3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	EMD Serono, Inc.
2851	Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn
2852	Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Novo Nordisk Inc.
2853	Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company
2854	Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2855	Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Eli Lilly and Company

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2856	Somatropin (rDNA)	Saizen	5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	EMD Serono, Inc.
2857	Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	EMD Serono, Inc.
2858	Somatropin (r-DNA) for injection	Serostim	3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	EMD Serono, Inc.
2859	Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2860	Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
2861	Somatropin (rDNA origin) injection	Norditropin	7/10/1987	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Novo Nordisk Pharmaceuticals
2862	Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	EMD Serono, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2863	Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc.
2864	Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
2865	Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc.
2866	Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company
2867	Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn
2868	somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company
2869	sonidegib	n/a	3/23/2015	Treatment of medulloblastoma	Novartis Pharmaceuticals Corp.
2870	sorafenib	Nexavar	12/12/2011	Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer	Bayer HealthCare Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2871	Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Bayer Pharmaceutical Corporation
2872	Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Bayer Pharmaceuticals Corporation
2873	sotalol (IV)	So-Aqueous	7/25/2008	For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.	Academic Pharmaceuticals
2874	Sotalol HCl	Betapace	9/23/1988	1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias	Berlex Laboratories, Inc.
2875	sotalol hydrochloride	Sotylize	2/10/2014	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Arbor Pharmaceuticals, LLC
2876	sotatercept	n/a	4/28/2014	Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferati ve neoplasms.	Celgene Corporation
2877	sotatercept	n/a	12/5/2013	Treatment of beta-thalassemia intermedia and major	Celgene Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2878	sparsentan	n/a	1/5/2015	Treatment of Focal Segmental Glomerulosclerosis	Retrophin, LLC
2879	spherical carbon adsorbent	n/a	12/19/2007	Treatment of chronic pouchitis	Ocera Therapeutics, Inc.
2880	spironolactone	Aldactone	5/22/2014	Use in pediatric patients with primary hyperaldosteronism	CMP Pharma, Inc.
2881	squalamine lactate	n/a	5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation
2882	staphylococcal aureus protein A	n/a	6/10/2015	Treatment of immune thrombocytopenic purpura	Protalex, Inc.
2883	Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Biotest Pharmaceuticals Corporation
2884	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of Hodgkin lymphoma.	Gamida Cell Ltd.
2885	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of acute lymphoblastic leukemia.	Gamida Cell Ltd.
2886	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of myelodysplastic syndrome.	Gamida Cell Ltd.
2887	stemchymal	n/a	12/16/2015	Treatment of polyqlutamine spinocerebellar ataxia	Steminent Biotherapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2888	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemopdialysis Solution	Accusol	5/29/2009	For use as a replacement solution in adults and children during Continous Renal Replacement Therapy	Nikkiso America, Inc.
2889	Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax.	Novatech SA
2890	Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion.	Novatech SA
2891	Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Bryan Corporation
2892	stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Biocodex
2893	Substituted imidazopyridine amide	n/a	12/22/2015	Treatment of active tuberculosis (TB).	Qurient Co., Ltd.
2894	Succimer	Chemet	3/22/1991	Treatment of mercury intoxication.	Sanofi Winthrop, Inc.
2895	Succimer	Chemet	11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc.
2896	Succimer	Chemet Capsules	5/9/1984	Treatment of lead poisoning in children.	Bock Pharmacal Company
2897	Sucralfate suspension	n/a	3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc.
2898	Sucralfate suspension	n/a	3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2899	Sulfadiazine	n/a	3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc.
2900	sulfamidase	n/a	5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Shire Human Genetic Therapies, Inc.
2901	Sulfapyridine	n/a	9/10/1990	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company
2902	sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Medigen Biotechnology Corporation
2903	sulthiame	n/a	7/25/2013	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Marathon Pharmaceuticals, LLC
2904	Superoxide dismutase (human)	n/a	3/6/1985	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership
2905	superoxide dismutase, gliadin	Etr019	4/30/2010	Treatment of amyotrophic lateral sclerosis	Verius Limited

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2906	Suramin	Metaret	5/6/1997	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company
2907	Synsorb Pk	n/a	7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc.
2908	Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH	n/a	2/4/2016	Treatment of ovarian cancer.	Soricimed Biopharma Inc.
2909	synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA	n/a	6/4/2014	Prevention of scarring post glaucoma filtration surgery	Isarna Therapeutics GmbH
2910	Synthetic 47 amino acid-long N-terminally myristoylated, HBV-L-protein derived lipopeptide	n/a	3/31/2015	Treatment of hepatitis D virus infection.	MYR GmbH
2911	Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid	Drepanol	10/24/1991	Prophylactic treatment of sickle cell disease.	Omex International, Inc.
2912	synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene	n/a	4/22/2015	Treatment of primary hyperoxaluria type 1	Dicerna Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2913	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/2013	Treatment of hemophilia A	Alnylam Pharmaceuticals
2914	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/2013	Treatment of hemophilia B	Alnylam Pharmaceuticals
2915	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/2012	Treatment of ischemic optic neuropathy	Quark Pharmaceuticals, Inc.
2916	synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Quark Pharmaceuticals, Inc.
2917	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/2012	Treatment of familial amyloidotic polyneuropathy	Alnylam Pharmaceuticals, Inc.
2918	synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA	n/a	2/8/2016	Treatment of primary hyperoxaluria type 1	Alnylam Pharmaceuticals, Inc.
2919	Synthetic human secretin	n/a	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2920	Synthetic human secretin	Chirostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
2921	Synthetic human secretin	n/a	6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
2922	Synthetic human secretin	n/a	6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
2923	Synthetic human secretin	n/a	9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Innovate Biopharmaceuticals, Inc.
2924	synthetic oligomer of 16 nucleotides	n/a	1/13/2015	Treatment of myotonic dystrophy Type I	Isis Pharmaceuticals, Inc.
2925	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Atox Bio, Inc.
2926	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/16/2013	Treatment of high altitude pulmonary edema	Apeptico Forschung und Entwicklung GmbH

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2927	Synthetic porcine secretin	Secreflo	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
2928	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
2929	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
2930	Synthetic porcine secretin	n/a	6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
2931	synthetic signal peptide of human mucin-1 (amino acids 1-21)	n/a	6/16/2015	Treatment of multiple myeloma.	Vaxil Bio Therapeutics Ltd.
2932	synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue	n/a	3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Chiesi USA, Inc.
2933	T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine	Neurovax	2/6/2014	Treatment of Pediatric Multiple Sclerosis	Immune Response BioPharma, Inc.
2934	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2935	T4 endonuclease V, liposome encapsulated	n/a	6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics
2936	taberminogene vadenovec	Trinam	10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Finvector Vision Therapies, Ltd.
2937	Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Astellas Pharma US, Inc.
2938	tacrolimus	Envarsus Xr	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Veloxis Pharmaceuticals, Inc.
2939	tacrolimus	n/a	7/6/2012	Treatment of hemorrhagic cystitis	Lipella Pharmaceuticals Inc.
2940	tacrolimus	n/a	3/16/2015	Treatment of pulmonary arterial hypertension.	Selten Pharma, Inc.
2941	tacrolimus	n/a	5/4/2015	Treatment of pulmonary arterial hypertension	Stanford University School of Medicine
2942	Tacrolimus	Prograf	4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc.
2943	tadalafil	Cialis(R); Adcirca(R)	5/4/2015	Treatment of Duchenne Muscular Dystrophy (DMD)	Eli Lilly and Company
2944	tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Eli Lilly and Company
2945	tafamidis	n/a	5/23/2006	Treatment of familial amyloid polyneuropathy	Pfizer, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2946	tafamidis meglumine	n/a	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Pfizer, Inc.
2947	tafenoquine	n/a	1/15/2013	Treatment of malaria	Glaxo Group Limited, England
2948	talactoferrin alfa	n/a	8/20/2003	For the treatment of graft versus host disease	Agennix, Inc.
2949	talactoferrin alfa	n/a	8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc.
2950	Taliglucerase alfa	Elelyso For Injection	9/3/2009	Treatment of Gaucher's disease	Pfizer, Inc.
2951	talimogene laherparepvec	Imlygic	3/14/2011	Treatment of stage IIb-stage IV melanoma	BioVex, Inc. (subsidiary of Amgen)
2952	Tamibarotene	n/a	10/11/2007	Treatment of acute promyelocytic leukemia (APL).	CytRx Corporation
2953	Tanespimycin	n/a	9/9/2004	Treatment of multiple myeloma	Bristol-Myers Squibb
2954	tarextumab	n/a	1/26/2015	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
2955	tarextumab	n/a	1/26/2015	Treatment of small cell lung cancer	OncoMed Pharmaceuticals, Inc.
2956	Targeted Gastrin 17 Complexed Peptide	n/a	5/14/2014	Treatment of pancreatic cancer	Tyg Oncology Ltd
2957	tasimelteon	n/a	4/30/2010	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Vanda Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2958	tasimelteon	Hetlioz	1/19/2010	Non-24-hour sleepwake disorder in blind individuals without light perception	Vanda Pharmaceuticals, Inc.
2959	taurine	n/a	3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Johan L. Van Hove, MD, PhD
2960	taurolidine	n/a	5/16/2016	Treatment of pancreatic cancer.	Geistlich Pharma NA, Inc.
2961	tazemetostat	n/a	2/4/2016	Treatment of malignant rhabdoid tumors (MRTs)	Epizyme Inc.
2962	TD-K6a.513a.12	Reveker	6/15/2006	Treatment of pachyonychia congenita	TransDerm, Inc.
2963	technetium Tc 99m tilmanocept	Lymphoseek	9/17/2014	Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck	Navidea Biopharmaceuticals
2964	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Immunomedics, Inc.
2965	Technetium Tc99m rh-Annexin V	Apomate	11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2966	Technetium Tc99m sulfur colloid injection, lyophilized	Technetium Tc99m Sulfur Colloi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma.	Pharmalucence, Inc.
2967	tecovirimat	n/a	9/29/2010	Treatment of orthopoxvirus infections.	SIGA Technologies, Inc.
2968	tecovirimat	n/a	12/27/2006	Treatment of smallpox.	SIGA Technologies, Inc.
2969	tecovirimat	n/a	12/18/2006	post exposure prophylaxis against smallpox	SIGA Technologies, Inc.
2970	teduglutide [rDNA origin]	Gattex	6/29/2000	Treatment of short bowel syndrome.	NPS Pharmaceuticals, Inc.
2971	Tegafur/gimeracil/oteracil	n/a	7/20/2006	Treatment of gastric cancer	Taiho Pharma USA, Inc.
2972	telatinib	n/a	5/17/2010	Treatment of gastric cancer	ACT Biotech Inc.
2973	telotristat etiprate	n/a	3/9/2012	Management of symptoms of carcinoid syndrome associated with carcinoid tumor	Lexicon Pharmaceuticals, Inc.
2974	temocillin sodium	Negaban	4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Belpharma S.A.
2975	Temoporfin	Foscan	10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Biolitec Pharma Ireland Ltd.
2976	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2977	Temozolomide	Temodal	10/18/2004	Treatment of newly diagnosed high grade glioma	Schering-Plough Research Institute
2978	temozolomide	n/a	11/25/2015	Treatment glioblastoma multiforme in pediatric patients	AmpliPharm Pharmaceuticals, LLC
2979	Temozolomide	Temodal	10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute
2980	Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Wyeth Pharmaceuticals, Inc.
2981	Teniposide	Vumon For Injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
2982	tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Gilead Sciences, Inc.
2983	teprotumumab	n/a	5/6/2013	Treatment of active (dynamic) phase Grave's orbitopathy	River Vision, Inc.
2984	terguride	Mysalfon, Teluron	5/17/2013	Treatment of systemic sclerosis	Gesellschaft fur klinische Spezialpraparate mbH
2985	Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2986	teriparatide	Forteo	4/18/2014	Treatment of hypoparathyroidism	Entera Bio, Ltd.
2987	Teriparatide	Parathar	10/28/1999	Treatment of idiopathic osteoporosis.	Biomeasure, Inc.
2988	Terlipressin	Glypressin	3/6/1986	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc.
2989	terlipressin	n/a	10/29/2004	Treatment of Hepatorenal Syndrome	Ikaria (INO Therapeutics)
2990	tesetaxel	n/a	12/22/2008	Treatment of gastric cancer	Genta Inc.
2991	tesetaxel	n/a	11/21/2008	Treatment of stages IIB, IIC, III, and stage IV melanoma	Genta, Inc.
2992	Tesevatinib	n/a	3/1/2016	Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD)	Kadmon Corporation, LLC
2993	Testosterone	Theraderm Testosterone Transdermal System	9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories
2994	Testosterone propionate ointment 2%	n/a	7/31/1991	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc.
2995	testosterone undecanoate (oral)	n/a	2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	SOV Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2996	tetra substituted prophyrin derivative containing manganese (III)	n/a	1/17/2014	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Aeolus Pharmaceuticals, Inc.
2997	tetra-substituted porphyrin derivative containing manganese (III)	n/a	3/16/2015	Treatment of idiopathic pulmonary fibrosis	Aeolus Pharmaceuticals
2998	Tetrabenazine	n/a	5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Prestwick Pharmaceuticals, Inc.
2999	Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Prestwick Pharmaceuticals, Inc
3000	tetrabenazine	n/a	7/1/2009	Treatment of Tourette's Syndrome in school-age children, ages 5-16	Valeant International (Barbados) SRL
3001	tetracosactide hexaacetate (beta 1-24-corticotrophin)	Synacthen Depot, S. Retard	10/31/2012	Treatment of infantile spasms	Cerium Pharmaceuticals, Inc.
3002	Tetraiodothyroacetic acid	n/a	5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot
3003	tetrandrine	n/a	5/19/2016	Treatment of chronic myeloid leukemia.	Escend Pharmaceuticals, Inc.
3004	Tezacitabine	n/a	1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Sanofi-Aventis US, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3005	thalidomide	n/a	9/19/1988	1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation	Pediatric Pharmaceuticals, Inc.
3006	Thalidomide	n/a	5/15/1995	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation
3007	Thalidomide	Synovir	3/11/1996	Treatment of HIV-associated wasting syndrome.	Celgene Corporation
3008	Thalidomide	n/a	1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation
3009	Thalidomide	n/a	3/5/1990	Prevention of graft versus host disease.	Andrulis Research Corporation
3010	Thalidomide	n/a	3/5/1990	Treatment of graft versus host disease.	Andrulis Research Corporation
3011	Thalidomide	n/a	2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation
3012	Thalidomide	n/a	5/1/1995	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3013	Thalidomide	Thalomid	4/6/1999	Treatment of Crohn's disease.	Celgene Corporation
3014	Thalidomide	Thalomid	10/14/1998	Treatment of multiple myeloma	Celgene Corporation
3015	Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Celgene Corporation
3016	Thalidomide	n/a	7/29/1998	Treatment of Kaposi's sarcoma.	Celgene Corporation
3017	Thalidomide	n/a	11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc.
3018	Thalidomide	Thalomid	9/27/2004	Treatment of myelodysplastic syndrome	Celgene Corporation
3019	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/2008	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Aldagen, Inc.
3020	Theranost 68 Ga RGD	n/a	10/1/2014	A Diagnostic for the management of Moyamoya disease (MMD)	Advanced Imaging Projects, LLC (AIP)
3021	Theranost 68Ga RGD	n/a	1/26/2015	Diagnostic for the clinical management of patients with tuberculosis	Advanced Imaging Projects, LLC
3022	theranost 68Ga-RGD	n/a	12/8/2014	Diagnostic for clinical management of patients with neuroblastoma	Advanced Imaging Projects, LLC
3023	Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Adienne S.A.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3024	thioureidobutyronitrile	Kevetrin	7/14/2015	Treatment of ovarian cancer	Cellceutix Corporation
3025	thioureidobutyronitrile	Kevetrin	1/20/2016	Treatment of pancreatic cancer.	Cellceutix Corporation
3026	thioureidobutyronitrile	Kevetrin	11/17/2015	Treatment of retinoblastoma.	Cellceutix Corporation
3027	Thymalfasin	Zadaxin	1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc.
3028	Thymalfasin	Zadaxin	5/3/1991	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc.
3029	Thymalfasin	Zadaxin	3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	SciClone Pharmaceuticals, Inc.
3030	Thymalfasin	Zadaxin	3/6/2000	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc.
3031	thymopentin	n/a	2/4/2011	Treatment of sarcoidosis.	Mondobiotech Laboratories AG
3032	thymosin beta 4	n/a	12/31/2013	Treatment of patients with neurotrophic keratopathy	ReGenTree, LLC
3033	Thymosin beta 4	n/a	5/28/2004	Treatment of epidermolysis bullosa.	RegeneRx Biopharmaceuticals, Inc.
3034	Thyrotropin alfa	Thyrogen	8/3/2001	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation
3035	Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3036	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/2000	Chronic myelogenous leukemia (CML)	Valeant Pharmaceuticals North America
3037	tigecycline	n/a	10/23/2013	Treatment of acute myeloid leukemia.	Trillium Therapeutics, Inc.
3038	Tilarginine acetate	n/a	4/11/2005	Treatment of cardiogenic shock	Arginox Pharmceuticals, Inc.
3039	tin ethyl etiopurpurin	n/a	11/4/2003	Prevention of access graft disease in hemodialysis patients	Miravant Medical Technologies
3040	tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc.
3041	Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Presutti Laboratories, Inc.
3042	Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D.
3043	Tiotropium bromide	Spiriva	1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc.
3044	tipelukast	n/a	10/20/2014	Treatment of idiopathic pulmonary fibrosis	MediciNova, Inc.
3045	Tipifarnib	Zarnestra	7/6/2004	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev.
3046	tiprelestat	Elafin	12/28/2012	Treatment of pulmonary arterial hypertension	Proteo Biotech AG
3047	tiptorelin pamoate	n/a	8/20/2012	Treatment of central precocious puberty	Debiopharm

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3048	tirapazamine	n/a	11/30/2015	Treatment of hepatocellular carcinoma	Teclison Limited
3049	tirapazamine	n/a	10/23/2002	Treatment of head and neck cancer	Sanofi-Aventis US, Inc.
3050	tirasemtiv	n/a	3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Cytokinetics Inc.
3051	Tiratricol	Triacana	8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires
3052	tisagenlecleucel-T	n/a	2/3/2015	Treatment of diffuse large B-cell lymphoma	Novartis Pharmaceuticals Corporation
3053	Tissue Plasminogen activator	n/a	4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Catherine Amlie-Lefond, MD
3054	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/2006	Treatment of osteonecrosis.	Aastrom Biosciences, Inc.
3055	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/2007	Treatment of dilated cardiomyopathy	Vericel Corporation.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3056	tivantinib	n/a	10/16/2013	Treatment of hepatocelular carcinoma	Daiichi Sankyo Pharma Development
3057	Tizanidine HCl	Zanaflex	1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc.
3058	Tobramycin	Tobi	6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Novartis Pharmaceuticals Corp.
3059	Tobramycin for inhalation	Tobi	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Novartis Pharmaceuticals Corp
3060	tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Genentech, Inc.
3061	tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Genentech, Inc.
3062	Tolcapone	n/a	12/24/2013	Treatment of transthyretin amyloidosis	SOM Innovation Biotech SL (SOM Biotech)
3063	tolerogen	n/a	2/5/2015	Treatment of myasthenia gravis	Toleranzia AB
3064	tolvaptan	Samsca	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Otsuka Pharmaceuticals Co., Ltd.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3065	Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Johnson & Johnson Pharmaceutical R & D, LLC
3066	topiramate injection	n/a	7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	CURx Pharmaceuticals, Inc.
3067	Toremifene	n/a	8/17/1993	Treatment of desmoid tumors.	Orion Corporation
3068	Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation
3069	Tosedostat	n/a	12/10/2008	Treatment of acute myeloid leukemia	CTI BioPharma Corporation
3070	Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	GlaxoSmithKline LLC
3071	trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma	Janssen Research & Development, LLC
3072	trabectedin	Yondelis	3/29/2005	Treatment of patients with ovarian cancer	Janssen Research & Development, LLC
3073	trabedersen	n/a	7/21/2009	Treatment of pancreatic cancer.	Isarna Therapeutics GmbH

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3074	trabedersen	n/a	8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Isarna Therapeutics GmbH
3075	trabedersen	Oncomun	6/5/2002	Treatment of malignant glioma	Isarna Therapeutics GmbH
3076	tralokinumab	n/a	7/24/2012	Treatment of idiopathic pulmonary fibrosis	MedImmune Ltd.
3077	Tramadol hydrochloride	n/a	4/26/2005	Management of postherpetic neuralgia	TheraQuest Biosciences, LLC
3078	Tramadol hydrochloride	n/a	1/28/2005	Treatment of painful HIV-associated neuropathy	TheraQuest Biosciences, LLC
3079	trametinib	Mekinist	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	Novartis Pharmaceuticals Corp.
3080	trametinib and dabrafenib	Mekinist And Tafinlar	9/20/2012	Treatment of Stage IIb through IV melanoma.	Novartis Pharmaceuticals Corp.
3081	Tranilast	Rizaben	12/2/2003	For the treatment of maligant glioma	Angiogen Pharmaceuticals, Pty. Ltd.
3082	tranilast	Rizaben	12/23/2010	Prevention of scarring following glaucoma filtration surgery	Altacor Ltd
3083	trans sodium crocetinate	n/a	12/3/2012	Treatment of brain metastasis	Diffusion Pharmaceuticals, LLC
3084	trans sodium crocetinate	n/a	7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Diffusion Pharmaceuticals, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3085	Transforming growth factor-beta 2	n/a	12/18/1992	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc.
3086	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/2013	Treatment of hepatocellular carcinoma	Eli Lilly and Company
3087	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/2013	Treatment of glioma	Eli Lilly and Company
3088	Transgenic human alpha 1 antitrypsin	n/a	5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited
3089	trastuzumab	Herceptin	12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc.
3090	trastuzumab	Herceptin	10/13/2009	Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction	Genentech, Inc.
3091	trebananib	n/a	8/30/2013	Treatment of ovarian cancer	Amgen, Inc.
3092	trehalose	n/a	11/17/2014	Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease)	BioBlast Pharma Ltd
3093	trehalose	Cabaletta	10/25/2013	Treatment of occulopharyngeal muscular dystrophy	BioBlast Pharma, Ltd.
3094	tremelimumab	n/a	3/18/2015	Treatment of malignant mesothelioma	MedImmune, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3095	tremelimumab	n/a	9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	MedImmune
3096	treosulfan	n/a	4/8/2015	Conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases in adults and pediatric patients.	Medac GmbH
3097	Treosulfan	Ovastat	5/16/1994	Treatment of ovarian cancer.	Medac GmbH
3098	treprostinil	Remodulin	6/4/1997	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp.
3099	treprostinil (inhalational)	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	LungRx, Inc.
3100	treprostinil sodium solution encolsed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump	n/a	12/29/2015	Treatment of pulmonary arterial hypertension	SteadyMed Therapeutics
3101	Tretinoin	Atra-Iv	1/14/1993	Treatment of acute and chronic leukemia.	Antigenics, Inc.
3102	Tretinoin	Atra-Iv	4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
3103	Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc.
3104	Tretinoin	n/a	4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3105	tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/2001	Treatment for hepatocellular carcinoma	Cell Works Inc.
3106	triciribine	n/a	2/1/2008	Treatment of multiple myeloma	VioQuest Pharmaceuticals, Inc.
3107	Trientine HCl	Syprine	12/24/1984	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research
3108	trientine hydrochloride	Syprine(R)	11/2/2010	Treatment of manganism.	Cerberus Princeton, LLC
3109	trientine tetrahydrochloride	n/a	3/10/2016	treatment of Wilson’s disease	GMP-Orphan SAS
3110	trifarotene	n/a	6/6/2014	Treatment of congenital ichthyosis	Galderma R&D, LLC
3111	triheptanoin	n/a	4/15/2015	Treatment of fatty acid oxidation disorders	Ultragenyx Pharmaceutical, Inc.
3112	Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Baylor Research Institute
3113	triheptanoin	n/a	10/21/2014	Treatment of glucose transporter type-1 deficiency syndrome	Ultragenyx Pharmaceutical, Inc.
3114	Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/2006	Treatment of fatty acid disorders	Baylor Research Institute
3115	Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3116	Trisaccharides A and B	Biosynject	4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd.
3117	Trisaccharides A and B	Biosynject	4/20/1987	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd.
3118	Trisaccharides A and B	Biosynject	4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd.
3119	Trisodium citrate concentration	Hemocitrate	6/15/1995	For use in leukapheresis procedures.	Hemotec Medical Products, Inc.
3120	Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.	CustomCare Pharmacy
3121	triterpenoid saponin	n/a	7/23/2014	Treatment of mantle cell lymphoma	Avicin Therapeutics, Ltd.
3122	Trypan blue	Membraneblue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Dutch Ophthalmic Research Center Int'l BV

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3123	Tumor necrosis factor-binding protein 1	n/a	1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	EMD Serono, Inc.
3124	Tumor necrosis factor-binding protein II	n/a	1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
3125	tumor-inflitrating lymphocytes; LN-144	n/a	6/9/2015	Treatment of malignant melanoma Stages IIb to IV	Lion Biotechnologies, Inc.
3126	TXA127	n/a	10/25/2013	Treament of acute radiation syndrome	US Biotest, Inc.
3127	Tyloxapol	Supervent	3/8/1995	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
3128	Type 1 native bovine skin collagen	n/a	2/1/2008	Treatment of diffuse systemic sclerosis	arGentis Pharmaceuticals, LLC
3129	ubenimex	n/a	11/19/2015	Treatment of pulmonary arterial hypertension.	Eiger BioPharmaceuticals, Inc.
3130	ubiquinol	Ubi-Q-Nol, Li-Q-Nol	4/12/2004	Treatment of Huntington's Disease	Gel-Tec, Division of Tishcon Corp.
3131	Ubiquinol, coenzyme Q10, ubiquinone	Ubi-Q-Nol	4/12/2004	Treatment of pediatric congestive heart failure	Gel-Tec, Division of Tishcon Corporation
3132	Ubiquinone	Ubi-Q-Gel	12/14/1999	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp.
3133	ublituximab	n/a	8/6/2010	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3134	ublituximab	n/a	9/5/2013	Treatment of Nodal marginal zone lymphoma	TG Therapeutics, Inc.
3135	ublituximab	n/a	9/5/2013	Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)	TG Therapeutics, Inc.
3136	udenafil	n/a	8/31/2015	Treatment of single ventricle congenital heart disease with Fontan physiology	Mezzion Pharma Co. Ltd.
3137	ulocuplumab	n/a	1/12/2015	Treatment of acute myeloid leukemia	Bristol-Myers Squibb Company
3138	Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	3/22/2001	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
3139	unoprostone isopropyl	Rescula	9/16/2010	Treatment of retinitis pigmentosa	R-Tech Ueno, Ltd.
3140	urea	n/a	11/7/2011	Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).	Orenova Group, LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3141	Urea for intravitreal injection	Neurosolve	12/14/2005	Treatment of retinitis pigmentosa	Vitreo Retinal Techologies, Inc
3142	uridine triacetate	n/a	8/9/2013	Treatment of hereditary orotic aciduria	Wellstat Therapeutics, Inc.
3143	uridine triacetate	n/a	5/1/2009	An antidote in the treatment of 5-fluorouracil or capecitabine poisoning	Wellstat Therapeutics Corp.
3144	uridine triacetate	n/a	9/3/2009	Treatment of mitchondrial disease	Wellstat Therapeutics Corporation
3145	Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	EMD Serono, Inc.
3146	Urogastrone	n/a	11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision
3147	Ursodiol	Urso 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Aptalis Pharma US, Inc.
3148	ursodiol	Ursofalk Suspension	10/23/2007	Treatment of cystic fibrosis liver disease	Asklepion Pharmaceuticals, LLC
3149	ustekinumab	Stelara	11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Johnson & Johnson Pharmaceutical & Development LLC

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3150	ustekinumab	Stelara	5/18/2016	Treatment of pediatric Crohn's disease (0 through 16 years of age)	Janssen Research & Development, LLC
3151	Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/2004	Treatment of severe complications from the smallpox vaccine	DynPort Vaccine Company LLC
3152	Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/2004	Treatment of complications of vaccinia vaccination	Cangene Corporation
3153	vadastuximab talirine	n/a	11/10/2015	Treatment of acute myeloid leukemia.	Seattle Genetics, Inc.
3154	Valine, isoleucine and leucine	Vil	1/5/1996	Treatment of hyperphenylalaninemia	Leas Research Products
3155	valine-valine-ganciclovir	n/a	5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Verenta Pharmaceuticals, Inc.
3156	Valproate	n/a	5/5/2008	Treatment of fragile X syndrome	Neuropharm Ltd,
3157	Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc.
3158	vancomycin	n/a	12/27/2012	Treatment of endophthalmitis	Fera Pharmaceuticals, LLC
3159	vancomycin hydrochloride (inhalational)	n/a	9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Savara Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3160	vandetanib	Caprelsa(R)	10/21/2005	Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma	AstraZeneca Pharmaceutical LP
3161	vapreotide	Octastatin	3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A.
3162	vapreotide	Octastatin	1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A.
3163	Vapreotide	Sanvar	4/6/2004	Treatment of symptomatic carcinoid tumors	H3 Pharma, Inc.
3164	vapreotide	Sanvar	1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiovision, Inc.
3165	vapreotide	Sanvar	11/4/2003	Treatment of acromegaly	H3 Pharma, Inc.
3166	Varbulin	Azixa	11/5/2009	Treatment of glioblastoma multiforme.	Myrexis, Inc.
3167	Varicella Zoster Immune Globulin (Human)	Varizig	11/7/2006	Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella	Cangene bioPharma, Inc.
3168	Varlitinib	n/a	8/5/2015	Treatment of cholangiocarcinoma.	ASLAN Pharmaceuticals
3169	vascular endothelial growth factor 165b	n/a	6/24/2008	Treatment of advanced melanoma stages IIb through IV.	PhiloGene, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3170	Vasoactive intestinal peptide	n/a	3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	mondoBIOTECH
3171	vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	n/a	5/13/2014	Treatment of pulmonary arterial hypertension, WHO Group 1	PhaseBio Pharmaceuticals, Inc.
3172	Vasoactive intestinal polypeptide	n/a	6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals
3173	Vasomera	n/a	11/19/2015	Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP).	PhaseBio Pharmaceuticals, Inc.
3174	vatiquinone	Vincerinone	1/31/2014	Treatment of Friedreich's ataxia	Edison pharmaceuticals, Inc.
3175	vatiquinone	Vincerinone	11/17/2014	Treatment of Rett syndrome	Edison pharmaceuticals, Inc.
3176	vatiquinone	Vincerinone	6/4/2014	Treatment of Leigh Syndrome	Edison Pharmaceuticals, Inc.
3177	velaglucerase-alfa	Vpriv	6/8/2009	Treatment of Gaucher disease	Shire Human Genetics Therapies, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3178	veliparib	n/a	9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	AbbVie, Inc.
3179	veliparib	n/a	5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	AbbVie, Inc.
3180	veliparib	n/a	12/17/2014	Treatment of brain metastases when used in combination with DNA-damaging agents	AbbVie Inc.
3181	veliparib	n/a	11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	AbbVie, Inc.
3182	veltuzumab	n/a	11/17/2014	Treatment of pemphigus	Immunomedics, Inc.
3183	veltuzumab	n/a	8/28/2008	Treatment of chronic lymphocytic leukemia	Immunomedics, Inc.
3184	veltuzumab	n/a	7/28/2015	Treatment of immune thrombocytopenic purpura.	Immunomedics, Inc.
3185	vemurafenib	Zelboraf	11/26/2013	Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation	Genentech, Inc.
3186	vemurafenib	Zelboraf	8/26/2014	Treatment of hairy cell leukemia (HCL).	Genentech, Inc.
3187	vemurafenib	Zelboraf	9/8/2014	Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600E mutation	Genentech, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3188	vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Hoffmann-La Roche, Inc.
3189	venetoclax	Venclexta	9/20/2012	Treatment of chronic lymphocytic leukemia	AbbVie, Inc
3190	venetoclax	n/a	2/4/2016	Treatment of acute myeloid leukemia.	AbbVie Inc.
3191	verteporfin	Visudyne(R)	3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Valeant Pharmaceuticals North America LLC
3192	vibriolysin	Vibrilase	6/16/2006	Debridement of severe, deep dermal burns in hospitalized patients	BioMarin Pharmaceutical Inc.
3193	vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	H. Lundbeck A/S
3194	vinCRIStine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Talon Therapeutics, Inc.
3195	vincristine sulfate liposomes	Marqibo	6/24/2008	Treatment of metastatic uveal melanoma.	Talon Therapeutics
3196	vintafolide	n/a	12/16/2013	Treatment of ovarian cancer	Endocyte, Inc.
3197	Virulizin	Virulizin	2/1/2001	Treatment of pancreatic cancer.	ZOR Pharmaceuticals, LLC
3198	vitamin A palmitate	n/a	7/14/2015	Prevention of bronchopulmonary dysplasia.	Advent Therapeutics, Inc.
3199	volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide	n/a	6/23/2015	treatment of familial chylomicronemia syndrome	Isis Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3200	volasertib	n/a	4/14/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
3201	von Willebrand Factor Human Concentrate	Wilfactin	5/29/2014	Treatment of Von Willebrand Disease	rEVO Biologics, Inc.
3202	vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Merck & Co., Inc.
3203	vosaroxin	n/a	10/28/2009	Treatment of acute myeloid leukemia	Sunesis Pharmaceuticals, Inc.
3204	Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/2010	Prevention of bronchopulmonary dysplasia.	Fox Pharma, Inc.
3205	Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc.
3206	xenon gas	n/a	12/3/2014	Treatment of hypoxic ischemic encephalopathy	Neuroprotexeon
3207	xenon gas	n/a	5/18/2015	To improve neurological outcome in hospitalized cardiac arrest patients.	Neuroprotexeon
3208	Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/2006	Treatment of Hodgkin's disease.	Alissa Pharma, LLC
3209	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/2012	Treatment of soft tissue sarcoma	OncoTherapy Science, Inc.
3210	Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembroyonic antigen IgG antibody	Cea-Cide	8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3211	Zalcitabine	n/a	12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT
3212	Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Hoffmann-La Roche, Inc.
3213	zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Glaxo Wellcome Inc.
3214	Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Lemmon Company
3215	Zoledronate	Zometa, Zabel	8/18/2000	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp.
3216	zoledronate D,L-lysine monohydrate (ZLM)	n/a	4/15/2015	Treatment of complex regional pain syndrome (CRPS)	Thar Pharmaceuticals
3217	zoledronic acid	Zometa, Reclast, Aclasta	5/6/2013	Treatment of complex regional pain syndrome (CRPS).	Axsome Therapeutics, Inc.
3218	Zosuquidar trihydrochloride	n/a	12/15/2005	Treatment of acute myeloid leukemia	Kanisa Pharmaceuticals, Inc.
3219	[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/2008	Treatment of metastatic melanoma, stages IIB, IIC, III and IV	Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)
3220	[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride	n/a	11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Aeolus Pharmaceuticals, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3221	[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt	n/a	2/14/2014	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Daiichi Sankyo, Inc.
3222	[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone	n/a	10/20/2014	Treatment of pancreatic cancer	Synovo GmbH
3223	[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	5/14/2014	Treatment of glioblastoma multiforme	Angiochem, Inc.
3224	[AC3-yCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/2011	Treatment of glioblastoma multiforme	Tocagen, Inc.
3225	[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Advanced Accelerator Applications
3226	[met5]-enkephalin	Opioid Growth Factor	1/24/2013	Treatment of pancreatic cancer	TNI BioTech, Inc.

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3227	[Î±â¿¿N-(2â¿¿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	4/15/2015	Treatment of breast cancer patients with brain metastases	Angiochem, Inc.
3228	{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide	n/a	4/10/2014	Treatment of ovarian cancer	VentiRx Pharmaceuticals, Inc.
3229		Dysport(R)	12/5/1991	Treatment of essential blepharospasm.	Ipsen Biopharmaceuticals, Inc.
3230		Nicord	4/28/2014	For the treatment of acute myeloid leukemia	Gamida Cell Ltd